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Background: Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disease. 
Glycaemic control is fundamental to management and involves frequent glucose monitoring, 
often using self-monitored blood glucose (SMBG) which carries considerable day-to-day 
burden. The use of flash glucose monitoring (FGM) systems as an alternative to SMBG is 
increasing. Literature is emerging regarding FGM associated-cutaneous adverse events 
(AEs). However, few studies have compared cutaneous AEs between FGM and SMBG and 
no studies have been conducted in youth with high-risk glycaemic control. Premature sensor 
loss is an additional issue associated with FGM use, of which existing literature is also 
limited. Thus, further research is required to investigate these issues and inform potential 
mitigating measures to improve user experience. 
Aims: There were three broad aims: 1) to evaluate frequency and characteristics of FGM 
associated-cutaneous AEs, with comparison to SMBG; 2) to evaluate premature FGM 
sensor loss; and 3) to evaluate the effectiveness of an additional adhesive patch to prolong 
FGM sensor life.  
Methods: Study 1 took advantage of adverse event and sensor loss data from a randomised 
controlled trial (RCT) among youth aged 13-20 years with T1DM and high-risk glycaemic 
control, in which participants were randomised to six-months of FGM use (intervention) or 
SMBG (control). Participants who completed the RCT were offered inclusion into Study 2, 
a crossover trial in which all participants received FGM. For Study 2, participants were 
allocated to receive a supplementary adhesive patch (intervention) or no additional adhesive 
(control) for three-months before crossing over into the opposite study arm. For both studies, 
all participants self-reported any cutaneous AEs fortnightly via an electronic questionnaire. 
Participants receiving FGM additionally reported any premature sensor loss and, for Study 
2, any patch use to determine adherence to study protocol.  
Results: Sixty-four individuals participated in Study 1 with a mean HbA1c (± standard 
deviation) of 96 (± 18) mmol/mol. Of completed questionnaires, 11% [40/362] from FGM 
participants and 11% [40/366] from SMBG participants reported a cutaneous AE (P=0.96). 
With regards to severity, 80.0% [32/40] of FGM and 82.5% [33/40] of SMBG cutaneous 
AEs were rated as mild (P=1.00). Only one participant ceased using FGM due to recurring 
cutaneous AEs. In Study 1, 24% [87/362] of questionnaires reported premature sensor loss, 
predominantly due to issues with the sensor adhesion. Only 3% [3/87] were related to a 
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cutaneous AE. Thirty-four participants enrolled in Study 2. Premature sensor loss was 
reported in 20% [32/162] of questionnaires from the intervention (additional adhesive patch) 
and 17% [26/152] from control (P=0.56). The per protocol analysis of intervention 
compliant questionnaires [196/314] showed similar findings (P=0.38). Additionally, there 
was no significant difference between cutaneous AEs among use or non-use of the adhesive 
patch (6% [5/78] and 3% [3/118], respectively, P=0.27). 
Conclusions: Among youth with T1DM and high-risk glycaemic control, cutaneous AEs 
associated with FGM use were common, mostly rated mild, and occurred at a similar 
perceived rate and severity comparative to SMBG. Premature FGM sensor loss was also 
commonly experienced among this cohort, however the use of an additional adhesive patch 
did not appear to significantly prevent this, nor cause additional AEs. Thus, awareness and 
further investigation of these issues and the effectiveness of other prevention or mitigation 






The candidate for this thesis was supervised by Associate Professor Benjamin Wheeler, Dr 
Sara Boucher and Associate Professor Barbara Galland from the Department of Women’s 
and Children’s Health, Dunedin School of Medicine, University of Otago. 
This thesis incorporates sub-studies of the ‘Managing Diabetes in a Flash’ randomised 
controlled trial (RCT) with the primary aim to evaluate the effect of flash glucose monitoring 
on glycated haemoglobin A1c (HbA1c) among youth with type 1 diabetes mellitus (T1DM) 
and high-risk glycaemic control. This main RCT was fully established and underway at the 
commencement of this thesis (1). This main “Flash” study consisted of a six-month RCT, in 
which participants received either usual care and a Freestyle Libre flash glucose monitoring 
(FGM) system, or usual care with standard self-monitoring of blood glucose (SMBG), 
followed by a six-month continuation phase in which all participants received FGM. The 
continuation phase was designed to encourage retention and engagement, especially among 
SMBG control group participants, throughout the main study. The main RCT, and 
subsequent sub-studies in this thesis, were a collaboration between investigators at the 
University of Otago based at the Department of Women’s and Children’s Health and Centre 
for Biostatistics of the Division of Health Sciences in Dunedin, the Department of 
Paediatrics in Christchurch and the Department of Paediatrics and Child Health in 
Wellington. 
The broad aims of this thesis were to evaluate cutaneous adverse events (AEs) associated 
with SMBG and FGM, and premature sensor loss related to the use of FGM, among youth 
with T1DM and high-risk glycaemic control. Accordingly, these areas of interest are covered 
in two respective studies and chapters (presented as research publications currently 
submitted or awaiting submission) within this thesis: 
1. Study 1 is presented in Chapter 2. This study compared the rates, types and severity 
of cutaneous AEs between the use of FGM and SMBG, and explored premature 
FGM sensor loss among youth with T1DM and high-risk glycaemic control. This 
study is entitled ‘Cutaneous adverse events in a randomised controlled trial of 
flash glucose monitoring among youth with Type 1 Diabetes Mellitus’. Data for 




2. Study 2 is presented in Chapter 3. This is a randomised crossover study which 
explored the impact of an additional adhesive patch to promote FGM sensor 
longevity, including associated cutaneous AEs. The study is entitled ‘The ‘Flash’ 
adhesive study: A randomised crossover trial using an additional adhesive 
patch to prolong Freestyle Libre sensor life among youth with Type 1 Diabetes 
Mellitus’. Data for analysis was obtained during the six-month continuation phase 
of the ‘Managing Diabetes in a Flash’ study. 
As part of this thesis, the candidate, Brooke Marsters, was responsible for completing a 
literature search and review and crafting the original written content of the entire thesis. Data 
collection for both studies presented in this thesis were obtained using the same method of 
sending participants electronic questionnaires every 14 days for the duration of the 12-month 
trial. The candidate joined the main study part way through data collection, and from that 
point on, her role involved sending out questionnaires, managing follow up attempts and 
collating data for analysis. In regards to Chapter 2, the candidate analysed all data, with 
demographic analysis confirmed by biostatistician Mr Andrew Gray (Centre for 
Biostatistics) to ensure consistency with the primary study. In regards to Chapter 3, the 
candidate analysed all initial data, and conducted additional statistical analyses with 
assistance by biostatistician Dr Michel de Lange (Centre for Biostatistics). For each chapter, 
the candidate interpreted study findings in collaboration with the research team and wrote 
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This introduction includes the background and a literature review that are essential 
knowledge leading into the two studies included in this thesis. Firstly, section 1.1 covers a 
general overview of type 1 diabetes mellitus (T1DM). Secondly, section 1.2 covers the 
management of T1DM and includes specific considerations for youth. Section 1.3 covers 
complications associated with T1DM. Finally, section 1.4 outlines the primary objectives of 
the studies included in this thesis. 
1.1 Type 1 Diabetes Mellitus (T1DM) 
T1DM, sometimes referred to as juvenile or insulin-dependent diabetes, is one of the most 
common chronic diseases of childhood (2, 3). This section covers an overview of the 
aetiology, pathogenesis, epidemiology, disease progression, clinical presentation and 
diagnosis of T1DM.  
1.1.1 Aetiology and pathogenesis  
T1DM is characterised by the progressive, autoimmune destruction of pancreatic β-cells, 
and resulting insulin deficiency (2-7). Insulin is a peptide hormone produced by the β-cells 
in the islet cells of the pancreas (8). Insulin is formed from the precursor preproinsulin which 
contains a signal peptide and an A, B and C amino acid chain) (9). Preproinsulin is cleaved 
to form proinsulin which then undergoes conversion into active insulin (comprised of the A- 
and B-chains) and C-peptide (comprised of the C-chain) [Figure 1] (9). Insulin is vital for 
glucose metabolism, which is primarily achieved by facilitating the uptake of glucose into 
target tissues (8). Consequently, the β-cell destruction, which occurs in T1DM, leads to 
elevated blood glucose levels (BGL), known as hyperglycaemia, and additional 
abnormalities in carbohydrate, fat and protein metabolism (3, 6). While the exact aetiology 
and pathogenesis of T1DM are not completely understood, they have been shown to be 
multifactorial (3-6). In particular, a combination of genetic susceptibility, environmental 
factors and the subsequent immunological response, contribute to the β-cell destruction and 







Figure 1: Schematic representation of the amino acid sequence of the human 
preproinsulin (A) and the conversion of proinsulin into biologically active insulin and 
C-peptide (B). Source: Matteucci et al. 2015 (8); Reproduced under the creative commons 
attribution-non-commercial 3.0 unported licence (CC BY-NC 3.0). 
1.1.1.1 Genetic susceptibility  
Approximately 10-15% of individuals who develop T1DM have a first or second-degree 
relative with the disease (4, 12). These individuals have a significantly higher lifetime risk 
of developing T1DM compared to individuals with no family history (3, 4, 12, 13). This risk 
is further heightened dependent on which family member has the disease and is two times 
more common among children with a T1DM diagnosis in the father (5%), compared to the 
mother (3%) (3, 12-14).  
Genome-wide association studies and consequent meta-analyses have found that over 60 
loci are linked with risk of developing T1DM, suggesting the aetiology of T1DM is 
polygenetic (3-5, 15). Notably, the human leukocyte antigen (HLA), located on chromosome 
6, is responsible for half of the genetic susceptibility to T1DM (4, 12, 14). In particular, 
certain combinations of DR and DQ alleles present at the HLA locus, determine genetic risk 
3 
 
and the consequent immunological response (2, 3, 6, 10). Specifically, the HLA-DR3 and 
HLA-DR4 haplotypes have demonstrated the highest risk and one or more of these HLA 
haplotypes are present in over 90% of individuals with T1DM (10, 16). The genetic 
susceptibility of the individuals without HLA haplotypes is primarily attributed to genes 
associated with pancreatic β-cell immune regulation, predominantly the insulin (INS), 
protein tyrosine phosphatase non-receptor type 22 (PTPN22), cytotoxic T-lymphocyte-
associated protein 4 (CTLA4) and interleukin 2 receptor alpha (IL2RA) genes (3, 10, 13). 
1.1.1.2 Environmental factors 
In conjunction with genetic susceptibility, environmental factors also contribute to the 
development of T1DM (2-4, 6, 11, 17). However, the underlying processes by which they 
trigger β-cell destruction are not fully understood (2-4). Several infective, chemical and 
nutritional factors have been identified as environmental triggers, either in combination or 
independently (3, 4, 6). Notably, congenital rubella and enterovirus infection, particularly in 
early childhood, have been associated with T1DM development (3, 4, 18-20). Early 
introduction of multiple foreign antigens in an infant’s diet, including cow’s milk and 
cereals, have also been linked with an increased risk of T1DM (3-5, 11).  
1.1.1.3 Immunological response 
T-cells are an essential component of the immune response; however, in certain individuals, 
a combination of these genetic and environmental factors triggers the atypical activation of 
T-cells (2-7, 10, 11). This abnormal response results in the formation of β-cell autoantibodies 
and consequently cause β-cell destruction and the development of T1DM (6, 7). 
Furthermore, specific β-cell autoantibodies can provide serological markers of T1DM (2-4, 
6, 10). These autoantibodies include glutamic acid decarboxylase 65 autoantibodies 
(GAD65), tyrosine phosphatase-like insulinoma antigen 2 (IA2), insulin autoantibodies 





Although T1DM can be diagnosed at any age (5), T1DM is one of the most common chronic 
diseases of childhood (5) and one of the most common forms of diabetes in youth (21). 
Among the majority of Western countries T1DM accounts for 90% of diabetes in children 
and adolescents; however, T1DM accounts for only 5-10% of diabetes globally across all 
ages (2, 3, 6, 7). In New Zealand (NZ) there are approximately 3,500 youth aged 0-19 with 
T1DM, of which approximately 10% are Māori and 4% Pacific Islanders (22, 23). Notably, 
the incidence of T1DM has been increasing worldwide for several decades (7, 21, 24). This 
trend has also been reflected in NZ among the general population, particularly among youth 
aged 10-14, as well as among Māori and Pacific Islanders, from data published in 2012 (25). 
Interestingly, despite the rising incidence in T1DM, there has been a decrease in the relative 
frequency of high-risk HLA genotypes, suggesting an increase in a combination of other 
T1DM associated genes and predisposing environmental factors (3, 14).  
1.1.3 Progression of T1DM  
The progression of T1DM can be characterised into four distinct stages (3, 12, 14). The rate 
of progression varies greatly between individuals and is often accelerated in infants and 
children in comparison to adults (2, 5, 12). Stages one and two reflect the early stages of 
T1DM and can last from months to years (2, 3, 5, 12, 14). These first two stages are 
characterised by the presence of β-cell autoantibodies and lack of clinical symptoms (2, 3, 
12, 14). However, in stage one, there is normal BGL (normoglycaemia), whereas, in stage 
two, there is progression to raised BGL (dysglycaemia) (2, 3, 12, 14). Stage three refers to 
the onset of clinical disease with the development to hyperglycaemia and clinical symptoms 
(2, 3, 12, 14). Finally stage four regards long-standing disease (3, 12).  
Additionally, approximately 80% of youth with T1DM, will develop a transient partial 
remission or honeymoon phase, following the initiation of exogenous insulin therapy (12). 
This phase represents a partial β-cell recovery, leading to an increase in endogenous insulin 
production and improved insulin sensitivity, resulting in a reduction in exogenous insulin 
requirements (12). Often, the partial remission begins within days or weeks of insulin 
therapy initiation and has a variable duration, ranging from weeks to years (12). Factors that 
appear to reduce the development or duration of this transient phase include a younger age 




1.1.4 Clinical presentation and diagnosis  
As a result of hyperglycaemia, T1DM classically presents with symptoms such as polyuria, 
polydipsia, enuresis, nocturia, lethargy, weight loss and polyphagia (2, 3, 12). Over time, 
chronic hyperglycaemia among children and adolescents may also present with growth 
impairment, increased susceptibility of infection and reduced concentration (3). Symptoms 
can present over days to months with a gradual or rapid increase in severity (2, 3, 12). 
Accordingly, the clinical characteristics can be classified as non-emergency presentation, as 
detailed above, or emergency, life-threatening presentations.  
Diabetic ketoacidosis (DKA) is a life-threatening presentation which develops in 
approximately 25% of youth aged 10-19 (27). In contrast, the proportion of adults that 
present with DKA is lower as adults often progress slower through the stages of the disease 
(2, 5). Symptoms indicative of DKA include nausea, vomiting, abdominal pain, tachycardia, 
hypotension, tachypnoea, confusion and drowsiness (12, 28). DKA results from a 
combination of insulin deficiency and an increase in counterregulatory hormones including 
glucagon, cortisol, catecholamines and growth hormone (28) and is characterised by 
hyperglycaemia (BGL > 11 mmol/L), metabolic acidosis (venous pH <7.3 or serum 
bicarbonate <15 mmol/l) and ketonaemia (blood β-hydroxybutyrate ≥3 mmol/L or moderate 
ketonuria) (12, 28). Importantly, if treatment is ineffective or delayed, DKA may become 
fatal (12, 28), a leading cause of which is cerebral injury (28). Risk factors for the 
progression to DKA include younger age, a delay in diagnosis and lower socioeconomic 
status (28). 
The American Diabetes Association (ADA) (2) and the International Society for Pediatric 
and Adolescent Diabetes (ISPAD) (3) outline criteria for an initial diagnosis of T1DM 
[Table 1]. While a bedside capillary blood test or urinary dipstick test can provide a simple, 
yet sensitive screening tool for evaluating glucose and ketone levels, a plasma glucose 
measurement by the laboratory is required to confirm the diagnosis (2, 3, 12). In the presence 
of clinical symptoms of hyperglycaemia or hyperglycaemic crisis such as DKA, a plasma 
glucose test >11.1 mmol/L (200 mg/dl) is sufficient to confirm the diagnosis of T1DM (2, 
3). Additional criteria, particularly in the absence of clinical symptoms, includes the testing 
of fasting plasma glucose, glycosylated haemoglobin A1c (HbA1c) or an oral glucose 
tolerance test (OGTT) (2, 3). Furthermore, serological markers of β-cell autoantibodies, as 




Table 1: Criteria for diagnosis of T1DM 
1. Symptoms characteristic of hyperglycaemic, with random plasma glucose concentration 
≥11.1 mmol/L (200 mg/dl). 
Or 
2. Fasting plasma glucose ≥7.0 mmol/L (126 mg/dl) in which fasting is defined as no 
caloric intake for at least 8 hours.a 
Or 
3. Two-hour postload glucose ≥11.1 mmol/L (200 mg/dl) during an oral glucose tolerance 
test (OGTT) performed using a glucose load containing the equivalent of 75g anhydrous 
glucose dissolved in water according to World Health Organisation OGTT guidelines.a 
Or 
4. HbA1c ≥48 mmol/mol (6.5%) from a test performed in a laboratory using a 
standardised, certified method.a, b 
aIn the absence of clear hyperglycaemia, repeat testing is required to confirm T1DM 
diagnosis. bHbA1c <48 mmol/mol does not exclude T1DM diagnosis as the role of HbA1c 
for diagnosis among children is uncertain. Table adapted from American Diabetes 





1.2 Management of T1DM  
Despite ongoing research, there is currently no cure for T1DM (5, 6). Consequently, T1DM 
management is life-long and continual due to the chronic nature of the disease (5, 6). T1DM 
care is multifaceted and requires a collaborative multidisciplinary team approach to 
management, working in conjunction with the patient, and in the case of children, also their 
family (2, 6, 7). Care focuses on improving glycaemic control and minimising diabetes-
related complications to ultimately assist in reducing the burden of disease and improving 
the patient’s quality of life (2, 5-7). Specifically, T1DM management incorporates frequent 
blood glucose monitoring and exogenous insulin administration, education and advice 
regarding diet and physical activity, psychological support and regular screening for co-
morbidities (2, 5-7, 29). This section will cover key components to T1DM care, while 
complications and co-morbidities associated with T1DM will be covered in the following 
section.  
1.2.1 Glycaemic control  
One vital aspect of T1DM management is optimising blood glucose levels (BGL) over time, 
often referred to as glycaemic control (2, 5-7, 30). Glycated haemoglobin A1c (HbA1c) 
provides an indicator of long-term glycaemic control (2, 30). The formation of HbA1c 
occurs through a non-enzymatic process, whereby glucose is attached to the β-chain of 
haemoglobin (31). Erythrocytes, which contain haemoglobin, are only in circulation for up 
to approximately 120 days (31). Thus, HbA1c reflects burden of glucose values over the 
past 8-12 weeks (2, 30, 31). In addition to HbA1c, emerging metrics of short-term glycaemic 
control include mean BGL; or the percentage of time spent in target blood glucose range 
(TIR) (2, 30, 32). The target glucose range is often defined as between 3.9 and 10.0 mmol/L 
(70-180 mg/dL), however this may vary between clinicians and individuals (2, 30, 32).  
Optimal glycaemic control, often reflected by a lower HbA1c, is associated with intensive 
management of T1DM and linked with a reduced risk of long-term diabetes-related 
complications and mortality (2, 7, 30, 31, 33, 34). Accordingly, international guidelines 
recommend a target HbA1c of <53 mmol/mol (7%) for both children and adults (2, 30). For 
patients with a history of hypoglycaemia unawareness or recurrent severe hypoglycaemia, a 
goal HbA1c of <58 mmol/mol (7.5%) may be more appropriate (2, 30). Additionally, 
guidelines from organisations, including the ADA (2) and the National Institute for Health 
and Care Excellence (35), have suggested a target of <48 mmol/mol (6.5%). Data from 
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population and clinic-based diabetes registers (36), including additional data from Australia 
(37) and the United States of America (US) (38), shows the majority of children and youth 
are not meeting a HbA1c goal of <58 mmol/mol. In addition, more recent data from USA 
indicates glycaemic control is worsening [Figure 2] (39). Furthermore, multiple factors, 
including certain ethnicities and low socioeconomic status (SES; low SES is indicative of 
living in areas of high deprivation), have also been independently associated with elevated 
HbA1c (40, 41). In NZ specifically, HbA1c is reportedly higher among Māori and Pacific 
Islanders and those with lower SES (42, 43).  
 
 
Figure 2: Average HbA1c by year of age: 2010-2012 versus 2016-2018. Orange line 
represents 2010-2012 cohort, and blue line represents 2016-2018 cohort. Participants must 
be contained in both cohorts with at least a 3-year duration for the 2010-2012 collection. 
* ≥80 years old are pooled. Source: Type 1 Diabetes Exchange, Foster et al. 2019 (39); 
Copyright Mary Ann Liebert, Inc; reproduced with permission. 
1.2.2 Glucose monitoring  
Frequent glucose monitoring is essential to achieving optimal glycaemic control and 
involves self-monitored blood glucose (SMBG) either independently or in combination with 
continuous or flash glucose monitoring systems (CGM and FGM, respectively) (2, 32). 
Glucose testing enables detection of hypo- and hyperglycaemia and assists with making 
informed dose decisions for insulin administration (timing and dosage), exercise, and 
nutritional therapy (2, 30).  
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1.2.2.1 Self-monitoring of blood glucose 
International guidelines recommend 6 to 10 finger prick capillary SMBG tests are performed 
daily to inform management decisions (2, 30). SMBG is recommended before and after 
meals, and increased testing advised with periods of physical activity and illness (2, 30, 44, 
45). Importantly, a greater SMBG frequency is associated with improved HbA1c with a 
reduction in HbA1c by up to 5.5 mmol/mol (0.5%) for each additional SMBG test (up to 5-
6 tests per day) as it provides more opportunities to optimise BGLs (32, 46-49). However, 
SMBG is associated with a considerable daily burden and has many limitations (50, 51). In 
particular, SMBG is only able to provide discrete BGL information at a specific point in 
time (32, 52). Errors with SMBG may occur due to unclean fingertips which can produce 
falsely elevated SMBG values (53, 54). Similarly, misreporting of SMBG is common, 
particularly in adolescence, which can negatively impact management decisions (55, 56). 
Thus, prevention and monitoring of hypo- and hyperglycaemia is limited, especially during 
the night when SMBG tests are rarely carried out (32, 57). Several barriers to SMBG testing 
have also been identified, including a longer duration of T1DM, low self-efficacy, increased 
anxiety and depression, and a lack of patient education (58, 59).  
1.2.2.2 Continuous glucose monitoring and flash glucose monitoring systems 
In response to this burden and the limitations of SMBG, the use of alternative glucose 
monitoring technologies, including CGM and FGM systems, are increasing (2, 32, 38, 39). 
CGM and FGM systems involve the subcutaneous placement of an enzyme-tipped electrode 
sensor which is secured by additional cutaneous adhesive [Figure 3] (2, 32, 57, 60). The 
sensor is self-inserted on the abdomen, gluteus or upper arm and instead of capillary blood 
glucose values, interstitial glucose concentrations are measured at intervals of between 1 to 
15 minutes for 6-14 days (2, 30, 32, 60-62). The mean absolute relative difference (MARD) 
between the CGM or FGM glucose value and a laboratory standard glucose level is an 
important measure of accuracy of these devices. Specifically, the MARD for CGM devices 
is 8-14% (32, 63-65) and for FGM devices, 9-14% (2, 66, 67), illustrating that these systems 
are similar and relatively accurate, which is vital for insulin dosing. Importantly, both 
systems display glucose values and trends on a receiving device and, in some instances, 
glucose data can be viewed remotely on smart devices via ‘cloud’ based platforms (2, 32, 
60). Thus, glucose monitoring systems offer a significant advantage in identifying glucose 
variability and patterns of hypo- and hyperglycaemia when compared to SMBG (32, 60). 
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Accordingly, these systems can be used for several glycaemic parameters including mean 
glucose levels and TIR over various lengths of time (2, 30, 32).  
There are key differences between the utilisation of CGM and FGM devices (2, 30, 32). 
Firstly, CGM systems, also known as real-time CGM systems, continuously send glucose 
information to a receiving device (2, 32, 60). Conversely, the cheaper, more recent, FGM 
systems, also referred to as intermittently scanned CGM systems, do not continuously relay 
glucose information (32). Instead, glucose information from FGM sensors is gained after 
holding the receiving device over the sensor (2, 30, 32, 67, 68). Consequently, only CGM 
devices allow alarms to be set for specific user-adjusted glucose levels to alert patients to 
glycaemic changes (2, 30, 32, 67-70). Interestingly, the next generation of the Freestyle 
Libre FGM (Freestyle Libre 2, Abbott Laboratories Limited) also enables a continuous 
transmission of the sensor data to a receiver device which subsequently allows alarms; 
however, it is not available in Australasia at this time. While alarms can provide considerable 
benefit and increased awareness of glycaemic changes, CGM studies have shown frequent 
alarms, especially at night, may cause some patients to experience alarm fatigue and lead to 
the dismissal of these alarms (32, 52, 69, 70). Additionally, current CGM systems often 
require a capillary blood glucose test for calibration (2, 32, 70), although advances to CGM 
accuracy have enabled a significant reduction of finger prick calibrations needed (32). 
Comparatively, FGM sensors are factory calibrated, eliminating the need for finger prick 
calibration (2, 30, 32, 67, 68).  
The use of CGM has shown significant improvements in HbA1c compared to SMBG use 
(71-77). Improvements to HbA1c are associated with consistent and increased CGM use, 
particularly among patients with high-risk glycaemic control (77-79). Reduced time in 
hypoglycaemia, especially prolonged nocturnal hypoglycaemia, is also correlated with 
CGM use in children and adults (57, 71, 72, 80). Similarly, emerging data from FGM use 
has demonstrated improvements in HbA1c (81-84) and time in hypoglycaemia was reduced 
by up to 46% among adults after 6-months of use (82). In addition, CGM and FGM use are 
associated with improvements in quality of life for patients and their families (68, 85-87).  
Currently, CGM and FGM devices have been approved for use in NZ patients aged over two 
and four years, respectively (32, 67). However, despite the availability of multiple CGM 
systems, the Freestyle Libre FGM system (Abbott Laboratories Limited®, Maidenhead, 
England) is the only FGM system currently available (32, 68). Specifically, the Freestyle 
Libre FGM system stores glucose values at 15-minute intervals for up to 14 days (2, 30, 32, 
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67, 68). However, issues regarding availability, cost and sensor wearability are barriers to 
CGM and FGM use (30, 32, 88). Specifically, CGM is significantly more expensive per year 
than FGM (US $3200-6400 compared to $1600, respectively) (89). Additionally, there is 










Figure 3: Images of a continuous glucose monitoring sensor (A and B; Guardian 3, 
Medtronic) and flash glucose monitoring sensor (C and D; Freestyle Libre, Abbott 




1.2.2.3 Emerging technologies for glucose monitoring  
Ongoing innovations in glucose monitoring technologies have seen the development of 
implantable CGM devices. In particular, the Eversense CGM (Eversense, Senseonics Inc., 
Maryland, US) is an emerging implantable glucose monitoring device approved for patients 
in NZ over 18 years of age (32, 90, 91). The Eversense CGM is a small sensor inserted 
subcutaneously on the upper arm by a health professional and requires daily finger prick 
tests for calibration (32, 90, 91). A separate transmitter is held over the sensor by adhesives, 
which both charges the sensor and continuously relays glucose information to a receiver (90, 
91). Unlike current CGM or FGM systems, the Eversense CGM transmitter can be removed 
at any point, without replacing the sensor (90, 91). As a result, the Eversense CGM can 
remain under the skin for up to 180 days (32, 90, 91). Sensor accuracy is well maintained 
over this time with a MARD of 8-12% (90, 91).  
Furthermore, patient-designed do-it-yourself (DIY) innovations are rapidly increasing in 
response to unmet needs by T1DM patients and their families (92). Specifically, third-party 
tools have recently been developed due to the significant cost of CGM systems which enable 
FGM sensors to be converted into a DIY CGM system (89). The MiaoMiao device, for 
instance, is a small Bluetooth transmitter which is placed over the FGM sensor at a one-off 
cost of US$139 (89). When a MiaoMiao device is paired with a smart phone or watch, FGM 
information is transmitted continuously between the two devices and allows the system to 
function similarly to a CGM device, including the ability to set alarms (89). Recently, a 
novel NZ study has suggested parents of children with T1DM using MiaoMiao and FGM 
may have improved quality of life (89). However, third party devices, like the MiaoMiao, 
are not as user-friendly as commercially available system and issues regarding the difficult 
setup process and connectivity are common (89). Additionally, there is currently no 
available safety data or regulatory approval for the use of these devices, thus patients are 
often reliant on online communities rather than health professionals for troubleshooting and 




1.2.3 Insulin therapy 
In combination with frequent glucose monitoring, administration of exogenous insulin 
analogues is essential for T1DM management (2, 6). Insulin therapy is required to 
commence as soon as possible after diagnosis and aims to optimise glycaemic control by 
covering insulin requirements throughout the day and night (basal) and at mealtimes 
(prandial) (2, 6, 93). In particular, intensive, individualised management and patient 
education are vital (2, 93). A range of insulin analogues are available, including rapid-, 
intermediate- and long-acting analogues, and are administered subcutaneously into the 
abdomen, gluteus, thigh or upper arm via various delivery mechanisms including insulin 
injections and insulin pumps (2, 6, 93, 94). Alternatives to administering insulin 
subcutaneously, such as oral and inhaled insulins, are still undergoing development (8, 95). 
However, due to issues with low absorption and uptake, insulin injections and pumps remain 
the primary method of insulin delivery (93, 96). Due to the delay in absorption and onset of 
action of insulin analogues currently available, international guidelines recommend rapid-
acting prandial insulin is given 15-20 minutes before the meal (2, 32, 93).  
Subcutaneous insulin dosing is influenced by weight, age, diet, physical activity and several 
other factors (93). Overall doses are usually expressed in units per kilogram of body weight 
per day (units/kg/day) and often range from 0.5 to 1.0 units/kg/day (2, 93). As patients in 
the partial remission phase produce small amounts of residual endogenous insulin, this phase 
is often defined as <0.5 units/kg/day (12, 93). Specific insulin regimens are explained in 
greater detail in the following sections. Regimens include twice-daily injections (BD); three 
or more daily injections, known as multiple daily injections (MDI); or continuous 
subcutaneous insulin infusions (CSII) (2, 93, 97). Choice of insulin regime may be 
dependent on insulin requirements, duration of T1DM, age, diet, physical activity and 
patient, family or clinician preference (6, 93, 94, 97). 
1.2.3.1 Twice daily and multiple daily injections 
BD and MDI insulin regimens deliver insulin subcutaneously using insulin pens or syringes 
(2, 93). Both BD and MDI regimens typically cover basal insulin requirements through 
twice-daily injections of an intermediate-acting or a daily injection of a long-acting insulin 
analogue (2, 93, 97). However, only MDI involves additional prandial injections of a rapid-
acting analogue (bolus) (5). MDI boluses can be adjusted based on the current BGL, 
carbohydrate intake and anticipated physical activity (5, 93). Therefore, MDI may provide 
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improved glycaemic control and greater flexibility than BD for optimising BGLs, especially 
among patients with inconsistent diet or physical activity (7, 33, 93).  
1.2.3.2 Continuous subcutaneous insulin infusion 
CSII delivers insulin via an insulin pump which is a small programmable device with a 
reservoir containing a rapid-acting insulin analogue (93). Insulin is administered via an 
insulin infusion site consisting of a subcutaneous needle or cannula and secured by a 
cutaneous adhesive and replaced approximately every three days [Figure 4] (32, 93). Pumps 
deliver rapid-acting insulin at a continuous basal rate and boluses when required by 
manually inputting current BGL or carbohydrate information (7, 32). Advanced features of 
insulin pumps include the capacity to set temporary basal rates and alter bolus patterns which 
provides greater accuracy and flexibility for insulin dosing (32). This is of particular benefit 
for situations when insulin requirements vary from the preprogramed rate, such as during 
physical activity (often decreased) and inter-current illness (often increased) (32, 93). Data 
from numerous studies have shown CSII is associated with greater improvements in 
glycaemic control and quality of life, and reduced time spent in hypoglycaemia when 
compared to insulin injection regimens (32, 76, 93). However, a high level of engagement 
from the patient or family is often required to commence and maintain insulin pump therapy 
(32, 93). Thus, CSII is rarely chosen as an initial insulin regimen (97), although it is 
successful at the time of diagnosis (32, 98). Despite this, the uptake of insulin pumps has 
been increasing both globally (39, 93) and in NZ (22, 23). Public funding in NZ for youth 
with T1DM is dependent on specific criteria and predominantly related to recurrent severe 
hypoglycaemia and elevated HbA1c (23). Notably, youth with an HbA1c >90 mmol/mol, 
do not qualify for public funding (23). Furthermore, there are a number of disparities with 
insulin pump use in NZ (22, 23). In particular, Māori, Pacific Island and Asian patients and 
those with high socioeconomic deprivation (as indicated by NZ deprivation index; NZDep13 
(43)) are significantly less likely to be using an insulin pump than NZ European patients and 
those with low socioeconomic deprivation (22, 23).  
1.2.3.3 Emerging technologies for insulin therapy 
Further advancements in diabetes management technology have led to an increase in the 
concurrent use of insulin pumps and glucose monitoring systems, known as sensor-
augmented pump therapy (SAP) [Figure 4] (32). SAP therapy enables glucose values from 
a CGM sensor to be transmitted to the insulin pump and represents the initial step to the 
15 
 
development of a fully automated glucose monitoring and insulin delivery system, known 
as a closed-loop system or artificial pancreas (6, 32). A number of automated insulin delivery 
systems are being developed and trialled, however, some individuals are opting to create 
DIY closed-loop systems, despite the lack of regulations (2). Regardless, most automated 
insulin delivery systems currently have a ‘hybrid’ approach which uses an algorithm to 
control basal insulin rates. Patient input, however, is required for prandial boluses due to the 
currently available rapid-acting insulin analogues (2, 32). Data from recent studies have 
shown improvements in HbA1c and quality of life, in addition to a reduction in glycaemic 
variability with SAP use compared to MDI (2, 32, 76, 99, 100). Furthermore, although 
current systems rely on both insulin infusion site and CGM sensors are placed separately, 
emerging alternatives include one site which combines both the subcutaneous insulin 
infusion cannula and glucose sensor (MiniMed Duo™, Medtronic, Dublin, Ireland) (101). 
Thus, the integration of insulin therapy and glucose monitoring technologies, particularly 
the development of a fully automated artificial pancreas has the potential to revolutionise 
T1DM management (6, 32). 
 
 
Figure 4: Image of an insulin pump, associated insulin infusion site and a continuous 
glucose monitor sensor placed on the abdomen (670G insulin pump with MiniMed 
Quick-Set infusion set and Guardian 3 continuous glucose monitor; Medtronic). These 
devices can currently be used in conjunction as sensor-augmented pump therapy or as a 




1.2.4 Management among youth 
The World Health Organisation defines youth as young persons between 10 and 24 years of 
age (102). As youth mature from child- to adulthood, they undergo adolescence, which is 
described as the period of significant physiological and psychological development 
experienced by youth (103, 104). This transitional phase can pose unique challenges, 
however, most youth adapt well (2, 103). Common difficulties include physical changes, 
social anxiety, and risk-taking behaviours such as alcohol and drug use (103-106). 
Specifically, among youth with T1DM, adolescence can present additional challenges for 
T1DM management (51, 93, 103). For instance, irregularities in dietary intake, irregular 
physical activity patterns, older age and pubertal status can impact insulin dosing decisions 
(51, 93, 103). Additionally, barriers to T1DM management include diabetes-related 
complications and metabolic and psychological co-morbidities (7, 103). These factors may 
contribute to the reduced adherence often seen among youth (38, 107). Furthermore, youth 
are often striving for increasing independence as they transition from child- to adulthood 
(46, 104, 107). Youth with T1DM are usually capable of performing their diabetes 
management tasks independently (108), however they still often require assistance with 
decision making and adapting to daily life changes (108). Although parental involvement 
can be beneficial, some parents and their children may experience significant family-child 
conflict which is associated with poorer glycaemic outcomes (103, 109). Accordingly, 
consideration of youth-specific, individualised and ongoing education, and shared decision 
making between the healthcare provider, patient and their family, are vital components in 





1.3 Complications with T1DM  
A range of complications are associated with T1DM. Thus, ongoing prevention, screening 
and mitigation of various diabetes-related co-morbidities is an essential aspect of diabetes 
care. This section will discuss metabolic and psychological complications, as well as issues 
associated with the use of insulin pumps and glucose monitoring systems. Of particular 
relevance to this thesis, complications with diabetes technology include cutaneous adverse 
events and sensor longevity of glucose monitoring systems. Although not covered in detail 
in this section, a range of other complications are associated with T1DM in youth including 
several autoimmune conditions, such as autoimmune hypothyroidism (Hashimoto’s 
thyroiditis) and coeliac disease (2, 110). 
1.3.1 Metabolic complications 
Metabolic complications arise from hypo- or hyperglycaemia experienced over a short or 
long duration (7, 30, 110). Accordingly, these complications are often classified as either 
acute or chronic. The most common acute complication is hypoglycaemia and is primarily 
due to excessive exogenous insulin administration, often related to inadequate carbohydrate 
intake (relative to insulin dose), physical activity or alcohol intake (7, 110). Hypoglycaemia 
is typically defined as a BGL ≤3.9 mmol/L, although patients with elevated glycaemic 
control, may experience symptoms of hypoglycaemia at a higher BGL (2, 110). Treatment 
requires the timely administration of glucose (including oral or intravenous) or 
intramuscular glucagon and, importantly, hypoglycaemia may be worsened if inadequate 
treatment is received (2, 110). In the majority of patients, hypoglycaemia is accompanied by 
autonomic symptoms such as sweating, tremor and palpitations (2, 110). Severe 
hypoglycaemia may further present with additional neurological symptoms including 
confusion, slurred speech, seizures, loss of consciousness and death (2, 110). Notably, the 
use of alcohol and illicit drug use among youth is common, including among youth with 
chronic illness (105, 106). This is of particular concern for youth with T1DM, as symptoms 
of hypoglycaemia may be mistaken for the effects of alcohol intoxication or recreational 
drug use, potentially delaying treatment and worsening hypoglycaemia (103, 110). In 
addition, severe hypoglycaemia can be exacerbated among youth due to risk-taking 
behaviour and irregularities of daily activities (103). Similarly, some individuals may 
develop hypoglycaemia unawareness, which occurs when patients do not experience any 
early warning adrenergic symptoms of hypoglycaemia. Therefore, individualised patient 
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education regarding the careful balance of insulin dosage, carbohydrate intake and physical 
activity is essential to the prevention of hypoglycaemia and subsequent management (2, 7). 
Hyperglycaemia, in contrast, is another acute metabolic complication defined as >10.0 
mmol/L (30). In patients with known T1DM, hyperglycaemia is caused by insufficient 
insulin administration which can be due to excess carbohydrate intake (relative to insulin 
dose), concurrent illness or insulin omission (30, 93). Notably, significant insulin deficiency, 
typically associated with prolonged hyperglycaemia, can lead to DKA (28). Furthermore, 
prolonged hyperglycaemia and elevated glycaemic control, as discussed previously, 
increases the risk of long-term co-morbidities (2, 7, 30, 31, 33, 34). Chronic metabolic 
complications include: microvascular complications, such as retinopathy, neuropathy and 
nephropathy; as well as macrovascular disease, such as cerebrovascular and coronary heart 
disease (6, 7, 103). In addition to hyperglycaemia, other risk factors include a longer duration 
of T1DM, elevated BMI, high blood pressure and smoking (7, 111, 112). Elevated long-
term glycaemic control, particularly common among youth (36-38), significantly increases 
the pathogenesis of these chronic complications (113). This progression further escalates 
with age, suggesting adolescence may be a critical period for the development and risk of 
complications later in life (113). Importantly, these micro- and macro-vascular 
complications are a leading cause of morbidity and mortality (6, 7). Specific screening 
methods for chronic diabetes-related complications include regular monitoring of 
albuminuria, lipids and blood pressure (112). Additionally, regular retinal photography and 
foot examinations to evaluate retinopathy and peripheral neuropathy, respectively, are also 
recommended (112). Thus, in combination with intensive insulin management and 
screening, patient education is vital for the prevention and delay of progression of these 
metabolic complications (2, 33, 34, 112). 
1.3.2 Psychological complications 
The management of T1DM can place a substantial burden on the individual and, in some 
instances, their family (2, 51). Consequently, several psychological comorbidities are 
associated with T1DM including anxiety, diabetes distress and disordered eating (2, 7, 114). 
Notably, these psychological complications can have a substantial negative impact on 
regimen adherence and glycaemic control, especially among youth (2, 114, 115). Firstly, 
anxiety symptoms and disorders are common among individuals with T1DM (2, 114, 116). 
In particular, recurrent or night-time hypoglycaemia can cause significant anxiety and fear 
of hypoglycaemia, often resulting in increased frequency of BGL monitoring or withholding 
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insulin doses (2, 7, 110, 115). This can lead to suboptimal T1DM management, poor sleep, 
reduced quality of life and disruptions to social and physical activities (103, 110, 115). 
Especially among youth, anxieties associated with not meeting target BGLs, may also result 
in misreporting of SMBG, which can present challenges to management decisions 
potentially resulting in insufficient insulin administration (2, 55, 116, 117). Furthermore, 
diabetes distress is a common psychological co-morbidity of T1DM (2, 104, 114). Diabetes 
distress refers to the negative emotions resulting from an individual’s experience of living 
with diabetes and the associated burden of the demanding and complex self-management (2, 
104). Approximately one-third of youth experience raised diabetes distress, similar to rates 
among adults (104). Notably, increased diabetes distress is associated with reduced self-
efficacy, self-care and adherence to diabetes management (2, 104). Finally, many factors 
contribute to the increased risk of developing disordered eating behaviours among patients 
with T1DM, especially young women (114, 118, 119). For instance, weight gain, often 
associated with insulin therapy and adolescence, can negatively impact body image 
perceptions, increasing the risk of disordered eating patterns (111, 118-120). One of the most 
commonly experienced disordered eating behaviours is withholding insulin administration 
in an attempt to lose weight (2, 121). Colloquially, this is termed ‘diabulimia’ (121). 
Importantly, concurrent T1DM and disordered eating is associated with increased fear of 
hypoglycaemia and diabetes distress, further exacerbating the negative glycaemic effects of 
psychological complications (2). Accordingly, regular monitoring for psychological 
complications is vital to enable early diagnosis and intervention (2, 114, 119). Furthermore, 
this emphasises the importance of a multidisciplinary approach to care which is tailored to 
each individual to balance optimal clinical outcomes and quality of life (2, 114).  
1.3.3 Complications associated with diabetes technology 
Insulin pumps and glucose monitoring systems are an increasingly common component of 
T1DM care, although there are a number of issues that can occur due to their use (2, 32, 122-
124). Importantly, both insulin pumps and glucose monitoring devices can lead to 
dermatological complications, also known as cutaneous adverse events (AE) (123, 125, 
126). Additional complications with insulin pumps include: mechanical, display or battery 
failure (122-124); problems with the insulin pump infusion set, such as insulin leakage, 
occlusion, or cannula dislodgment (32, 93, 122-124); or changes in ambient temperature and 
atmospheric pressure resulting in the formation of air bubbles (93, 123, 127, 128). Insulin 
leakage, especially, is a common occurrence which occurs with both insulin injections and 
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insulin pump use and cannot be entirely avoided due to inherent limitations of subcutaneous 
insulin administration (93, 124). Further complications with glucose monitoring systems 
include: problems with CGM and FGM sensor loss (32, 70, 86, 129, 130); a delay between 
interstitial and blood glucose values (70, 131); errors with finger prick glucose values used 
for calibrations (53, 54); and potential drug interferences (132, 133). In particular, 
acetaminophen (also known as paracetamol), has been shown to interfere with some CGM 
sensors and result in falsely elevated glucose values, although this does not affect FGM 
systems (132, 133). Ultimately, the majority of these complications can lead to receiving 
excess or insufficient insulin, which can directly contribute to metabolic complications (32, 
123).  
1.3.3.1 Cutaneous adverse events 
Insulin pumps and glucose monitoring systems all require the insertion of a subcutaneous 
cannula or sensor which is held in place by adhesive (2, 32). Consequently, this can lead to 
cutaneous AEs, which can pose management challenges for both patients and healthcare 
providers (32, 134).  
1.3.3.1.1 Cutaneous adverse events associated with insulin pump therapy 
Cutaneous AEs associated with insulin pump use are well-reported, with approximately 40-
90% of CSII users experiencing a dermatological complication associated with the device 
(125, 126, 135). Interestingly, some studies have shown the risk of experiencing a cutaneous 
AE is independent of age, glycaemic control, SES and type of insulin infusion site (125, 
126, 135). CSII-related cutaneous AEs are often attributable to the infusion site insertion, 
insulin infusion or adhesive (136-138). Additionally, while most cutaneous AEs are rated as 
mild (123), increased severity is associated with lower body mass index (BMI) (139).  
Commonly reported symptoms include erythema (redness), pruritus (itching), eczema, 
scarring, irritation, infection and lipodystrophy (abnormal fat distribution) (123-126, 139, 
140). Previously, infections have been one of the most commonly reported cutaneous AEs 
associated with insulin pump use (137, 140). Data from more recent studies, however, shows 
the rate of infection associated with CSII use is declining, likely due to advances in insulin 
pump technology (126, 135). Although infection is rarely caused by insulin injections (93), 
the risk of infection is increased with CSII use due to poor hygiene for insertion of the insulin 
pump infusion site and the prolonged time between infusion set changes (137). Notably, 
infection can present further challenges to T1DM management and can increase the risk of 
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DKA (28, 45). In addition, using the same infusion site over several days may lead to 
changes in subcutaneous adipose tissue (lipodystrophy) (141, 142). Lipodystrophy is a well-
recognised cutaneous complication associated with all types of subcutaneous insulin 
administration (138, 143) which can lead to reduced insulin absorption and consequently 
unpredictable BGLs (32, 111, 144). Specifically, lipohypertrophy (adipose accumulation) 
results from the synthesis of fat and protein stimulated by insulin administration into the 
subcutaneous tissue, usually due to repeated insulin delivery at a certain site (141, 142). 
Lipoatrophy (adipose loss), on the other hand, often occurs as a result of an immune reaction 
to the exogenous insulin, causing adipose degradation (111, 145). With regards to pump 
therapy, lipohypertrophy is frequently experienced whereas lipoatrophy is much less 
common (124, 135, 139, 143, 145). However, despite the common occurrence of cutaneous 
AEs, they are rarely the cause for discontinuation of CSII use (126, 137, 139). 
1.3.3.1.2 Cutaneous adverse events associated with glucose monitoring technologies  
Cutaneous complications associated with CGM or FGM use are also increasingly reported. 
One recently published systematic review by our research group, found a rate of one 
cutaneous AE for every eight weeks of CGM or FGM use (146). The review showed the 
rates of people experiencing a cutaneous AE varied widely between studies, potentially due 
to differences in AE collection methods. In particular, the reported occurrence was typically 
higher in trials when the site was inspected by researchers, compared to self-reported AEs. 
Data from observational studies, including CGM or FGM related AEs, show over 70% of 
participants eventually experience a cutaneous complication (125, 126, 147). In addition, 
the majority of cutaneous AEs related to CGM or FM use are mild (146). While the above 
literature includes cutaneous AEs from both CGM and FGM use, reporting of cutaneous 
complications specific to FGM use is significantly more limited (146). Emerging literature, 
specific to FGM supports these findings and illustrates cutaneous AEs from FGM systems 
are common and mostly mild (66, 67, 83, 84, 147-149). 
Commonly reported symptoms relate to either sensor insertion or wear (67, 70, 83, 84, 146). 
Overall, erythema (55%), pruritus (11%) and induration (9%) are the most frequently 
reported cutaneous complication from CGM or FGM use (146). Other common symptoms 
include infection, pain, bleeding and bruising (146). In some instances, individuals may 
develop allergic contact dermatitis (ACD), an inflammatory immune reaction, which 
typically presents with erythema and irritation (134, 150). While the development of ACD 
often requires prolonged exposure to an allergen, repeated exposure may result in a more 
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rapidly occurring reaction (32, 134, 150). Importantly, several studies have identified 
allergens, namely acrylates, present in the adhesive of both CGM and FGM sensors as a 
causative agent for dermatological complications (136, 151-156). In particular, ethyl 
cyanoacrylate is an allergen present in the Dexcom Platinum G4 (Dexcom, San Diego, 
California) CGM adhesive, known to lead to ACD (151, 152). On the other hand, isobornyl 
acrylate from Freestyle Libre FGM adhesive contributes to ACD (153-156). Skin irritation 
may be further exacerbated by humidity, high temperatures or exercise (70, 111).  
In addition, various studies illustrate that participants experience less pain or bleeding 
related to the use of CGM (157, 158) or FGM (66, 86, 149) systems when compared to 
capillary SMBG. However, early negative experiences with CGM or FGM, including 
cutaneous AEs, may deter youth from using this glucose monitoring technology and are a 
common reason for stopping use (32, 86, 146). Irritation from adhesives, in particular, is 
often the primary reason given for discontinuation of CGM across all ages (88, 157). Despite 
this, the rate of discontinuation due to FGM-related cutaneous AEs is low, ranging from 1-
8% of participants using FGM (83, 84, 147, 148).  
1.3.3.1.3 Potential prevention measures  
As many individuals will continue to use insulin pumps and glucose monitoring systems 
despite experiencing cutaneous AEs, preserving skin integrity, reducing cutaneous AEs and 
preventing premature sensor loss are increasingly important aspects of T1DM care (83, 84, 
126, 147). Several measures are recommended to reduce cutaneous AEs resulting from 
pump, and glucose monitoring system use (70, 129, 134). Importantly, many of these 
methods can be used concurrently to further reduce dermatological complications (129). 
Good hygiene regarding site preparation and regular rotations of the sensor or cannula 
insertion site is vital to preventing cutaneous complications, especially infection, irritation, 
rash and dry skin (68, 70, 129). Typically, this involves the use of an alcohol wipe to clean 
the skin, then, once completely dry, the device can be inserted (70). In combination with 
proper sterile technique, regular changes to the insertion site are crucial to avoid AEs (32, 
93, 111). This is particularly important with insulin pump use as issues relating to infusion 
cannulas often increase from day three onwards (159). Accordingly, replacing the site 
approximately every two or three days is vital for preventing infection and lipodystrophy 
(32, 93, 145). However, in some individuals, lipoatrophy may not resolve with these 
recommendations, although, switching the insulin analogue used can be beneficial (70, 145). 
Alternative prevention methods, commonly used for glucose monitoring technologies 
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includes minimising skin exposure to the adhesive through the use of barrier sprays (such as 
Cavilon™ spray; 3M, Minnesota, US) or barrier tapes (such as Tegaderm®; Smith & 
Nephew, Minnesota, US), ensuring a gap or opening is available for the needle to go through 
(68, 70, 129). The use of topical creams, such as hydrocortisone cream (1%) to manage 
cutaneous AE symptoms, may be beneficial (111). Furthermore, emerging research is 
ongoing regarding the off-label use of fluticasone propionate spray, typically used to treat 
upper airway hypersensitivity reactions (134, 160). These studies show fluticasone spray is 
a promising method to reduce cutaneous complications (134, 160). 
1.3.3.2 Premature sensor loss 
Sensor adhesion and durability is another common issue with glucose monitoring systems, 
with frequent reports of sensors being removed or ended (intentionally or accidentally) 
before their anticipated end (32, 70, 86, 129, 130). Typically, premature sensor loss occurs 
due to reduced sensor adhesion and can result from sweating or physical activities, especially 
water-based activities (70, 86, 129, 130). Existing literature regarding rates or proportions 
of premature sensor loss is limited, especially related to FGM systems and regarding the 
impact of cutaneous AEs on sensor durability. Data from one recent prospective study 
illustrated premature sensor loss occurred in 7-32% of CGM sensors (65). Comparatively, a 
recent qualitative study found 69% of youth using FGM systems experienced at least one 
early sensor loss over six-months (86).  
Accordingly, various methods to promote sensor adhesion and duration have been 
recommended, which include adhesive wipes or liquids, or external tapes or wraps (70, 129, 
134). The use of external tapes or wraps is commonly recommended and used to prevent 
premature sensor loss (70, 129, 134). Additional adhesive tape can be used to secure the 
sensor, while external wraps can assist in securing the sensor without the need for additional 
adhesives (70, 129). Importantly, to help reduce moisture and consequent cutaneous AEs, 
tapes need to be cut to the specific CGM or FGM shape to enable ventilation for the CGM 
transmitter or FGM ventilation hole (129). One example of an external tape for FGM sensors 
are RockaDex patches (RockaDex, New Zealand), which come in a variety of colours 
[Figure 5]. RockaDex patches are pre-cut kinesiology tape placed over the Freestyle Libre 
FGM sensor, which does not obscure the ventilation hole in the centre of the sensor. Notably, 
this adhesive patch is comprised of cotton, nylon and acrylic and does not contain known 
causative agents such as isobornyl acrylate, zinc oxide or latex; thus, is not thought to 




Figure 5: Image of RockaDex adhesive patch (green) used to secure the Freestyle Libre 
flash glucose monitoring sensor (white) to the back of the upper arm.  
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1.4 Thesis Objectives 
The broad aims of this thesis were to evaluate cutaneous AEs associated with SMBG and 
FGM; and premature sensor loss related to the use of FGM in youth aged 13 to 20 years. 
Importantly, this thesis takes advantage of the data collected during the ‘Managing Diabetes 
in a Flash’ RCT which focused on youth with T1DM and high-risk glycaemic control (1). 
Specifically, this thesis contributes to the emerging body of literature describing the rates, 
types and severity of cutaneous AEs associated with FGM use in comparison with SMBG; 
establishing a rate of premature FGM sensor loss; and evaluating the impact of an additional 
adhesive patch to attempt to promote FGM sensor longevity. These are areas few studies 
have addressed, particularly regarding youth with high-risk glycaemic control.  
1.4.1 Chapter 2 (Study 1) 
In general, limited literature is available relating to cutaneous complications associated with 
FGM. As FGM is an emerging glucose monitoring technology of which uptake is increasing, 
it is important to understand the impact on cutaneous AEs comparative to SMBG. However, 
to date, no studies have established a direct comparison between cutaneous AEs associated 
with these two glucose monitoring options among youth, nor the prevalence of premature 
FGM sensor loss. 
Accordingly, among youth with T1DM and high-risk glycaemic control, the objectives of 
this chapter were to: 
1. Evaluate the frequency, types and severity of participant reported cutaneous AEs 
associated with the Freestyle Libre FGM system and SMBG; and 




1.4.2 Chapter 3 (Study 2) 
Existing literature indicates that preventing premature FGM sensor loss is vital to improving 
the glycaemic benefit gained with consistent use. Furthermore, preventing early sensor loss 
may reduce the significant burden and cost to the individual or healthcare system. While 
various methods to promote sensor longevity have been proposed and are commonly used 
clinically, further research is required to establish the effectiveness of measures such as an 
additional adhesive patch. Given known concerns regarding adhesives related to FGM 
sensors, safety and preserving skin integrity is an important consideration. 
Accordingly, among youth with T1DM and high-risk glycaemic control, the objectives of 
this chapter were to: 
1. Evaluate whether adding an additional adhesive patch to FGM sensors reduces the 
frequency of premature FGM sensor loss; and 
2. Evaluate whether the use of an additional adhesive patch contributes to additional 
cutaneous AEs.  
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2.1 Abstract  
Background: Literature regarding flash glucose monitoring (FGM) associated cutaneous 
adverse events (AE) is limited. This study among youth participating in a six-month 
randomised controlled trial (RCT) aimed to compare cutaneous adverse events (AE) 
between FGM and self-monitored blood glucose (SMBG) use and evaluate premature FGM 
sensor loss. 
Methods: Patients aged 13-20 years with type 1 diabetes mellitus were randomised to 
intervention (FGM and usual care) or control (SMBG and usual care). Participants self-
reported cutaneous AEs electronically every 14 days. Reports were analysed to determine 
frequency, type and severity of cutaneous AEs, and premature sensor loss.  
Results: Sixty-four participants were recruited; 33 randomised to FGM and 31 to control. 
In total, 80 cutaneous AEs were reported (40 in each group), however the proportion of 
participants experiencing AEs was greater in the FGM group compared to control (58% and 
23% respectively, P=0.004). FGM participants most frequently reported erythema (50% of 
AEs), while controls most commonly reported skin hardening (60% of AEs). For FGM 
users, 80.0% of AEs were mild, 17.5% moderate and 2.5% severe. Among controls, 82.5% 
of AEs were mild and 17.5% moderate. One participant ceased using FGM due to recurring 
cutaneous AEs. Additionally, over 6-months, 82% of FGM participants experienced at least 
one premature sensor loss, largely unrelated to an AE.  
Conclusion: Cutaneous FGM-associated AEs are common, and mostly rated as mild. 
However, the majority of users continued FGM despite AEs. Awareness of cutaneous 
complications and mitigation measures may reduce cutaneous AEs and improve the overall 





Frequent self-monitored blood glucose (SMBG) is an essential aspect of modern type 1 
diabetes mellitus (T1DM) care (33, 161, 162). It is also a marker of overall diabetes 
adherence and, as such, increasing SMBG frequency is associated with improved HbA1c by 
up to 0.5% (5.5 mmol/mol) with each additional capillary SMBG up to 5-6 tests per day (46-
49). Capillary SMBG carries with it considerable day to day burden (50, 58, 59), limitations 
for the prevention and monitoring of hypo- and hyper- glycaemia (57, 82), as well as issues 
around misreporting (55, 56). In response to this, the use of continuous glucose monitoring 
(CGM) and flash glucose monitoring (FGM) systems is increasing (39, 52).  
Compared to SMBG, use of CGM has shown improvements in HbA1c (71-75), especially 
with consistent and increased CGM use (77-79). A meta-analysis showed even greater 
benefits among those with sub-optimal glycaemic control (77). Use of CGM also reduces 
time spent in hypoglycaemia in both children and adults, particularly prolonged nocturnal 
hypoglycaemia (57, 71, 72, 80). Similarly, FGM use has also demonstrated improvements 
in HbA1c and reduced time spent in hypoglycaemia by up to 46% among adults after 6 
months of use (81-84). Both CGM and FGM reduce the burden of SMBG (84, 147), as well 
as the misreporting of SMBG (55, 56), which may assist in improvements to glycaemic 
control, and the overall burden of living with diabetes (163).  
A downside of CGM and FGM technology is the need for subcutaneous placement of a 
sensor as well as adhesives use to secure sensors for periods of up to 14 days. Literature on 
cutaneous adverse events (AEs) is emerging, with a recent systematic review finding a rate 
of one event for every eight weeks of CGM or FGM use (146), but other real-world data 
suggests this may be considerably under-reported (75, 82, 84, 126, 147, 153, 164). While 
data on cutaneous AEs for FGM is included in the systematic review (146), literature in 
comparison to CGM is limited, especially regarding the severity of AEs and the frequency 
of patients who cease use due to cutaneous AEs particularly among youth with high-risk 
glycaemic control.  
This study therefore aimed to evaluate participant reported cutaneous AEs and sensor use 
associated with the Freestyle Libre FGM system compared to usual care with SMBG as part 




2.3.1 Study Design 
This study is a part of a larger, multi-centre, industry independent RCT conducted across 
the Capital and Coast, Canterbury, South Canterbury and Southern District Health Boards 
of New Zealand, which consisted of a six-month comparison between SMBG and FGM on 
several clinical and psychosocial outcomes (1). In brief, RCT participants were randomised 
by an offsite biostatistician in batches using a 1:1 ratio to either an intervention group, who 
received six-months supply of the Freestyle Libre FGM system® (Abbott Laboratories 
Limited, Maidenhead, England) combined with usual clinical care, or into a control group, 
who continued with capillary SMBG and usual care. FGM group participants were advised 
on good hygiene regarding site preparation and sensor insertion (as recommended by the 
manufacturer) and participants reporting a first cutaneous AE were subsequently provided 
with advice to prevent further AEs (134), including minimizing exposure to the FGM 
adhesive by using barrier sprays (Cavilon™) and barrier tapes (Tegaderm™). 
Hydrocortisone cream (1%) was also provided to minimize recurrent cutaneous AEs.  
Data was collected from April 2018 to May 2019. Ethics approval was granted by The 
Southern Health and Disability Ethics Committee (17/STH/240). The trial was registered 
with the Australian New Zealand Clinical Trials Registry (ACTRN12618000320257p; 
http://www.anzctr.org.au/ACTRN12618000320257p.aspx on 5 March 2018 and was issued 
a Universal Trial Number (U1111–1205-5784) by the World Health Organization 
International Clinical Trials Registry. 
2.3.2 Participants 
Youth aged 13-20 years, inclusive, with T1DM ≥ 12 months and high-risk glycaemic control 
(mean pre-study HbA1c ≥ 75 mmol/mol [≥9%] over the previous 6 months) were eligible to 
participate. Participants were recruited from paediatric and adult diabetes clinics from 
Canterbury, Capital and Coast, South Canterbury, and Southern District Health Boards, 
spanning the lower half of New Zealand. Additional inclusion criteria were prescribed ≥ 0.5 
units of insulin/kg/day and intending to continue with routine clinical care during the six 
month RCT. Exclusion criteria included any severe diabetes related complications; other 
severe or uncontrolled medical or psychiatric co-morbidities; currently using a CGM or 
FGM device or has used one continuously within the previous four months (except for brief 
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inpatient or clinical use); using another device or enrolled in a drug study that could affect 
glucose measurements; pregnancy, lactation or planning to become pregnant; or the inability 
of the individual or legal guardian to give written informed consent.  
2.3.3 Data collection 
Basic demographic participant data was collected during the first study visit. During the six-
month trial, participants self-reported AEs via an electronic safety questionnaire 
[Appendices 1h and 1i]. Each safety questionnaire collected information including the type 
of cutaneous issue, overall severity of the cutaneous issue (self-reported as ‘no problem’, 
‘mild’, ‘moderate’ or ‘severe’) and whether the participant experienced a premature sensor 
loss defined as a sensor ending prior to the expected 14-day duration. Participants were also 
able to identify multiple symptoms in each AE report and rated the severity of the overall 
AE. Data were collected electronically and managed using the REDCap™ (Research 
Electronic Data Capture) survey administration tool (165, 166). Safety questionnaires were 
timed to coincide with the day each sensor change was due, totalling 13 safety questionnaires 
for each participant over the six-month (26 week) period. Up to three contact attempts were 
made to non-responders. Participants were also asked to send photos of cutaneous AEs to 
research staff to aid in documenting AEs.  
2.3.4 Statistical analyses 
Data were analysed to determine frequency, type, and severity of reported cutaneous AEs 
for both the intervention and control groups. Data were also analysed to determine the 
frequency of sensor loss prior to the anticipated 14-day sensor end. Cutaneous AEs rated as 
‘no problem’ were combined with ‘mild’ responses for analysis. Appropriate summary 
statistics were calculated for all variables of interest (means and standard deviations for 
normally distributed continuous variables, medians and 25th and 75th percentiles for non-
normally distributed continuous variables, and counts and percentages for categorical 
variables). P-values below 0.05 were considered statistically significant. All statistical 





2.4.1 Participant characteristics  
A total of 64 participants were recruited into the study, 33 randomised to the FGM-
intervention group and, 31 into the control group (SMBG). For participant flow, see Figure 
6. Overall, baseline demographics were similar between the intervention and control groups 
[Table 2]. For combined groups, the average age (± standard deviation) was 16.7 (± 2.1) 
years and the average duration of diabetes was 7.4 (± 3.8) years. The baseline mean HbA1c 
was high-risk at 96 (± 18) mmol/mol, consistent with the recruitment aims of the RCT. The 
response rate of questionnaires was 84% (362/429) and 91% (366/403) for the FGM group 



















Figure 6: Cutaneous adverse event study CONSORT flow diagram; *Participants received 1 questionnaire every 14 days, totalling 13 safety 
questionnaires per participant for the duration of the study; Abbreviations: FGM, flash glucose monitoring; SMBG, self-monitored blood glucose; 
AE, adverse event 
Allocated to control 
(SMBG) (n=31) 
 
Diabetes clinic visits.  
Received study overview (n=140) 
Assessed for eligibility (n=77) 
Recruited into study and  
randomised (n=34) 
Declined (n=43) 
Unable to contact (n=20) 
Not meeting inclusion criteria (n=13): 
• Mean HbA1c <75mmol/mol  (n=4) 
• FGM user (n=4) 
• Age >20 years (n=3) 
• T1D duration <12 months (n=1) 
• Not diagnosed with T1D (n=1). 




Safety questionnaires sent to 
participants* (n=403) 
 
Safety questionnaires sent to 
participants* (n=429) 
 
Complete SMBG safety 
questionnaires (n=366) 
 






AE reports (total n=40): 
• Mild (n=33) 
• Moderate (n=7) 
• Severe (n=0) 
 
Cutaneous FGM-associated 
AE reports (total n=40): 
• Mild (n=32) 
• Moderate (n=7) 
• Severe (n=1) 
 




associated AE reported 
(n=326) 
 
Safety questionnaires not 
complete (n=67) 
No cutaneous FGM-
associated AE reported 
(n=322) 
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Table 2: Baseline characteristics of intervention and control participants 








Age (years), mean (± SD) 16.6 ± 2.1 16.5 ± 1.9 16.7 ± 2.2 
Male 33 (52) 17 (52) 16 (52) 
Prioritized ethnicity     
 New Zealand European/European 37 (58) 18 (55) 19 (61) 
 Māoria 16 (25) 9 (27) 7 (23) 
 Pacific Islander 10 (16) 5 (15) 5 (16) 
 Asian 1 (2) 1 (3) 0 (0) 
Deprivation (NZDep2013)    
 Low deprivation (1-3) 19 (30) 10 (30) 9 (29) 
 Medium deprivation (4-7) 26 (41) 12 (36) 14 (45) 
 High deprivation (8-1) 19 (30) 11 (33) 8 (26) 
Education or employment statusb    
 In education (secondary) 42 (66) 21 (64) 21 (68) 
 In education (tertiary) 11 (17) 5 (15) 6 (19) 
 In employment 10 (16) 6 (18) 4 (13) 
 Not in education or employment 1 (2) 1 (3) 0 (0) 
BMI z-scorec, mean (± SD) 0.69 ± 1.00 0.67 ± 1.05 0.72 ± 0.96 
Duration of diabetes (years), mean (± SD) 7.5 ± 3.8 7.0 ± 3.5 8.0 ± 4.0 
Insulin therapy    
 MDI 55 (86) 29 (88) 26 (84) 
 CSII 9 (14) 4 (12) 5 (16) 
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Insulin estimated total daily dose (units), 
median (IQR) 
72 (31) 73 (33) 70 (24) 
HbA1c (mmol/mol), mean (± SD) 96 ± 18 94 ± 18 99 ± 18 
SMBG checks per day, mean (± SD) 2.4 ± 2.9 2.3 ± 1.7 2.5 ± 4.0 
Previous skin problemd    
 Non-specific eczema or dermatitis 8 (13) 4 (12) 4 (13) 
 Adhesive reactione 1 (2) 1 (3) 0 (0) 
 Other 3 (5) 1 (3) 2 (6) 
aMāori are the indigenous population of New Zealand. bPercentages for education or 
employment status of all participants do not add to 100% due to rounding to the nearest 
whole number. cBMI z-score calculated using Centre for Disease Control Guidelines. 
dPrevious skin problem was self-reported; eone participant reported a non-specific skin 
reaction to a surgical dressing. NZDep2013, New Zealand 2013 index of socioeconomic 
deprivation; BMI, body mass index; MDI, multiple daily injections; CSII, continuous 
subcutaneous inulin infusion; IQR, interquartile range; HbA1c, glycated haemoglobin A1c; 




2.4.2 Frequency of adverse events 
Frequency of cutaneous AEs reported from completed safety questionnaires across all 
participants were similar. For the FGM group, 40/362 (11%) of safety questionnaires 
reported at least 1 FGM-associated cutaneous AE, compared to the control group, where 
40/366 (11%) of safety questionnaires, reported at least 1 SMBG-associated adverse event 
(P=0.96). Consequently, the FGM group had a cutaneous AE rate of 1 event for every 18.1 
weeks of use, similar to the control group who had a cutaneous AE rate of 1 event for every 
18.3 weeks of use. The number of participants involved in the respective AE reports was not 
evenly distributed between groups. FGM-associated AEs involved 19/33 (58%) of 
participants, whereas SMBG-associated AEs involved 7/31 (23%) of participants (P=0.004).  
Among the FGM group, 11 (33%) of participants reported 1 AE; 5 (15%) reported 2-4 AEs; 
and 3 (9%) reported 5 or more AEs. One participant, who reported the greatest number of 
AEs (a total of 8 separate events), was the only FGM participant to cease using FGM (at 24 
weeks due to these cutaneous AEs, despite trying multiple interventions to prevent or 
improve them, including: skin drying measures, rotating sites, provided with preventive 
Cavilon™ barrier spray, and provided with hydrocortisone steroid creams). Conversely, in 
the control group, 1 (3%) of participants reported 1 AE; 3 (10%) reported 2-4 AEs; and 3 
(10%) reported 5 or more AEs.  
2.4.3 Adverse events symptoms 
The average number of symptoms reported per AE was similar among the control group 
AEs compared to the FGM group AEs (2.3 symptoms compared to 2.1 respectively, 
P=0.69), however the type and frequency of reported AE symptoms varied [Table 3]. Images 
of FGM-associated cutaneous AEs are shown in Figure 7. 
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Abrasion  1 (3) 1 (3) 0 (0) 0 (0) 
Bleeding 5 (13) 4 (12) 1 (3) 1 (3) 
Bruising 8 (20) 4 (12) 3 (8) 2 (6) 
Dent  0 (0) 0 (0) 11 (28) 2 (6) 
Erythema  20 (50) 11 (33) 4 (10) 2 (6) 
Infection 2 (5) 2 (6) 0 (0) 0 (0) 
Lump 3 (8) 3 (9) 8 (20) 1 (3) 
Pain 10 (25) 7 (21) 10 (25) 1 (3) 
Pruritus 17 (43) 8 (24) 11 (28) 3 (10) 
Rash 7 (18) 6 (18) 3 (8) 1 (3) 
Scarring 4 (10) 3 (9) 18 (45) 3 (10) 
Skin hardening 1 (3) 1 (3) 24 (60) 5 (16) 














Figure 7: Cutaneous adverse events associated with flash glucose monitoring use; 
Reported symptoms are A Bruising; B Erythema; C Erythema, pruritus, rash, pain and 
bleeding; D Erythema and lump; and E Erythema and pruritus. 
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2.4.4 Severity of adverse events 
There was no significant difference between groups for the frequency of AE reports that 
were rated mild, moderate or severe (P=1.00) [Table 4]. However, while the control group 
had no AEs rated as severe, one participant in the FGM group rated one FGM-associated 
AE as severe and was the only participant to cease FGM use. 




















Mild  32 (80.0) 20 (60.6) 33 (82.5) 8 (25.8) 
Moderate 7 (17.5) 4 (12.1) 7 (17.5) 7 (22.6) 
Severe 1 (2.5) 1 (3.0) 0 (0) 0 (0) 
aSeverity ratings are given for the cutaneous adverse event as a whole and not for individual 
symptoms.  
2.4.5 Premature sensor loss 
The majority (82%) of participants experienced at least 1 premature sensor loss during the 
6-month study. Of the total completed safety questionnaires from the FGM group, there 
were 87 (24%) detailed reports of premature sensor loss available for analysis, with some 
reporting multiple causes for premature loss. Cutaneous AEs accounted for a minority 3 
(3%) of premature sensor loss. The most common reasons for premature sensor loss (n=87) 
were: loss of adhesion 74 (64%), sensor malfunction or damage 12 (10%) and accidental 
removal 5 (4%). A further 8 (7%) were unspecified.  
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2.5 Discussion 
This study confirms that self-reported cutaneous AEs from both SMBG and FGM are 
common. The majority of FGM-associated cutaneous AEs reported in this study were rated 
as mild, in contrast to a previous study showing an increased incidence of severe FGM-
associated cutaneous AEs (82). Only one participant ceased using FGM, providing 
confirmatory evidence that most people will continue to use FGM or CGM despite 
cutaneous AEs (83, 84, 126, 147). A study in which FGM-associated cutaneous AEs were 
confirmed by clinician inspection also reported lower rates of moderate and severe AE 
ratings compared to self-reported AEs (67) suggesting the perceived severity of self-reported 
AEs may be higher. Premature sensor loss is also common among patients using FGM, 
however, this was primarily related to adhesive issues and not cutaneous AEs.  
Previous studies have shown a wide range in the reported frequency and proportion of 
participants that experience cutaneous AEs. Although this study found that the majority of 
participants experienced at least one FGM associated AE over a six-month period, the rate 
of AEs was lower than summarized in a recent systematic review (146), which reported a 
cutaneous CGM/FGM-associated AE rate of 1 event for every 8 weeks of use, compared 
with one event for every 18.1 weeks of FGM use in the current study. However, the 
proportion of participants, including children and youth, that experience FGM associated 
cutaneous AEs also varies widely between studies, ranging from 6% to 55% (67, 82-84, 147, 
148). These studies included both retrospective and real-time reports of AEs, as well as self-
report and clinician confirmed AEs and differences between the two. These differences in 
reporting rates are likely due to the contrasting methodology utilized to capture AEs.  
A novel aspect of this study is that no existing studies have compared cutaneous AEs 
associated with FGM to SMBG among youth (66, 67, 83, 84, 147-149). Overall, total AEs 
were similar to FGM-associated AEs, however, significantly more participants from the 
FGM group reported at least one cutaneous AE compared to the control group. Additionally, 
other studies suggest cutaneous AEs are under-reported for both SMBG and FGM use (67, 
83, 129, 130). One possible reason for an under representation of SMBG-associated 
cutaneous AEs is that a certain amount of cutaneous discomfort is expected with SMBG use 
(50, 58, 59). This may be ‘normal’ for most participants and therefore may not be reported 
as an AE by the majority of participants. An important observation is that fewer than 10% 
of participants were responsible for approximately 50% of the cutaneous AEs reported for 
each group. This suggests that a minority of participants may be particularly susceptible to 
recurrent cutaneous AEs, or their impact, similar to previous studies (83, 84).  
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The participants in our study were actively managed and had 24-hour access to research staff 
to aid in the prevention, as well as management of subsequent cutaneous AEs. Thus, active 
prevention and management may explain why the cutaneous AEs rate was lower in this 
study compared to a recent systematic review and why our study had fewer moderate or 
severe AEs than a previous study (82, 146). However, youth, especially those with high-risk 
glycaemic control are well known to have reduced adherence (38, 56, 60, 107). Therefore, 
while advice was given regarding methods to prevent and manage recurrent cutaneous AEs, 
the effect of these measures remains uncertain.  
Among FGM users, this study found that sensor loss was common and primarily due to 
issues with the sensor adhesive, not cutaneous AEs. Spontaneous separation and accidental 
removal (for example, being knocked accidently) were both commonly reported. The 
adhesive used in the Freestyle Libre FGM sensors can cause contact dermatitis and is also 
likely responsible for some of the AEs reported in this study (129, 130, 153). For these cases, 
future changes to the adhesive may prevent premature sensor loss due to cutaneous AEs and 
help prevent accidental removal of sensors. These may be particularly important issues 
during adolescence as various lifestyle aspects may contribute to increased risk of cutaneous 
AEs, premature sensor loss, and sensor trauma.  
Strengths of this study include carefully collected data from an independent, non-industry 
sponsored, multi-centre randomised controlled trial, with a systematic approach to collect 
AE data. Inclusion of a control group comparison provided a balanced perspective on 
cutaneous AEs and severity. However, as this study focuses on youth with very high-risk 
glycaemic control, these results may not be generalizable to other youth or age groups. The 
active management of second and greater cutaneous AEs may have also reduced the AE 
rate, contributing to under-reporting. Regardless, this study reflects real world management 
of these issues and does not impact initial cutaneous AE reporting.  
In conclusion, use of the Freestyle Libre FGM system results in frequently experienced 
cutaneous AEs which are reported at a similar rate to SMBG-associated AEs. 
Discontinuation over a six-month period due to cutaneous adverse events appears rare, with 
the majority of AEs rated as mild. While sensor loss is common among youth in this study 
population, this did not relate to cutaneous AEs. Awareness of these cutaneous issues and 
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Background: Although strategies to prevent premature sensor loss for flash glucose 
monitoring (FGM) systems may have substantial benefit, limited data is available. This 
study among youth with high-risk type 1 diabetes mellitus evaluated whether an additional 
adhesive patch over FGM sensors would: reduce premature sensor loss frequency and not 
cause additional cutaneous adverse events (AEs). 
Methods: This is a six-month, open label, randomised crossover trial. Participants were 
recruited at completion of prior ‘Managing Diabetes in a Flash’ randomised controlled trial 
and allocated to three months of Freestyle Libre FGM sensors with either standard adhesive 
(control) or additional adhesive patches (RockaDex, New Zealand) (intervention), before 
crossing over to the opposite study arm. Participants self-reported patch use or non-use, 
premature sensor loss and cutaneous AEs fortnightly via an electronic questionnaire. 
Results: Thirty-four participants were enrolled: mean age (±SD) 17.0 (±2.2) years; mean 
HbA1c (±SD) 89 (±16) mmol/mol (10.3% ±1.4%). The response rate of questionnaires was 
77% (314/408). Premature sensor loss was reported in 18% (58/314) of questionnaires: 20% 
(32/162) from intervention and 17% (26/152) from control (P=0.56). Thirty-eight percent 
(118/314) of questionnaires were non-compliant to protocol allocation. However, per 
protocol analysis showed similar findings. No significant difference in AEs was reported 
between compliant adhesive patch use and non-use (6% [5/78] and 3% [3/118], respectively, 
P=0.27). 
Conclusion: Additional adhesive patch use does not appear to prevent premature FGM 
sensor loss. However, the low risk of AEs and low cost of an adhesive patch suggests an 
individualized approach to their use may still be warranted. 
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3.2 Introduction  
Continuous glucose monitoring (CGM) and flash glucose monitoring (FGM) systems for 
the management of type 1 diabetes mellitus (T1DM) are an increasingly used alternative to 
traditional self-monitored capillary blood glucose (SMBG) (39, 52). CGM and FGM 
systems measure interstitial glucose values, and have a range of potential advantages in 
comparison with SMBG, including improvement in glycaemic control (71-75, 82-84), 
especially when used consistently (77-79).  
Premature sensor loss is a common experience (65, 86, 167), and contributes to negative 
sensor experiences, particularly when the user has self-funded the technology. Hence, the 
use of additional adhesive in an attempt to improve sensor longevity is a common strategy 
used by patients in real life. However, there is no data available to support whether this 
strategy is effective. Further, sensor adhesives, particularly those containing isobornyl 
acrylate, have led to increasingly reported cutaneous adverse events (AEs) (153-156). Thus, 
there is concern that additional adhesives may compound this risk. While common, the 
emerging literature specific to FGM suggests cutaneous AEs are predominantly rated as 
mild (67, 84, 147, 153, 167), and rarely result in the cessation of use (83, 84, 147). Currently, 
measures used to prevent and mitigate cutaneous AEs include education on good hygiene 
regarding site preparation and sensor insertion; barrier sprays, creams and tapes; and 
hydrocortisone cream (70, 129, 134). Newer alternatives for the management of cutaneous 
AEs include fluticasone spray, of which research is ongoing (160).  
Although data concerning the epidemiology and prevention of AEs is expanding, literature 
discussing sensor duration and methods to optimize comfort and duration are limited. 
Previous data has suggested premature loss occurs in 7-32% of CGM sensors (65) and 24% 
of FGM sensors (167). In particular, one study among youth with unhealthy glycaemic 
control found while the majority of users experienced at least one episode of premature 
sensor loss, the majority were due to adhesive issues and not AEs (167). Additionally, sensor 
duration has recently been raised as one of the key barriers to adolescent use and success 
with FGM (86). Particular concerns arise among children and adolescents engaged in 
activities such as contact sport, physical work, and even the action of changing clothes which 
all present opportunities for sensor adhesive to become compromised and may contribute to 
reduced sensor life (70, 129, 147).  
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Given the substantial costs to patients and health systems of funding sensors, strategies to 
optimize sensor adhesion and sensor life could be of considerable benefit. Therefore, this 
study aimed to evaluate whether adding an additional adhesive patch to FGM sensors among 
youth with T1DM: 1) reduces the frequency of premature sensor loss; and 2) does not 
contribute to additional cutaneous AEs.  
 
3.3 Methods 
3.3.1 Participants and study design 
This was a six-month, open label, randomised crossover study. All participants, at 
completion of the six-month ‘Managing Diabetes in a Flash’ randomised controlled trial 
(RCT) (1) were invited to be included in this adhesive sub-study. In brief, participants were 
aged 13-20 years at the commencement of the RCT, with T1DM duration ≥ 12 months, and 
high-risk glycaemic control (mean pre-study HbA1c ≥ 75 mmol/mol [≥9%] over the 
previous 6 months). There were no additional inclusion or exclusion criteria for this sub-
study. Participants who consented to the adhesive sub-study were randomised into two 
groups by an offsite biostatistician. For the first three months of this study, group one were 
allocated to receive the intervention phase first, and were provided with a three-month 
supply of adhesive patches to place over the sensor. Group two were allocated to the control 
phase first and instructed not to use any additional adhesive products to prevent sensor loss. 
For the second three-month portion of this study, each group crossed over [Figure 8].  
When participants were scheduled to receive the intervention, a variety of coloured 
RockaDex adhesive patches [https://www.rockadex.co.nz, RockaDex, New Zealand (NZ)] 
were provided. RockaDex adhesive patches are kinesiology tape pre-cut for the FGM sensor 
and do not obscure the sensor nor the hole for ventilation. The adhesive patch is made from 
cotton, nylon and acrylic and contains no latex, zinc oxide or isobornyl acrylate. Prior to the 
commencement of FGM, all participants were advised on good hygiene regarding site 
preparation and sensor insertion (as recommended by the manufacturer) to help prevent 
cutaneous AEs. Adhesive removal wipes and education on patch removal were provided to 
all participants to allow patches to be replaced if required during an ongoing FGM sensor 
session. Alternatively, participants were able to apply an additional RockaDex patch over 
top of the existing patch.  
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Ethics approval was granted by the Southern Health and Disability Ethics Committee 
(17/STH/240) and conforms to the provisions of the Declaration of Helsinki. The trial was 
registered with the Australian New Zealand Clinical Trials Registry 
(ACTRN12618000320257p; http://www.anzctr.org.au/ACTRN12618000320257p.aspx 
and was issued a Universal Trial Number (U1111–1205-5784) by the World Health 
Organization International Clinical Trials Registry. 
3.3.2 Data collection  
Data were collected from April 2018 to November 2019. Baseline demographic and clinical 
data from participants were collected at the start of the RCT, with the exception of age, 
height, weight, duration of diabetes and HbA1c data which were updated at the 
commencement of this sub-study [Table 5]. During this sub-study, participants were sent an 
identical safety questionnaire every 14 days which was timed to coincide with the day each 
sensor change was due [Appendix 1h]. Each participant received 6 questionnaires per 
intervention phase and 6 questionnaires per control phase, totalling 12 questionnaires over 
the 6-month (24 week) period. After the first three-month phase of this study, questionnaire 
timing was adjusted to account for previous sensor loss and changes to the scheduled study 
visit time. Thus, no washout period was required between study arms. Each safety 
questionnaire included questions regarding use or non-use of an adhesive patch (to report 
adherence to the study protocol), if the participant experienced a sensor loss (defined as loss 
prior to the expected 14-day duration), and any cutaneous AEs the participant experienced 
and the corresponding severity. Information was collected electronically and managed using 
the survey administration tool REDCap™ (Research Electronic Data Capture) (165, 166). 
Up to three contact attempts were made to non-responders. Participants were also asked to 
send photos of cutaneous AEs to research staff to aid in documenting and describing AEs. 
3.3.3 Statistical analyses 
Appropriate summary statistics were calculated for all variables of interest (means and 
standard deviations for normally distributed continuous variables, medians with 25th and 75th 
percentiles for non-normally distributed continuous variables, and counts and percentages 
for categorical variables). A linear mixed binomial model with sensor loss as the response 
variable was fitted. For the intention to treat analysis, the predictor of interest was patch 
allocation. For the per protocol analysis, we removed all questionnaires where patch use 
differed from patch allocation. A model with patch use as a predictor was also used with 
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sex, the NZ deprivation index (NZDep13; a measure of socioeconomic status (43)), and 
study phase as fixed effects, in addition to a random intercept for each participant. The odds 
ratio was estimated for all coefficients. All confidence intervals (CI) are 95% and all P-
values were calculated using Fisher’s exact test. P-values below 0.05 were considered 
statistically significant. Baseline demographic and clinical characteristic statistical analyses 
were performed using Stata® v15.1 (StataCorp LLC, Texas, US). All other statistical 




Figure 8: Adhesive study CONSORT flow diagram; n represents individuals unless 
otherwise stated. 
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3.4.1 Patient characteristics 
A total of 34 of 64 participants who completed 6-months of the ‘Managing Diabetes in a 
Flash’ trial were recruited into this study. There were 17 participants randomised to receive 
the adhesive patches first and 17 were randomised to the control group, before crossing over 
after 3-months. Baseline demographic and clinical data are summarized in Table 5 and were 




Table 5: Participant characteristics 
Variable, n (%) Participants (n=34) 
Age (years), mean (± SD) 17.0 ± 2.2 
Malea 20 (59) 
Prioritized ethnicitya  
 New Zealand European/European 21 (62) 
 Māorib 8 (24) 
 Pacific Islander 5 (15) 
Deprivation (NZDep2013)a  
 Low deprivation (score: 1-3) 11 (32) 
 Medium deprivation (score: 4-7) 16 (47) 
 High deprivation (score: 8-10) 7 (21) 
BMI z-scorec, median (IQR) 0.81 (0.04-1.44) 
Duration of diabetes (years), mean (± SD) 8.8 ± 3.6 
HbA1c (mmol/mol), mean (± SD)  89 ± 16 
Insulin regimena  
 MDI 29 (85) 
 CSII 5 (15) 
Previous skin problema, d  
 Non-specific eczema 5 (15) 
 Adhesive reactione 1 (3) 
 Other 2 (6) 
aData obtained from the primary study. bMāori are the indigenous population of New 
Zealand. cBMI z-score calculated using Centre for Disease Control Guidelines; two 
participants unable to generate BMI z-score as over 20 years of age at the commencement 
of this study. dPrevious skin problem was self-reported; eOne participant reported a non-
specific skin reaction to a surgical dressing. SD, Standard deviation; NZDep2013, New 
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Zealand deprivation index 2013, a marker of socioeconomic status; BMI, Body mass index; 
HbA1c, Glycated haemoglobin A1c; MDI, Multiple daily injections; CSII, Continuous 
subcutaneous insulin infusion.  
3.4.2 Intention to treat analysis 
The response rate of completed questionnaires was 77% (314/408). There was no significant 
difference in response rate between the first three-month phase and the crossover phase of 
this study. Overall, premature sensor loss was reported in 18% (58/314) of questionnaires, 
involving 65% (22/34) of participants. Twelve percent (4/34) of participant’s experienced 1 
premature sensor loss, 35% (12/34) participants experienced 2-3 premature sensor losses 
and 15% (5/34) participants experienced ≥4 premature sensor losses. Regardless of 
allocation, among participants that reported sensor loss, 50% (11/22) participants had the 
same proportion of premature sensor loss with and without patch use, 27% (6/22) 
participants had a higher proportion of premature sensor loss with patch use and 23% (5/22) 
participants had a lower proportion of premature sensor loss with patch use compared to no 
patch.  
Sensor loss was reported in 17% (26/152) of questionnaires from participants allocated to 
control and 20% (32/162) of questionnaires from participants allocated to intervention 
(OR=1.20, CI=0.65-2.21, P=0.56) [Table 6, Figure 9]. With regards to actual use of the 
adhesive patch, regardless of allocation, 21% (23/112) of questionnaires that used a patch 
reported sensor loss, whereas 17% (35/202) of questionnaires which did not use the patch 
reported sensor loss. There was no significant difference in sensor loss between these two 
groups (OR=1.23, CI=0.65-2.30, P=0.54). The linear mixed model showed the unadjusted 
estimate of the odds ratio for patch loss, under intention to treat, was 1.28 (CI=0.66-2.47, 
P=0.46). Similarly, when adjusted for sex, NZDep13 and study phase, this was also not 
significant (OR=1.04, CI=0.31-3.45, P=0.26), nor if patch use (rather than allocation) was 
the predictor (OR=1.04, CI=0.32-3.43, P=0.79). 
3.4.3 Per protocol analysis 
Overall, 38% (118/314) of questionnaires were non-compliant to the allocation of use or 
non-use of an adhesive patch. 22% (34/152) of questionnaires of participants allocated to 
control reported using a patch. Comparatively, 52% (84/162) of questionnaires from 
participants allocated to the intervention did not use the adhesive patch.  
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A per protocol analysis was therefore completed, with all questionnaires that were non-
compliant with allocation and adhesive use or non-use excluded, leaving 196 questionnaires 
available for analysis. Premature sensor loss was reported in 15% (18/118) of questionnaires 
compliant with no adhesive patch use and 19% (15/78) of questionnaires compliant with the 
adhesive patch use (OR=1.49, CI=0.60-3.75, P=0.38) [Table 6, Figure 9]. When controlled 
for sex, deprivation and study phase this comparison was also not significant (OR=1.49, CI= 
0.48-4.62, P=0.26).  
 
A)   B)  
Figure 9: Reported sensor longevity by intervention group: A) Intention to treat analysis 
(comprised of all completed questionnaires); B) Per protocol analysis (comprised of 
completed questionnaires compliant with patch allocation); Green represents sensors with 








































































































3.4.4 Cutaneous adverse events 
Overall, there were 19 cutaneous AEs, involving 26% [9/34] participants. One cutaneous 
AE was reported for every 33 weeks of use. With regards to severity 58% [11/19] reports of 
cutaneous AEs were rated as mild, 42% [8/19] were rated as moderate and no AEs were 
rated as severe. There was no significant difference between reports of cutaneous AEs 
between the control and intervention group (7% [10/152] and 6% [9/162] respectively, 
P=0.81) nor for the per protocol analysis between the control and intervention group 
allocation when participants reported being compliant (3% [3/118] and 6% [5/78] 
respectively, P=0.27). 
 
Table 6: Comparison of premature sensor loss and cutaneous adverse event reports 
Analysis Variable, n (%) 
Questionnaires 






Intention to treat 
Premature sensor loss 26/152 (17) 32/162 (20) 0.56 
Cutaneous adverse event 10/152 (7) 9/162 (6) 0.81 
Per protocol 
Premature sensor loss 18/118 (15) 15/78 (19) 0.38 
Cutaneous adverse event 3/118 (3) 5/78 (6) 0.27 
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3.5 Discussion  
While simple in design, this is the first randomised trial to evaluate if FGM sensor life can 
be prolonged by adding an additional adhesive patch. The main finding is that there is no 
difference in rate of premature sensor loss before the expected 14-day sensor session life, 
whether or not an adhesive patch is used. Overall premature sensor loss was reported in 18% 
of sensor sessions. In addition, minimal cutaneous AEs were experienced by both groups, 
suggesting the use of additional adhesive patches is not harmful, and does not appear to 
contribute to the burden of cutaneous AEs. 
Premature sensor loss is an important issue, with sensor loss of CGM and FGM occurring 
in approximately 7-32% of CGM use among adults (65) and 24% of FGM sensors among 
youth (167). Importantly, one observational study found when all FGM sensors are secured 
by an additional plaster, premature sensor loss was numerically lower and occurred in 20% 
of sensors (169). As sensors are a considerable cost to healthcare, a simple cheap patch 
(approximately 1 USD) is an attractive concept to prolong sensor life. Although, the overall 
percentage of FGM sensors which ended prematurely in this study was reduced compared 
to previous studies (167, 169), data from this study was not supportive of routine use of 
additional adhesive patches. However, this study found that at an individual level, 23% of 
people may have experienced the benefit of fewer reported premature sensor with patch use, 
compared to no patch use, suggesting that it remains possible there is a cost-benefit for 
certain individuals.  
Importantly, cutaneous AEs were minimal and similar between groups. These have been 
studied previously and show FGM associated cutaneous AEs are common (67, 84, 147, 153, 
167). Although a recent study reported a rate of 1 cutaneous AE per 18 weeks of FGM use 
(167), the rate of AEs in this study was lower, at a rate of 1 cutaneous AE per 33 weeks of 
FGM use. Previous studies have shown that the adhesive component of the sensor, which 
contains isobornyl acrylate (154), has been identified as the probable cause for some FGM-
associated cutaneous AEs (130, 136, 146, 147, 154). Thus, given there is a clear need for 
measures to prevent premature sensor loss and adhesive patches may benefit some 
individuals, safety is important, especially regarding the use of additional adhesives. The 
additional adhesive patches used in this study do not contain isobornyl acrylate which may 
provide a possible reason why an increase in cutaneous AEs was not associated with patch 
use. In addition, study participants were actively managed by research staff and 
recommendations for the prevention and management of cutaneous AEs, associated with 
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either the FGM sensor or the additional adhesive patch, which could also suggest a reason 
for the minimal cutaneous AEs reported. However, it is possible if participants experienced 
a FGM-associated AE they chose not to use or continue to use an adhesive patch when 
allocated. 
The key strength of this study is data collected from an independent, non-industry sponsored 
randomised crossover trial, which has a systematic methodology and approach to data 
collection. The adjustment of questionnaire timing prior to crossover enabled previous 
sensor loss to be accounted for and ensured questionnaires were both timed to coincide with 
each 14-day sensor and consistent throughout the trial. The novel comparison between the 
use of an additional patch compared with no additional measures to prolong sensor life is 
also important. However, as this study focused on a small group of youth from a wider study 
with high-risk glycaemic control, the generalizability of these findings remains unclear. Past 
studies have found youth have reduced adherence to T1DM management (38, 107), 
including misreporting of SMBG (55, 56). As premature sensor loss and adhesive patch use 
data were self-reported by participants, it is possible that participants falsely reported sensor 
loss or patch use, which could suggest why similar rates of sensor loss were reported with 
and without patch use. This may provide a reason for the non-adherence seen, but also it is 
reassuring that the premature sensor loss rate was only 18% in this highly complex patient 
population. In addition, the exact duration of each sensor was not collected in this trial. Thus, 
it is possible that the use of an additional adhesive patch prolonged sensor life, but not for 
the entire 14-day period.  
In conclusion, this randomised crossover trial provides no evidence that an additional 
adhesive patch has any significant advantage for the prevention of premature FGM sensor 
loss compared to no additional adhesive. Importantly, this study also found the use of an 
additional adhesive patch did not contribute to additional cutaneous AEs. Ultimately, while 
the results of this trial suggest additional patches should not be routinely recommended, 
given their low risk and cost, with some possible benefits in some individuals, an 
individualized approach to their use is warranted. 
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 General Discussion  
4.1 Discussion 
This thesis aimed to expand on emerging literature regarding the extent and nature of 
cutaneous AEs associated with FGM systems, as well as explore the issue of early sensor 
loss and a potential method to prevent this. The specific aims of this thesis were to: evaluate 
participant reported cutaneous AEs and sensor use associated with the Freestyle Libre FGM 
system in comparison with usual care involving SMBG; and, evaluate whether an additional 
adhesive patch over FGM sensors reduced the frequency of premature sensor loss, without 
contributing to additional cutaneous AEs. Importantly, this thesis focuses on youth with 
T1DM and high-risk glycaemic control.  
These research objectives were developed to take advantage of the ‘Managing Diabetes in 
a Flash’ RCT which was fully established and running at the commencement of this thesis 
(1). To re-cap, this main study comprised of a six-month RCT, in which participants received 
either the Freestyle Libre FGM system or usual care with SMBG, followed by a six-month 
continuation phase in which all participants received FGM. Chapter 2 (Study 1) utilises data 
from the six-month RCT and Chapter 3 (Study 2) takes advantage of the continuation phase 
for a crossover trial. Accordingly, the studies incorporated into this thesis provide exposure 
to various research methodologies involving survey data collection and subsequent analyses. 
The two studies included in this thesis complement each other. In particular, both studies 
illustrate cutaneous AEs and premature sensor loss are commonly experienced issues 
associated with FGM use among youth with T1DM and high-risk glycaemic control. In 
Chapter 2 (Study 1), the key findings indicate cutaneous AEs are common among FGM use, 
and although sensor loss is frequently experienced, they often result due to adhesive issues, 
not cutaneous AEs. Chapter 3 (Study 2) further reinforces premature sensor loss is common 
and indicates that the use of an additional adhesive patch to prevent sensor loss, in general, 
is not effective among this population. Consequently, these studies highlight implications 
for current and emerging glucose monitoring technologies. 
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4.1.1 Extent and nature of cutaneous adverse events with flash glucose 
monitoring systems 
The two studies included in this thesis illustrate FGM-related cutaneous AEs are common 
and experienced by a large portion of users. The findings from these studies indicate 26-
58% of users will experience at least one cutaneous complication associated with FGM over 
a six-month period. This confirms the findings of a recent systematic review completed in 
2019 (146), although, the proportion of individuals that experience dermatological AEs with 
FGM widely varies between studies, ranging from 6-55% of participants (67, 82-84, 147, 
148). Notably, the range reported in the systematic review includes studies in which 
cutaneous AEs were either self-reported or confirmed by clinicians (146). Thus, the variation 
is likely due to contrasting methodologies utilized to capture cutaneous AEs (146). 
Importantly, this thesis found the majority of cutaneous AEs were rated as mild. This is 
similar to existing evidence, which highlights mild cutaneous AEs are frequently 
experienced by FGM users (66, 67, 83, 84, 147-149). Although there is currently no 
evidence that frequent mild cutaneous complications contribute to poorer quality of life, 
recurrent cutaneous AEs may increase the burden associated with T1DM management. 
Chapter 2 (Study 1) further illustrates that compared to SMBG, FGM-related cutaneous AEs 
occur at a similar rate and severity. Notably, results indicate the frequency of particular 
cutaneous symptoms varied between the two glucose management methods, with erythema 
most commonly reported among FGM users and skin hardening among SMBG users. This 
suggests that, while FGM reduces certain burdens associated with SMBG such as regular 
finger pricking (66, 86, 149), issues with cutaneous complications are still a commonly 
experienced problem with FGM. Moreover, in accordance with current literature, both 
Chapter 2 (Study 1) and Chapter 3 (Study 2) indicate the majority of FGM users will 
continue to use these devices despite experiencing cutaneous issues (83, 84, 147, 148). The 
low rate of discontinuation among this real world study, may be attributable to the 
differences in cutaneous symptoms, in combination with patients preferring to tolerate FGM 
cutaneous AEs, rather than revert back to SMBG (66, 86, 149). Thus, the perceived benefits 
of FGM on quality of life and glycaemic control in comparison to SMBG (68, 82-84, 86, 
87) may be a contributing factor to continuing FGM use. 
In addition, several proposed measures to reduce and manage cutaneous symptoms 
including additional adhesive patches or cohesive bandages, are low cost and low burden 
options which can be individualised to the patients’ particular situation and preferences (70, 
58 
129, 134). For the studies included in this thesis, participants were informed of methods to 
promote skin integrity and prevent cutaneous AEs as well as given 24-hour access to 
research staff to aid in the management of any cutaneous complications experienced. This 
may explain why the rate of cutaneous AEs experienced in these studies was lower than the 
previous systematic review indicates (146) and may also contribute to the low rate of 
discontinuation. Accordingly, prevention and mitigation of cutaneous AEs related to FGM 
use are vital to improving user experience and minimising the potential burden of commonly 
experienced cutaneous AEs. Emerging methods to mitigate cutaneous AEs, such as the use 
of fluticasone spray, although not suggested to participants in the studies included in this 
thesis, may further reduce the rates and severity of cutaneous AEs (134, 160).  
4.1.2 Impact of cutaneous adverse events on premature sensor loss 
Secondly, this thesis supports current evidence that premature FGM sensor loss is commonly 
experienced and indicated the majority of FGM users will experience at least one premature 
sensor loss over a six-month period (32, 65, 70, 86, 129, 130). In addition, Chapter 2 
identifies causes of premature sensor loss and found cutaneous AEs are not the predominant 
cause, suggesting the impact of cutaneous complications on sensor loss is minimal. Instead, 
these results illustrate FGM sensor loss commonly occurs due to issues with sensor adhesion, 
including spontaneous separation or accidental removal from being knocked, in accordance 
with current suggestions of why sensor loss may occur (70, 86, 129, 130). This is of 
particular relevance due to the high frequency of cutaneous AEs reported in Chapters 2 and 
3, and in recent studies (66, 67, 83, 84, 147-149). 
Current CGM and FGM literature indicates the cost is a significant barrier to use and a 
common reason for patient discontinuation (30, 87, 88). Thus, premature sensor loss may be 
particularity frustrating and burdensome, particularity for funders. This is of particular 
relevance to individuals in NZ as, although SMBG supplies have public funding, there is 
currently no public funding available for patients to access FGM (US$1600 per year) (89). 
Thus, premature sensor loss may place a substantial financial burden on NZ patients. 
Accordingly, this thesis, in conjunction with previous data, reinforces that the prevention of 
premature sensor loss is essential to future care and may improve FGM usability (70, 129, 
134). Greater improvements in glycaemic outcomes are associated with consistent and 
increased use of CGM devices, especially among individuals with high-risk glycaemic 
control (77-79). One recent study among youth in particular, demonstrated that CGM use 6-
7 days per week compared to 0-5 days per week was associated with an average 
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improvement in HbA1c of 5.5 mmol/mol (0.5%) after six-months (79). Thus, in combination 
with the similarities between the positive impact of CGM and FGM use on HbA1c (71-77, 
82-84) and quality of life (68, 85-87), increased use of FGM may have further benefits. 
However, in some instances, when an individual experiences a premature FGM sensor loss, 
a replacement may not be readily accessible or able to be inserted. As a result, sensor loss, 
especially frequent loss, may lead to temporary discontinuation or transient use, potentially 
reducing glycaemic or psychological outcomes. Consequently, the prevention of FGM 
sensor loss is essential for improving the usability of this system as well as potentially 
improving clinical outcomes and reducing the overall burden of T1DM management.  
4.1.3 Impact of sensor loss prevention methods 
Thirdly, a key finding from Chapter 3 is that although the overall percentage and rate of 
premature FGM sensor loss was lower than reported in Chapter 2 and in existing literature 
(65, 86), the routine use of an additional adhesive patch was not of significant benefit for 
reducing premature sensor loss. Although not beneficial at a whole study level, Chapter 3 
identified that certain individuals did perhaps benefit from the use of a supplementary 
adhesive. In particular, some individuals who did report sensor loss without a patch, reported 
a significant reduction in sensor loss with patch use. Thus, this supports current literature 
that suggests attempts to prolong sensor life need to be individualised to help reduce 
commonly experienced premature sensor loss and the associated financial and clinical 
burden (70, 129). 
Importantly, given there are known issues regarding cutaneous impacts of FGM adhesives 
(130, 153-156), safety is an essential aspect of potential prevention measures, particularly 
with the use of supplementary adhesives to promote sensor longevity (129, 130, 134). A key 
finding from Chapter 3 was that the use of the additional custom designed RockaDex patch, 
did not contribute to additional cutaneous complications. Notably, there were minimal 
differences in the rate and proportion of individuals who experienced cutaneous AEs 
between use and non-use of the RockaDex patch, likely due to the composition of the patch 
and the absence of known causative allergens including isobornyl acrylate (153-156). The 
active management by research staff to assist in the mitigation of cutaneous AEs throughout 
the primary study may also be a contributing factor to the lower rates of cutaneous AEs 
described in comparison to recent literature and findings from Chapter 2 (70, 129, 134). 
Overall, the low incidence of cutaneous complications demonstrated in Chapter 3 suggests 
the use of supplementary adhesive tapes, such as RockaDex, are not harmful and do not 
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appear to contribute to the burden of cutaneous AEs. Thus, a low cost and low burden option 
of an adhesive patch is an attractive concept for some individuals to attempt to prolong 
sensor life, reduce barriers to FGM and improving usability (129, 134). 
As this thesis only focused on one method to prolong sensor duration using an additional 
adhesive patch, future research to establish the effect of other measures would be beneficial 
(134). Further investigation into the impact of prevention measures on the precise duration 
of sensor life is also warranted and could provide a better indication of their effect. 
Typically, clinics often recommend limiting the number of additional prevention methods 
involving adhesives to attempt to avoid cutaneous complications, although adhesives and/or 
other methods used in combination may provide further benefit for prolonging sensor 
duration (70, 129, 134). Therefore, it is crucial to take into account both individual 
circumstances and preferences, in addition to potential benefit (70, 129). For instance, 
anecdotally, some patients may find self-applying a supplementary adhesive or external 
cohesive wrap may be difficult or may feel they are too noticeable and draw unwanted 
attention, thus reducing the usability and potential benefit of these options. This may provide 
a reason for the non-adherence with patch use reported in Chapter 3. Consequently, certain 
individuals, may benefit from other prevention methods, such as the use of liquid adhesives 
applied to the skin before insertion (129, 134). Accordingly, given premature sensor loss is 
an important and common issue, and an individualised approach to prevention is warranted, 
these findings prompt additional investigation and consideration of other methods to prolong 
sensor life.  
4.1.4 Implications for current and emerging glucose monitoring 
technologies 
Given the pivotal role of glucose monitoring devices for future T1DM care and the 
development of a fully automated insulin delivery system (6, 32), reducing the burden and 
improving the usability of glucose monitoring systems is vital. As demonstrated by this 
thesis and current literature, the majority of FGM users (83, 84, 147, 148), as well as CGM 
users (126), will continue to use these devices despite frequently experienced mild cutaneous 
AEs and premature sensor loss. This highlights that although mitigation measures are often 
utilised (70, 129, 134), the underlying cause of these issues also needs to be addressed (134). 
Firstly, changes to glucose monitoring systems need to occur to enable a reduction in 
cutaneous AEs related to sensor insertion or application (130, 134). Cutaneous 
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complications regarding sensor insertion could be minimised by increasing the longevity 
and durability of sensors, enabling longer time between replacements (130). Although not 
yet available in NZ, the implantable Eversense CGM can remain implanted under the skin 
for up to 180 days before requiring replacement (32, 90, 91). As the Eversense CGM requires 
a healthcare professional to implant the sensor, potentially with improved hygiene compared 
to most users, this, in combination with a longer duration between sensor replacements, may 
contribute to a reduction in cutaneous AEs related to sensor application (91). However, it is 
important to take into consideration that increased duration between sensor replacements 
may exacerbate cutaneous AEs associated with sensor wear, emphasising the importance of 
addressing improvements to adhesives. While research is emerging, existing literature 
describes only 10% of Eversense users experienced a cutaneous AE (160), compared to 26-
58% of FGM users as indicated in this study. Similarly, the majority of these cutaneous 
complications are rated as mild, although the cutaneous AEs related to the implantable CGM 
were all attributable to sensor insertion and not sensor wear (160). Thus, emerging research 
suggests despite increased sensor duration, this alternative approach to glucose monitoring 
technology may have a significant benefit to the reduction in cutaneous complications, 
especially related to sensor wear (91). Alternatively, the perceived reduction in cutaneous 
AEs associated with the Eversense CGM may be attributed to under-reporting which is 
common among initial, company funded studies (82, 84, 91) 
Secondly, changes to the adhesives used to secure the sensor could also provide a solution 
to frequently experienced cutaneous AEs related to sensor wear (130, 134). In some cases, 
the identification of causative agents for cutaneous complications has led to their removal. 
For instance, ethyl cyanoacrylates identified as a causative factor for contact dermatitis (151, 
152) present in the adhesive of the Dexcom Platinum G4 CGM was removed in subsequent 
versions (170). Similar alterations could be seen with FGM sensors with the removal of 
isobornyl acrylate (153-156). In addition, further research to identify any other contributing 
allergens present in all glucose monitoring technologies is required to inform patients with 
known sensitivities and encourage manufacturers to make alterations to the adhesives used 
(134).  
Finally, as this thesis demonstrates premature sensor loss is frequently experienced by the 
majority of FGM users, improving sensor durability for both FGM and CGM systems is 
essential to the usability of these devices (70, 129). For instance, increasing the adhesion of 
the adhesives used could prevent premature sensor loss from physical activities or 
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accidentally being knocked. Changes to the composition of the adhesives used for better 
adhesion despite sweating or water-based activities is an alternative. Notably, while the 
Eversense CGM sensor is implanted subcutaneously, the transmitter, held over the sensor 
and secured by adhesives, can be removed and replaced at any time without requiring the 
replacement of the sensor (90, 91). Accordingly, whether spontaneous or accidental, or due 
to cutaneous AEs, the removal of the transmitter does not impact the subcutaneous sensor 
(90, 91). This has the potential to be more easily managed as there is no need to replace both 
the subcutaneous and external component of the sensor which occurs with premature sensor 
loss among FGM and CGM systems, thus assisting in improving usability and consistent 
use. However, it is important to take into consideration that improved sensor durability and 
increased duration between sensor replacements may exacerbate cutaneous AEs associated 
with sensor wear, emphasising the importance of addressing improvements to adhesives.  
Ultimately, removing the need to use adhesives entirely could have a substantial benefit on 
usability and consequent clinical outcomes. However, current and emerging technology 
indicate adhesives are likely to remain a vital component of these devices in the near future 
(146). Consequently, changes should be made, predominantly to the adhesives, to improve 
the usability of glucose monitoring devices and reduce the burden of T1DM management. 
Moving forward, once alterations to current and emerging glucose monitoring systems have 
been made to reduce cutaneous complications and premature sensor loss, these technologies 




The key strengths of this thesis include the incorporation of two complementary non-
industry sponsored studies conducted using systematic methodologies to investigate 
cutaneous AEs and premature sensor loss with FGM use among youth with T1DM and high-
risk glycaemic control. The focus on youth with high-risk glycaemic control is of particular 
importance given how prevalent elevated HbA1c is during this life stage (36-39). Thus, 
methods to improve HbA1c among this age group are vital for long-term management and 
reducing the risk of diabetes-related complications (2, 7, 30, 31, 33, 34). While existing 
literature indicates FGM systems is associated with less pain and bleeding compared to 
SMBG (66, 86, 149), no existing studies provide a comparison of cutaneous AEs between 
the use of FGM and SMBG among youth (66, 67, 83, 84, 147-149). Thus, the novel study 
design and findings of Chapter 2 are vital to establishing a direct comparison between FGM 
and SMBG using the same cohort and study methods and importantly, illustrate perceived 
experiences of associated cutaneous AEs occur at similar rates and severity between the two 
glucose monitoring methods.  
For both studies, data was carefully collected electronically and managed using the 
REDCap™ survey administration tool across all participating research centres (165, 166). 
Frequent questionnaires reduced potential effects of recall bias as participants were able to 
report cutaneous AE and sensor loss data at regular intervals, timed to coincide with each 
14-day FGM sensor. For Chapter 3, the timing of the questionnaires was also adjusted prior 
to the start of the study, and again at the crossover period, to account for previous sensor 
loss and changes to the scheduled study visit time. In addition, up to three contact attempts 
were made for each questionnaire to encourage response. This may explain the overall high 
response rate of 83% and 77% for Chapters 2 and 3, respectively, which is of particular 
significance given the non-adherence demonstrated in Chapter 3 and non-adherence to 
overall T1DM management suggested by all participants’ high-risk glycaemic control.  
Finally, despite sensor loss described as a common issue with both CGM and FGM use, no 
studies to date have illustrated a rate of sensor loss (32, 70, 86, 129, 130). This is unique and 
important data that has emerged from both studies and assists in establishing the prevalence 
of premature sensor loss in a real world setting. Similarly, Chapter 3 yields information 
about the impact of an additional adhesive patch on FGM sensor loss, which, to the best of 
my knowledge, has not been reported before. Given the clear need for methods to prevent 
premature sensor loss, the impact of various options to promote sensor longevity is essential 
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for informing patients to develop a beneficial and individualised approach (70, 129). In 
particular, as an adhesive patch is a commonly used clinical tool, without any prior evidence 
supporting its use, this research highlights this important issue and prompts additional 
investigation of the effectiveness of other alternatives on reducing premature sensor loss 
(70, 129, 134). 
4.3 Limitations  
As with all research, the work described in this thesis has limitations. Of particular 
importance, the generalisability of these results is unclear as this thesis focuses on youth 13-
20 years of age with high-risk glycaemic control, as reinforced by the substantially elevated 
HbA1c of this population. Youth in general, often have reduced adherence to diabetes 
management primarily due to the challenges associated with adolescence (51, 93, 103). 
Other contributing factors to reduced adherence among youth include diabetes-related 
psychological complications, particularly prevalent, which is associated with elevated 
glycaemic control (2, 114, 115). With regards to the findings of this thesis, acceptability and 
compliance to study protocols may have also impacted the self-reported SMBG and FGM 
cutaneous AEs as well as premature sensor loss, especially related to patch use or non-use. 
For instance, as elevated HbA1c is associated with reduced SMBG (32, 46-49), the rate of 
SMBG-related cutaneous AEs may be under-reported. Alternatively, non-adherence to 
guidelines for the prevention or management of cutaneous AEs may have increased their 
risk of cutaneous complications and subsequently led to an over-report of cutaneous AEs. 
Moreover, emerging research indicates the relationship between glycaemic control and 
physical activity is complex, especially among youth (44). Therefore, given cutaneous AEs 
and premature sensor loss may be exacerbated by exercise and sweating (70, 86, 129, 130), 
the prevalence of these issues may vary depending on levels of exercise, age or glycaemic 
control. Consequently, the generalisability of the findings in this thesis may be limited. 
Regarding Chapter 3, an additional limitation is participants were self-selected for inclusions 
into this study once they had completed Study 1 (Chapter 2). Although, the majority of FGM 
users continued use despite cutaneous AEs, it is possible individuals who had experienced 
cutaneous AEs or premature sensor loss, especially recurring or of increased severity, during 
Study 1, may have opted not to be included in Study 2. In addition, one intervention 
participant discontinued FGM during the first study and did not complete the initial study, 
thus was not invited into the second study. In combination, this may have led to a selection 
bias. Furthermore, as approximately half of those recruited into the first study (n=64) 
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accepted inclusion into this study (n=34), generalisability is limited due to this small sub-
group of individuals.  
Finally, another limitation of this thesis is data were obtained from self-reported 
questionnaires. With regards to cutaneous AEs associated with CGM and FGM, the reported 
occurrence is typically higher when the site is inspected by research staff or clinicians (66), 
compared to when self-reported (171). Thus, cutaneous AEs findings from this thesis may 
be under-reported. On the other hand, as premature sensor loss and use of an additional 
adhesive patch for Chapter 3, were self-reported, it is possible that participants falsely 
reported sensor loss or patch use, which could provide a reason premature sensor loss was 
similar whether a supplementary patch was used or not. Although obtaining this data would 
potentially have been more accurate if confirmed by research staff, this methodology would 
may have been too resource intensive and may have presented unnecessary or additional 
burden on participants. 
4.4 Future directions 
Findings from this thesis, in combination with existing research, indicate several important 
considerations for future research as previously mentioned, and are summarised below: 
Firstly, future investigation of cutaneous AEs, premature sensor loss, and associated 
prevention and management methods among a wider range of participants would enable 
more generalizable findings regarding the impact of these FGM-related issues and potential 
solutions. In addition, larger, observational studies over a longer duration would establish 
the rates of these complications over time.  
Secondly, further exploration of methods to prevent and manage cutaneous AEs and reduce 
premature sensor life are necessary. Observational trials, for instance, may assist in 
establishing the benefit of particular prevention or management methods, and their 
subsequent impact on cutaneous complications. Other options, such as the use of fluticasone 
spray applied topically to the site appears a promising alternative (160), although trials are 
awaited to establish its effectiveness for cutaneous AE prevention. With regards to 
prevention of premature sensor loss, further investigation of other methods to promote 
sensor durability, such as cohesive wraps and liquid adhesives (70, 129, 134), are required 
to help assess the impact on sensor duration. Future research would also benefit from 
evaluating precise sensor duration to better establish the effects of prevention methods. 
Longer observational studies with a larger cohort of participants would also assist to better 
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establish the effectiveness of these prevention and management methods for both cutaneous 
AEs and premature sensor loss. In combination, this would contribute towards informing 
guidelines for an individualised approach tailored to the patients’ needs and preferences, 
particularly patients who experience cutaneous AEs with increased severity or have known 
sensitivities to causative allergens identified in FGM adhesives. This may enable patients to 
better manage any cutaneous complications and improve FGM user experience, rather than 
having to return to SMBG which carries particular limitations and burdens. Additionally, 
findings from longer observational studies may provide benefit for prevention and 
management of similar issues experienced with CGM systems.  
Finally, future research among current and emerging glucose monitoring technologies needs 
to include causes and subsequent solutions to reducing cutaneous AEs and premature sensor 
loss. This is of particular importance as, although the removal of adhesives entirely may be 
beneficial, emerging literature indicates adhesives are likely to remain a key component of 
device use in the immediate future (90, 91, 146, 172, 173). For example, all of the following 
emerging glucose monitoring technologies currently require an adhesive component: the 
implantable Eversense sensor (90, 91); minimally invasive CGMs, which uses silicon 
microneedles and a sensing probe to measure glucose values in more superficial layers of 
the skin compared to current technologies (172, 173); and, noninvasive transdermal CGMs, 
which measure glucose through ultrasonically permeated skin sites (174). Thus, further 
investigation of these alternative technologies for glucose monitoring is required to establish 
rates, types and causes of associated cutaneous complications and generate potential 
solutions with the aim of improving user experience and subsequently, quality of life among 




In conclusion, this thesis has examined cutaneous AEs and premature sensor loss among 
youth with T1DM and high-risk glycaemic control. It has demonstrated the cutaneous AEs 
related to FGM use are common and predominantly rated mild and occur at a similar 
perceived frequency and severity compared to SMBG use. In addition, this thesis found 
premature sensor loss is commonly experienced, although the use of an additional adhesive 
patch does not appear to significantly prevent this. Clinicians and patients should be made 
aware of cutaneous complications and premature sensor loss associated with FGM use and 
the importance of providing individualised advice to patients in order to prevent and mitigate 
these issues. Cutaneous AE and premature sensor loss associated with FGM and potential 
prevention methods required further investigation. Importantly, reducing these negative 
experiences with the aim of improving usability of FGM and other glucose monitoring 
technologies, may help improve clinical outcomes and quality of life for individuals with 
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Managing diabetes in a ‘flash’: Investigating a novel glucose monitoring system 




Adolescence is a time when healthy glycaemic control is the hardest to achieve for 
those living with type 1 diabetes mellitus (T1DM). Frequent self-monitoring of 
glucose levels is positively correlated with glycaemic control and thereby 
preventing long-term diabetes complications. Adolescents with sub-optimal 
glycaemic control are typically non-adherent with glucose monitoring. Flash 
glucose monitoring (FGM) technology is a novel technology that allows users to 





The overall study aim is to investigate the use of flash glucose monitoring (FGM) 
in a real-world setting among adolescents with T1D and a history of suboptimal 
glycaemic control. The primary objective is to investigate the impact of 6-months 
of FGM on glycaemic control (as measured by HbA1c). The secondary 
objectives are to investigate the acceptability and feasibility of using FGM to self-
monitor glucose levels, FGM-associated adverse events (i.e. skin problems, 
diabetic ketoacidosis, severe hypoglycaemia), and changes in treatment 




We hypothesize FGM will improve glycaemic control and glycaemic monitoring 
behaviour in adolescents with sub-optimal glycaemic control. Further, we 
hypothesize that FGM will be acceptable to adolescents, will improve their quality 
of life, and reduce the burden of care upon themselves and their caregivers.  
 
Design and Outcomes 
 
This research is divided into two phases. The first phase of this research is a 6-
month randomised controlled trial (RCT) investigating FGM in addition to usual 
care vs usual care (control). The RCT is designed to explore the effectiveness of 
FGM among adolescent patients with type 1 diabetes with a history of suboptimal 
glycaemic control (mean HbA1c ≥75mmol/mol in past 6 months). Adolescents will 
be recruited from the Southern District Health Board (SDHB) catchment (including 
South Canterbury), Canterbury District Health Board (CDHB), and Capital and 
Coast District Health Board (CCDHB). Participants will be randomised in equal 
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numbers to either a 6-month supply of FGM supplies or a waitlist control group. 
The primary outcome will be measured at 6 months.   
During the second 6-month continuation phase of this research, the intervention 
group will be provided FGM for an additional 6-months to explore all outcomes at 
12 months. During the same extended trial period, the waitlist control group will 
crossover and commence FGM for six months. The purpose of offering FGM to 
the waitlist group is to encourage retention and engagement. Neither group will 
undergo a washout period. The longitudinal study of the intervention group will 
enable an investigation of FGM on 12-month outcomes. The 6-month follow-on 
study of FGM among the waitlist control group will provide further evidence of the 
impact of FGM over a 6-month time period.  
 
Primary outcome 
• HbA1c at 6-months 
Secondary outcomes 
 
RCT – between groups analysis at 6 months 
• HbA1c at 3-months 
• Mean number of sensor scans (FGM only)/blood glucose level tests over 
the preceding 14 days  
• FGM acceptability  
• Diabetes treatment satisfaction  
• Quality of life  
• Health economic evaluation 
• Days off from school or work associated with diabetes 
• Clinic visits, GP visits, ED visits, hospital admissions 
• Frequency of FGM-associated adverse events including, but not limited to, 
severe hypoglycaemia, diabetic ketoacidosis, skin irritations and reactions, 
and sensor failures from baseline to the end of the trial period for each 
study group. 
Observational study (continuation study) – within group analysis at 12 months 
• HbA1c (FGM group: baseline – 12 months; Control group (crossing over 
into intervention at 6-months: 6 months – 12 months) 
• Mean number of sensor scans/blood glucose level tests over the preceding 
14 days  
• FGM acceptability  
• Diabetes treatment satisfaction  
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• Quality of life  
• Days off from school or work associated with diabetes 
• Clinic visits, GP visits, ED visits, hospital admissions 
• Frequency of FGM-associated events including, but not limited to, severe 
hypoglycaemia, diabetic ketoacidosis, skin irritations and reactions, and 
sensor failures from baseline to the end of the trial period for each study 
group. 
 
Intervention and Duration 
 
The total duration of the study is 12 months. The randomised controlled trial will 
occur for the first 6 months followed by a 6-month observational (continuation) 
study. Participants allocated to the FGM group will be given a FreeStyle Libre 
reader, a 12-month supply of sensors (given in 3 monthly aliquots), and access to 
FreeStyle Libre software. This is in addition to standard diabetes clinic care, with 
the study only providing support for technical issues with the device. The waitlist 
control group will continue usual standard care for the first six months of the study. 
At six months, the waitlist control group will crossover and be provided a FreeStyle 
Libre reader, a six-month supply of sensors (in 3-monhtly aliquots), and access to 
FreeStyle Libre software. 
 
Sample Size and Population 
 
64 participants will be recruited for the study and equal numbers of participants will 
be allocated to either FGM group or the waitlist control group. The target 
population is Southern District Health Board (SDHB) catchment (including south 
Canterbury), Canterbury District Health Board (CDHB), and Capital and Coast 
District Health Board (CCDHB) adolescent patients with type 1 diabetes aged 13-
20 years, inclusive, with a pre-study mean HbA1c of ≥ 75 mmol/mol in the 




This will be the first study to explore the effectiveness of FGM among adolescents 
who are struggling to monitor and maintain blood glucose levels in the ideal range. 
There is significant potential for FGM to improve the lives of adolescents with type 
1 diabetes, and reduce the burden of care for themselves, their caregivers and 
health community. Demonstration of efficacy may encourage translation of this 
technology into regular and best practice care, particularly if cost effectiveness can 
be shown in this study or in future studies related to this work. 
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1. Study Objectives, Background, Study Rationale 
 
1.1 Study Objective 
 
The overall study aim is to investigate the use of flash glucose monitoring (FGM) 
in a real-world setting among adolescents with T1D and a history of suboptimal 
glycaemic control (mean HbA1c level ≥ 75 mmol/mol in the previous 6 months). 
The primary objective is to investigate the impact of FGM over 6 months on 
glycaemic control (as measured by HbA1c). The secondary objectives are to 
investigate the acceptability and feasibility of using FGM to self-monitor glucose 
levels, adverse events (i.e., cutaneous, diabetic ketoacidosis, severe 
hypoglycaemia), changes in treatment satisfaction and psychosocial variables, 




In New Zealand, there are about 2,500 children and youth aged 0-19 living with 
type 1 diabetes (T1D),(1) and the incidence is growing annually.(2, 3) T1D cannot be 
cured; therefore, patients must intensely manage blood glucose levels for the rest 
of their lives.  
 
Adolescence is a high risk period where glycaemic control is at its worst.(4, 5) 
Between 2013 and 2014 a large study of the T1D Exchange Clinic registry found 
the mean HbA1c (a measure of glycaemic control) for 13-17 year olds was 9.0% 
(75 mmol/mol), which was above the recommended <7.5% (58 mmol/mol) target 
set by the International Society for Pediatric and Adolescent Diabetes (ISPAD).(6) 
Suboptimal glycaemic control contributes to emergency department visits and 
hospital admissions due to life-threatening episodes of diabetic ketoacidosis (DKA; 
insufficient insulin resulting in the body producing ketone bodies) and severe 
hypoglycaemia (low blood glucose levels that requires assistance from another 
person to treat). Diabetes technology enables patients to better control their 
glucose levels. One cohort study with a seven-year follow-up found children (mean 
age 11.5 (3.7) years) with the poorest glycaemic control (≥8.5% [69.4 mmol/mol]) 
who were started on insulin pump therapy had the greatest reduction in HbA1c (up 
to 0.9% [9.8 mmol/mol]) compared with the control group,(7) revealing that young 
people with unhealthy glycaemic control also can benefit from diabetes technology 
and may demonstrate the greatest improvement in glycaemic control compared to 
those with better glycaemic control. Research investigating other new diabetes 
technology is needed. 
 
The international recommendation for self-monitoring glycaemic control in children 
and adolescents is to check glucose levels four to six times a day.(6) Self-
monitoring of blood glucose frequency is associated with better metabolic 
control.(8) Young people struggle to adhere to self-monitoring recommendations for 
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many reasons, including physical discomfort from pricking their fingers, social 
pressure to ‘fit in’,(9) fear of negative reactions to suboptimal glucose readings, (10) 
and adjusting to less parental involvement in their diabetes management.(11) 
 
Continuous glucose monitoring (CGM) technology has shown promise as a tool to 
help patients with T1D achieve better glycaemic control. (12, 13) CGM simplifies self-
monitoring by continuously sending glucose readings from a sensor implanted 
under the skin to a device that displays and stores accurate and up-to-date 
glucose levels. Sensor derived glucose data is then used in the moment or 
retrospectively to guide therapeutic decisions. One observational study of youth 
(mean age of 12.7 ± 2.9 years, mean HbA1c of 7.9% ± 0.9%) found consistent 
CGM use (6-7 days/week at 6 months) was associated with an improvement in 
HbA1c at 3 months compared with baseline (HbA1c 7.4 ± 0.7%, p = 0.030) and 
the improvement was sustained at 6 months (Hba1c 7.5 ± 0.6%, p = .500), 
whereas using CGM 0-5 days/week was associated with no significant change in 
HbA1c over 6 months.(14) However, the literature on the efficacy of CGM in young 
people with T1D has shown mixed results.(15)Factors that may have contributed to 
these results are that they used now-obsolete CGM devices, the requirement for 
capillary blood sampling calibration, and alarm ‘fatigue’. 
 
The newest generation of CGM, called flash glucose monitoring (FGM), has 
improved on barriers to CGM use by incorporating factory calibrated sensors into 
the system, extending sensor sessions from 7 days to 14 days, eliminating alarms 
associated with high or low glucose levels, and being more affordable. FGM 
requires users to attach a small sensor to the back of their arm to monitor 
interstitial glucose levels and no finger sticks are required. FGM users simply scan 
the sensor with a handheld reader, which immediately displays their glucose level. 
FGM technology provides accurate glucose information,(16, 17) is associated with 
reduced risk for hypoglycaemic events,(18) and is appealing to young people with 
diabetes and their caregivers.(17) A multicentre randomised controlled trial found in 
adults with well controlled diabetes (HbA1c ≤58 mmol/mol [7.5%]) FGM improved 
time spent in hypoglycaemia.(15) While this data is in patients who are motivated 
and already achieving healthy glycaemic control, unlike the average teenager with 
diabetes, it nonetheless supports investigation in future studies among patients 
with less well controlled diabetes and in younger age groups. 
 
FGM is approved as a replacement for fingerstick glucose monitoring in children 
as young as four years of age in Europe(19) (and in NZ from 1/2/18) and could 
improve glucose monitoring and subsequently glycaemic control, among 
adolescents. This instant access to glucose levels is particularly suited for young 
people where motivation is lacking and the burden of disease is high. Given 
adolescents’ propensity for new technology,(20) FGM may provide an important 




1.3 Study Rationale 
 
There is an urgent requirement to develop novel interventions that improve 
glycaemic control and the lives of adolescents with sub-optimal glycaemic control. 
The effects of sub-optimal control are far reaching both in the short term on their 
own quality of life, mental health, and the burden on their caregivers and the 
health system, but also long term impacts with respect to the development of 
diabetes complications and the high health cost associated with this. 
 
2. Study design  
 
This is a 6-month randomised controlled study incorporating a waitlist control 
group to which participants will be randomised, followed by a 6-month 
observational continuation study. Participants will be recruited from three district 
health board catchments (Canterbury, Capital and Coast, and Southern) and 
allocated in equal numbers to either a 12-month supply of FGM supplies or a 
waitlist control group (Figure 1) who, to encourage retention and engagement, at 
6-months will receive six months of FGM supplies (Figure 2).  
 
 
Figure 1. RCT study design. 
 




2.1.1 Randomised controlled trial  
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• Change in HbA1c from baseline 
 
Secondary outcomes  
 
• Mean number of daily blood glucose level tests over the preceding 14 days  
• FGM acceptability  
• Change in Diabetes treatment satisfaction from baseline 
• Change in quality of life from baseline 
• Total days off from school or work associated with diabetes from baseline 
• Total diabetes clinic visits from baseline 
• Total health care professional visits (general practitioner, nurse) from 
baseline 
• Total emergency department visits from baseline 
• Total hospital admissions from baseline 
• Total FGM-associated events including, but not limited to, severe 
hypoglycaemia, diabetic ketoacidosis, skin irritations and reactions, and 
sensor failures from baseline to the end of the trial period for each study 
group from baseline 
 
Within group analysis (FGM group only): 
 
• Mean number of daily sensor scans over the preceding 14 days 
 
2.1.2 Continuation study 
 




• Change in HbA1c from baseline (FGM group only) 
 
Secondary outcomes  
 
• Mean number of sensor scans over the preceding 14 days  
• Mean number of blood glucose level tests over the preceding 14 days  
• FGM acceptability  
• Total FGM-associated events including, but not limited to, severe 
hypoglycaemia, diabetic ketoacidosis, skin irritations and reactions, and 
sensor failures from baseline to the end of the trial period for each study 
group from 6-months 
 
FGM group only 
 
• Change in diabetes treatment satisfaction from baseline  
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• Change in quality of life from baseline  
• Total days off from school or work associated with diabetes from baseline 
• Total diabetes clinic visits from baseline 
• Total health care professional visits (general practitioner, nurse) from 
baseline 
• Total emergency department visits from baseline 
• Total hospital admissions from baseline 
 
Waitlist control group only (this group will crossover to FGM at 6-months) 
 
• Change in HbA1c from 6 months 
• Change in diabetes treatment satisfaction from 6 months  
• Change in quality of life from 6-months 
• Total days off from school or work associated with diabetes from 6 months 
• Total diabetes clinic visits from 6 months 
• Total health care professional visits (general practitioner, nurse) from 6 
months 
• Total emergency department visits from 6 months 




2.2.1 Study participants and recruitment 
 
Participants must meet all of the inclusion criteria to participate in this study.  
 
Inclusion criteria:  
1) aged 13 to 20 years, inclusive;  
2) diagnosed with T1D for at least 12 months;  
3) mean HbA1c of ≥ 75 mmol/mol over the past 6 months;  
4) >0.5 units of insulin/kg/day (with no restrictions based on insulin regimen);  
5) Plans to continue with routine clinical care during the 6-month study 
6) currently residing in and expecting to remain in regions served by the 
Canterbury, Capital and Coast, South Canterbury, and Southern District 
Health Boards for the following year; 
7) Ability to understand study procedures, including English language 
proficiency, and to comply with them for the entire length of the study. 
 
All candidates meeting any of the exclusion criteria at baseline will be excluded from 
study participation. 
 
Exclusion criteria:  
1) Any severe diabetes related complications (nephropathy on treatment, 
retinopathy with associated visual loss – milder degrees will not be 
excluded);  
2) Other severe uncontrolled medical or psychiatric co-morbidity/severe 
mental illness;  
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3) currently using a CGM device or has used one continuously (other than for 
intermittent hospital use) within the previous 4 months;  
4) participation in another device or drug study that could affect glucose 
measurements during the study period;  
5) pregnancy, lactation, or plans to become pregnant; 
6) inability of individual or legal guardian to give written informed consent. 
 
The duration of the study enrolment period will be approximately six months. Participants 
will be recruited from DHBs during regular paediatric and adolescent diabetes clinic visits.  
 
2.2.2 Sample size and power calculation 
 
Based on our data from an earlier study in this population, the standard deviation of 
HbA1c amongst those with values 80 mmol/mol or greater (and irrespective of self-
monitoring blood glucose frequency) was 18.6 mmol/mol.(21, 22) Assuming a correlation 
between repeated measures of 0.7, a sample size of 58 would provide 80% power to 
detect a difference in changes of HbA1c of 10.93mmol/mol (1% in old terminology) using 
a two-sided test at the 0.05 level. This would be considered a clinically important 
difference and similar to other proven technologies such as insulin pumps or CGMS.(23) 
To account for a small amount of missing data and loss to follow-up, we will recruit a 
sample size of 64 (32 participants per group) at baseline. 
 
2.2.3 Study enrolment procedures 
 
During routine clinical visits, adolescents and their parent/caregiver (if under 16 years of 
age) will be given a Participant Information Sheet for the RCT and continuation study 
(Appendix 1). Written assent (if under 16 years of age) or consent will be obtained at the 
time of the visit or at a later date if the child/caregiver/whanau wish to have more time to 
consider participation in the study. The parent/caregiver will be provided with their own 
Participant Information Sheet for the parent/caregiver-specific study if their child is eligible 
for the main study (ie, the RCT and continuation study). See Figure 2 and Figure 3 for 









Figure 3. Flow of participants (parents/caregivers) 
 
 
2.2.4 Pre-screening procedure 
 
Clinicians will provide potentially eligible patients and their parent/guardian with an 
overview of the study and explain the basic inclusion and exclusion criteria. The numbers 
of those declining along with reasons (for statistical purposes), need to be emailed 
through to Sara Boucher for inclusion in subsequent CONSORT statement. 
 
Basic inclusion criteria: 
 
1) aged 13 to 20 years, inclusive;  
2) diagnosed with T1D for at least 12 months;  
3) Plans to continue with routine clinical care during the 6-month study 
4) currently residing in and expecting to remain in regions served by the 
Canterbury, Capital and Coast, South Canterbury, and Southern District 
Health Boards for the following year; 
5) Ability to understand study procedures, including English language 
proficiency, and to comply with them for the entire length of the study. 
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Basic exclusion criteria: 
 
1) currently using a CGM device or has used one continuously (other than for 
intermittent hospital use) within the previous 4 months;  
2) participation in another device or drug study that could affect glucose 
measurements during the study period;  
3) pregnancy, lactation, or plans to become pregnant; 
4) inability of individual or legal guardian to give written informed consent. 
 
The numbers of those found ineligible from the pre-screen, along with reasons, need to 
be emailed through to Sara Boucher for inclusion in subsequent CONSORT statement.  
 
Those who are potentially eligible for the study after pre-screening will be given a 
Participant Information Sheet and Consent/Assent Form (as appropriate). Participant 
Information Sheets and Consent Forms can be emailed or posted if that is their 
preference. Potential participants who provide written informed consent during the clinic 
visit can be screened immediately and, if eligible, be booked for Visit 1. 
 
Potential participants who express interest in the study will be followed-up by research 
staff via phone and email within 3 days. Those declining the study invitation will be asked 
for a reason; however, a reason does not have to be given. 
 
Declining the invitation to participate in either the RCT or the qualitative study will not 
affect a potential participant’s care in anyway.  
 
Before the next screening procedure is performed, informed consent must be obtained 
from adolescents and parents who wish to be part of the study. There will be two 
consenting processes, one for the RCT and another for the qualitative study (anticipated 
to be SDHB only at this stage).  
 
2.2.5 Obtaining consent, screening, allocating study ID number 
 
Those who wish to be in the study will be scheduled for Visit 1 where they will sign 
consent/assent (as appropriate), be screened for eligibility (if not completed during the 
clinic visit), given an ActiGraph, and schedule Visit 2 (Baseline visit, approximately 7 days 
from the screening visit).  
 
This screening step requires accessing patient records (during clinic based care when 
possible).  
 
Screening will ensure the participant meets the following inclusion criteria: 
 
1) mean HbA1c of ≥ 75 mmol/mol over the past 6 months;  
2) >0.5 units of insulin/kg/day (with no restrictions based on insulin regimen);  
 
Screening will ensure the participant does not meet the following exclusion criteria: 
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1) Any severe diabetes related complications (nephropathy on treatment, 
retinopathy with associated visual loss – milder degrees will not be 
excluded);  
2) Other severe uncontrolled medical or psychiatric co-morbidity/severe 
mental illness;  
3) pregnancy, lactation, or plans to become pregnant; (see procedures for 
pregnancy testing). 
 
All candidates meeting any of the exclusion criteria will be excluded from study 
participation. If not eligible, the participant will be notified immediately. 
 
2.2.6 Pregnancy testing procedures 
 
All females must complete a urine pregnancy test before being allocated to a study group. 
Ideally this is done at the time of usual clinic visit and while other screening procedures 
are occurring – following the consent process. The approved pregnancy test is Phoenix 
MedCare Easy Check. The urine specimen will be collected in a clean, dry container. 
Research staff will follow the manufacturer’s guidelines for conducting the test. The urine 
specimen and test will be disposed of immediately following appropriate procedures. 
 
In the event that a positive pregnancy test is detected during participant screening, the 
subject will be ineligible for the study. In this unlikely scenario, an individual approach will 
be taken tailored to the situation to preserve confidentiality and safety of the participant. 
As a first step, the PI at the local site will make appropriate referrals to obstetric 
services/primary care while conserving patient confidentiality.      
 
2.2.6 Allocating a study identification number 
 
Participants will be allocated a study identification (ID) number by Sara Boucher prior to 
being allocated to a study group when there is confirmation they meet study inclusion 
criteria. Study IDs will indicate the study (FLASH) and the site where they were recruited 
(Christchurch- CH, Dunedin-DUN, Wellington-WEL). 
 
Eg, FLASH01CH, FLASH02DUN, FLASH03WEL 
Parents - FLASH01CH–PAR, FLASH02DUN–PAR, FLASH03WEL–PAR 
 
2.2.7 Group allocation (allow 1 week for AG to allocate new participants) 
 
Participants will give written consent or assent, as appropriate, before allocation to FGM 
(intervention group) or conventional self-monitoring of blood glucose (waitlist control 
group). Participant study IDs and appropriate baseline characteristics (sex, HbA1c) will be 
sent to the biostatistician (AG) for minimization using uninformative group codes (e.g. 
“apples” and “oranges” - the biostatistician will remain blinded to actual group allocations 
until the planned statistical analyses are completed). A small random component will be 
used in minimization to preserve allocation concealment along with randomising the order 
of participants when minimizing. Minimization will be used to produce groups relatively 
balanced in terms of two key prognostic factors (sex, HbA1c 75-100 mmol/mol vs HbA1c 
> 100 mmol/mol). During Visit 2, participants will be notified of their group allocation only 
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after completing baseline questionnaires. Apples = intervention group. Oranges = 
control group. Once allocated to a group, investigators and study staff (other than the 
biostatistician performing statistical analyses) will not be blinded to group allocation. To 
maintain the integrity of the study, the planned statistical analyses will be performed by a 
biostatistician (AG) blinded to group allocation.  
 
2.2.8 Study Intervention Group 
 
During the study, all participants will receive standard diabetes care from their usual 
paediatric diabetes clinic. These clinics are attended regularly (usually a minimum every 3 
months) to provide diabetes care by a multi-disciplinary team (paediatric 
endocrinologist/diabetologist, diabetes nurse specialist, dietician, psychologist/social 
worker). Retrospective glucose readings will be downloaded from the FGM 
reader/glucose meter during clinic visits and will be formally reviewed with a healthcare 
professional for personalised glucose management. Between scheduled study visits 
participants will have the usual ability to contact the clinical team as is routine for all 
patients. In line with standard diabetes care, all participants will be encouraged to self-
mange using current or historical glucose data to optimise glucose control. 
 
At Visit 2, participants allocated to the intervention group will have the Abbott Freestyle 
Libre fitted, receive training on sensor insertion, and be given a reader and sensors to 
continue FGM use in 3-month intervals. The FreeStyle Libre FGM system (Figure 1) 
consists of an easy to apply, wear and use interstitial glucose sensor and glucose reader.  
 
 
Figure 1. FreeStyle Libre system 
 
The sensor is worn in the upper arm for up to 14 days and requires no blood tests for 
calibration. The reader is held over the sensor to obtain a reliable and accurate glucose 
reading on demand. The reader stores glucose data, is downloaded to the FreeStyle 
software at the end of each session. In one adult study using the FreeStyle Libre 
system,(15) 53% (63/120) of participants in the FGM group experienced adverse or 
serious events; however, none of the 5 serious adverse events were related to the device. 
248 sensor insertion-site signs and symptoms incidents were reported across 65 
participants, which all resolved. Those incidents expected to be due to sensor insertion 
included pain (the most commonly reported sensor insertion issue), bleeding, oedema, 
induration, and bruising. Incidents associated with sensor wear included: erythema (the 
most commonly reported sensor wear issue), itching, and rash. No hypoglycaemic events 
(n=7) were considered to be device related. 
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Intervention group participants will then continuously use sensor glucose data as per the 
device labelling for self-management of glucose throughout the duration of the study. 
Participants will be given access to the FreeStyle Libre device software, which they can 
use at home to review their sensor data if they wish. Protective dressing (eg, TubiGrip, 
kinesiology tape) for the sensor will also be provided to reinforce the adhesive, as the 
adhesive may come loose from excessive sweating or forceful contact (eg, during sports). 
 
In addition, appropriate study questionnaires and demographics will be collected at visit 1 
also (see section 3.1 Evaluations). 
 
At Visit 3, fourteen days after the start of the sensor session, the sensor will be removed 
and the site inspected for any adverse reactions. Participants will insert their own sensor 
under supervision at this visit and will insert their sensor on their own during the 
remainder of the study.  
 
At each follow-up assessment visit (Visits 4-7), sensor data will be downloaded into 
FreeStyle Libre 1.0 software. Research staff will review the data. If data shows the 
participant experienced low glucose during any night (under 4 mmol/L between the hours 
10pm to 7am) then research staff will contact the participant’s diabetes clinical care team.  
 
Participants will keep their FreeStyle Libre system at the completion of their participation 
in the study. Readers are under warranty until March 2020.  
 
All diabetes care will be as per standard clinic care, with the study only providing the 
device and education on how to use the device. Participants will be instructed to contact 
Abbott Customer Service for technical problems related to the reader and sensor (eg, 
malfunction, early sensor loss).  
 
As a safety precaution, participants will be advised to perform finger stick glucose level 
measurements to confirm their blood glucose level before therapeutic interventions or 
corrective action if hypo- or hyperglycaemic glucose levels or symptoms occur.  
 
2.2.9 Waitlist control Group 
 
Participants allocated to the control group will receive standard diabetes care (as 
described above) from their usual provider. Participants in this group will continue to self-
monitor blood glucose levels using conventional finger stick blood glucose testing with 
their own glucometer. If participants do not have a working glucose meter then one will be 
provided. Participants will be given access to appropriate software (CareLink – a free web 
based program from Medtronic for data from insulin pumps, or SmartLog – a free web 
based program from Pharmaco for CareSens meters) which they can use at home to 
review their blood glucose data if they wished. No additional intervention will be provided 
during the 6-month primary study period. At 6 months, the group will be offered a 6-month 
FGM intervention as part of a continuation study. Continuation study data will be used for 




2.2.10 Clinical support 
 
 
Dunedin study participants should contact the following individual(s)/team for clinical 
support: 
Jenny Rayns  0274984519  jenny.rayns@southerndhb.govt.nz 
 
 
2.2.11 FreeStyle Libre technical support 
 
Participants will be instructed to ring Abbott’s New Zealand customer service at 0800 106 
100 for technical support (e.g., questions not answered in the User Manual, reader/sensor 
failure, sensor loss). Support is available in English 24/7. Clinical questions will be 
directed back to the appropriate clinical team.     
 
2.2.12 Ordering FreeStyle Libre (FSL) supplies  
 
FreeStyle Libre (FSL) sensors have an expiration date 1 year from being manufactured. 
Sara Boucher will be responsible for ordering FSL supplies. Participants will only be 
provided with a 3-month supply at a time. For the RCT, a 3-month FSL supply will be 
couriered to Christchurch and Wellington for distribution for each intervention group 
participant as soon as Sara has been notified that a participant has been allocated to the 
FSL group in those regions. The next lot of 3-month supplies will be sent out for all 
participants prior to their 3 and 6-month visits. Additionally, a 3-month supply for waitlist 
control group participants will be sent to each study site prior to the 6-month visit. The 
final lot of FSL supplies will be sent out prior to the 9-month visit.  
 
2.2.13 Site visits 
 
Ben Wheeler and Sara Boucher will visit Christchurch and Wellington sites prior to 
recruitment at those sits. These visits will enable a run through of the study protocols with 
the research team (co-investigators and research assistants) at each site. 3.2 Enrolment, 
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Informed Consent  X         
Eligibility Criteria X         
Demographics X         
Actigraphy  X  X X     
PSQIa X   X X     
HbA1c X X  X X  X X  
Height and weight          
BGL/FGM monitoring   X  X X  X X  
BGL/FGM 
acceptability 
   X X  X X  
Treatment satisfactionb           
DTSQsd   X  X X  X X  
DTSQcde      X   X  
Quality of Lifec           
EQ-5D-3L  X  X X  X X  
HFSd  X  X X  X X  
PedsQL Generic 
Core Scalesd 
 X  X X  X X  
PedsQL Diabetes 
Module 3.0d 
 X  X X  X X  
Time off school/work         X 
Adverse events          X 
a) Pittsburgh Sleep Quality Index (PSQI) 
b) Diabetes Treatment Satisfaction Questionnaire-status (DTSQs), Diabetes Treatment Satisfaction Questionnaire-change (DTSQc) 
c) Paediatric Quality of Life Inventory (PedsQL), Hypoglycaemia Fear Survey (HFS), EuroQol-5D-Youth (EQ-5D-3L) 
d) Adolescent report and parent/guardian report versions of the questionnaire to be completed 
e) Both intervention and control groups complete DTSQc at 6-month assessment; only the control group crossing over to FGM will complete DTSQc at 12-month 
assessment 
f) Denotes assessment during continuation phase of study 
g) Both intervention and control groups complete DTSQc at 6-month assessment; only the control group crossing over to FGM will complete DTSQc at 12-month 
assessment 
h) Denotes assessment during continuation phase of study 
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The enrolment date is the day the individual signs the consent form and has met all the 
screening criteria.  
 
3.2.2 Baseline Assessments 
 
For participants who have successfully been screened for eligibility and are enrolled into 
the study, baseline assessments are performed against which to measure the study 
outcomes.  
 
Psychosocial data, diabetes treatment acceptance, and self-monitoring device 
acceptability will be collected via paper questionnaires or an electronic survey system (ie, 
REDCap) at baseline and each follow-up assessment. These should be completed prior 
to disclosing study group.   
 
3.2.3. Follow-up Visits 
 
Visits will be scheduled on the days indicated in the Schedule of Evaluations ± 14 days.  
All adolescents will receive a $20 gift voucher as a token of appreciation at each follow-up 
assessment.  
 
3.3 Description of Assessments 
 




Demographic data (ie, age, sex, ethnicity) will be collected from patients’ clinical records. 
The address where the participant lives more than 50% of the time will be used to assess 
their NZDep2013(26) score. NZDep2013 is the most recent index of socioeconomic 
deprivation. NZDep2013 provides a deprivation score for each meshblock in New 
Zealand. “Meshblocks are geographical units defined by Statistics New Zealand, 
containing a median of approximately 81 people in 2013.”(26) NZDep2013 deprivation 
scores apply to areas rather than individual people, but is being used instead of collecting 
potentially sensitive household income data.  
 
3.3.2 Pre-study clinical data 
 
Date of diabetes diagnosis (for subsequent calculation of duration of diabetes), insulin 
regimen, insulin dosing, DKA in past 6 months, severe hypoglycaemia events (defined as 
requiring the assistance of another person to treat) in the past 6 months, SMBG 
frequency in the past 14 days, and HbA1c levels in the past 6 months, and most recent 
height and weight will be collected from clinical records. 
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3.3.3 Diabetes Treatment Satisfaction  
 
The Diabetes Treatment Satisfaction Questionnaire (DTSQs) is a validated 12-item self-
report measure of a patient’s current treatment satisfaction and the DTSQc is a validated 
12-item self-report measure of change in a patient’s satisfaction with their diabetes 
treatment regimen, which was developed to overcome potential ceiling effects (ie, where 
respondents score maximum or near-maximum satisfaction at baseline and can show 
little or no improvement at follow-up).(27) A self-report 14-item parent version of the 
DTSQs measures a parent’s satisfaction with their teen’s diabetes treatment. A self-report 
12-item parent version of the DTSQc measures a change in a parent’s satisfaction with 
their teen’s diabetes treatment. The DTSQs Parent/Teen are used at baseline and follow-
up to provide a ‘difference’ score for comparison. Scores can be compared between teens 
and their parents’ reports.  
 
3.3.4 Glucose monitoring device acceptability 
 
Adolescents will self-report FreeStyle Libre acceptability using a non-validated instrument. 
On a scale of 0 (strongly disagree) to 5 (strongly agree), participants will rate their opinion 
in regards to the following areas: acceptability of sensor application, wear/use of the 
device and comparison to SMBG.(17) 
 
3.3.5 Glucose monitoring, levels, and trends, insulin dosing 
 
During each assessment, retrospective glucose readings will be downloaded from the 
FGM reader/glucose meter for the previous 2 weeks. At the 6-month and 12-month visits, 
an additional 6-month summary of all device data will be downloaded.   
 
During each assessment, retrospective insulin dosing will be downloaded from the insulin 
pump for the previous 2 weeks. At the 6-month and 12-month visits, an additional 6-
month summary of all device data will be downloaded.   
 
3.3.6 Glycaemic control 
 
Participants will have HbA1c (the gold standard measure of glycaemic control) measured 
using a DCA Vantage Analzyer (Siemans), or equivalent machine, which has acceptable 
levels of accuracy and reliability and is available at all study sites. 
 
3.3.7 Height and weight 
 
Participants will be asked to wear light clothing and remove shoes before their height and 
weight measurements. Height will be measured to the nearest 0.1 cm using a standard 




3.3.8 Psychosocial variables 
 
The Hypoglycaemia Fear Survey (HFS) is a validated 25-item self-report measure of 
behaviours that teens may engage in as a result of fear of hypoglycaemia and specific 
worries related to various aspects of hypoglycaemia.(28) The first step in scoring is to 
generate two scores: a Behaviour Subscale Score and a Worry Subscale Score. The sum 
of each set of items for the two subscales is then divided by the total number of items in 
each scale/subscale to obtain an item mean score. Overall, higher scores reflect greater 
fear of hypoglycaemia. A higher score on the Behaviour Subscale reflects a greater 
tendency to avoid hypoglycaemia and/or its negative consequences. A higher score on 
the Worry Subscale indicates more worry concerning episodes of hypoglycaemia and its 
consequences. A self-report 25-item parent version measures behaviours that parents 
may engage in as a result of fear of hypoglycaemia and specific worries related to various 
aspects of hypoglycaemia. 
 
To accommodate the different number of items in the adult version for participants in the 
older age rage, the analysis will use mean item scores. 
 
3.3.9 Quality of Life 
 
The EuroQol-5D-3L (EQ-5D-3L) is a validated 16-item self-report standardised measure 
of adolescents’ health status and provides a simple, generic measure of health.(29)  
 
The Paediatric Quality of Life Inventory Generic Core Scales (PedsQLTM) is a validated 
23-item self-report measure of adolescents’ general health. A self-report 23-item parent 
version measures. Emotional, Social, and School Functioning Scales scores can be 
summed to provide a Psychosocial Health Summary Score. The physical Functioning 
Scale Score provides a Physical Health Summary Score. Higher scores indicate better 
health-related quality of life.  
 
The Paediatric Quality of Life Inventory Diabetes Module for Type 1 diabetes (PedsQLTM 
Version 3.0) is a validated 28-item self-report measure of T1D specific health-related 
quality of life in adolescents.(30) A self-report 28-item parent version measures their 
adolescent’s T1D specific health-related quality of life. Higher scores indicate lower 
problems. 
 




Adolescents will wear an ActiGraph (ActiGraph, BT3XP, Pensacola, FL) on the non-
dominant wrist for 7 days and 8 nights (continuously), except during activities involving 
water (e.g., showering, swimming) prior to the baseline and 3- and 6-month follow-up 
visitsand complete a sleep diary over the same period. The ActiGraph is a motion sensor 
worn like a wrist-watch that gives objective information about sleep and waking including 
sleep disturbance. The intention of collecting activity measures is to describe participants’ 
usual level of daily activity (focus on moderate-vigorous physical activity; MVPA?), 
including duration of sleep, and nighttime awakenings. The data will enable an analysis to 
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investigate the association between wearing the FreeStyle Libre and changes in activity 
due to less fear of hypoglycaemia.  
 
Actigraphy initialisation and screening methods will be adapted from those described in 
Meredith-Jones et al.(31) ActiGraphs will be initialized using 15 s epochs, in the uniaxial 
mode and processed with the normal frequency filter. A valid day is defined as at least 8 
hours of wear time over the 24-h period, and participants will be excluded from the 
analysis if fewer than 3 valid days of wear are obtained. Puyau cut points scaled for 15 s 
epochs will be used to identify activity intensities.(32) The count-scaled algorithm will be 
used for sleep-screening: relevant age group wake and bed times will be selected and the 
automated algorithm will search 3 h forward and 2 h backward from the selected time to 
determine sleep onset and offset for each participant file. Outputs are then computed for 
non-wear, wear-time, sedentary, light, moderate, and vigorous activity for the period of 
time identified as “wake”.  
 
ActiGraphs will be couriered to participants 10 days before their scheduled visit and they 
will then return the ActiGraph at their assessment visit. Research staff in Wellington and 
Christchurch will return the ActiGraphs to Dunedin via internal mail so that data can be 
downloaded.  
 
Sleep quality and quantity 
 
The Pittsburgh Sleep Quality Index (PSQI)(33) yields subjective information about sleep 
quality and sleep quantity. The PSQI is a 19-item self-report questionnaire that measures 
sleep quality during the previous month to discriminate between good and poor sleepers. 
Originally devised as a 21-item score, 2 items related to sleeping with a bed partner are 
not included for adolescents. The PSQI generates 7 domains for subjective sleep quality, 
sleep latency, sleep duration, sleep efficiency, sleep disturbance, sleep medication, and 
daytime dysfunction, with each component score ranging from 0 to 3, and summed to 
produce a global score. A global score > 5 suggests a “poor sleeper” with significant sleep 
complaints. In the context of the PSQI, “day-time dysfunction” is the composite of 2 
component scores, from one question evaluating sleepiness and the other evaluating lack 
of enthusiasm. The algorithm for “sleep duration” will be adjusted to reflect sleep 
recommendations for adolescents as 1 hour longer than adults, as was done by Galland 
et al.(34) Responses will be coded as ≥ 8 hours = 0, <8 and ≥ 7 hours = 1, <7 and ≥ 6 
hours = 2, and < 6 hours = 3. The PSQI has been shown to have good reliability with high 
internal consistency (Cronbach’s alpha = .77),(33) with item-rest correlations ranging from 
0.43 to 0.61. Sleep timing variables will be collected from the PSQI.  
 
3.3.11 Time off from school or work related to diabetes 
 
Adolescents will be sent a link to an electronic survey every 2 weeks to report any 
adverse events, this includes time away from school/work due to illness (eg, clinic visits, 
hospital admission, staying home due to illness) and will be asked to specify how many, if 
any, days away from work/school were related to their diabetes and whether or not 
someone (eg, caregiver) had to take time off of work to care for them. The purpose of 
collecting such data is to determine the feasibility of collecting this data, and its 
appropriateness, in preparation for a cost-benefit analysis in a future larger study. 
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3.4 Safety Assessments 
 
Participants will be instructed to take a picture on their phone and send it to research staff 
immediately if they notice a cutaneous issue associated with wearing the sensor. Clinical 
research staff will then advise if medical treatment is necessary. Safety will also be 
monitored fortnightly using the adverse event questionnaire/dairy.  
 







o Subcutaneous haemorrhage 
 
• Diabetic ketoacidosis (DKA) 
• Severe hypoglycaemia (i.e., child experiences altered mental status and as 
a result is unable to assist in their care, or is semiconscious or 
unconscious) 
 
Sensor-wear-related symptoms will be recorded as adverse events by participants in their 
study diary and also from 2 weekly adverse event questionnaire (electronic – see below).  
Particular emphasis to participants is to report to us any more severe events that last for 
more than 7 days, or if the patient requires prescription medication for the event to 
resolve, in line with a previous study.(15) More severe patient perceived adverse events 
should be examined by their healthcare professional and ideally photographed, described, 
and given a rating assessment of mild, moderate or severe.  
 
For more significant or persistent adverse events involving skin - a barrier product will be 
offered (eg, Cavilon spray) or drug therapy (eg, zinc ointment, Fenistil gel, or 
hydrocortisone cream) as prescribed, and be instructed to relocate the sensor to another 
area of the skin such that the effects are maintained at a tolerable level. Ultimately, the 
decision to continue or discontinue the use of the FreeStyle Libre when localised skin 
symptoms occur will be made in consultation with the participant (in no previous studies 
has a health care professional recommended cessation based on cutaneous events).  
 
For safety monitoring purposes, participants will be sent a link to an electronic survey (ie, 
developed in REDCap software) via text or email fortnightly (to coincide with sensor life) 
to record any episodes of severe hypoglycaemia (i.e., child experiences altered mental 
status and as a result is unable to assist in their care, or is semiconscious or 
unconscious) (35) and/or diabetic ketoacidosis (DKA), sensor failure rates, or adverse 
events (e.g., pain, itching, redness, subcutaneous haemorrhage, infection) (Appendix 3). 
Non-responders will be followed up with a phone call if the questionnaire is not filled out 
within three days (questionnaires can be completed by phone with research staff if 
needed). Participants will be referred to their general practitioner or emergency 
department, as appropriate, for management of medical events. An internal Safety 
Monitoring Committee will be comprised of the following clinical investigators (BW, MD, 
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EW, KM). The Committee will be notified of severe adverse events (events associated 
with being in the study, which result in harm to a participant) immediately after being 
reported to research staff. The Committee will then discuss any necessary action. Non-
urgent events (cutaneous events) will be reported to the lead investigator after being 
reported to research staff.  
 
3.5 Data analysis 
 
Means and standard deviations will be reported for continuous variables (i.e., age, 
diabetes duration, HbA1c, glucose monitoring behaviour, questionnaire scores) and 
categorical variables will be described as the number and percent of participants in each 
category (i.e., sex, ethnic group, insulin regimen). Adverse events will be categorised by 
the type of event (e.g., severe hypoglycaemia, DKA, sensor insertion issues, sensor wear 
issues). The frequency of events will be reported by event category. The proportion of 
total adverse events for each category will be calculated as the number of events in the 
category divided by the total number of adverse events. A mixed linear model will be used 
to test the difference in HbA1c, with the primary outcome being at 6-months, between the 
intervention and control groups using data from all time points with a random participant 
effect used to accommodate the repeated measures and a group-time interaction to 
model differences in longitudinal changes. Changes in number of glucose measurements 
performed and patient-reported outcome measures (i.e., PedsQL, EQ-5D-3L, HFS, and 
DTSQ scores) from baseline through to 6 months will be calculated by comparing scores 
from control and intervention group participants again using linear mixed models with all 
collected data included. Some secondary analyses, such as those involving the wait-list 
control after they cross over, will only include participants from one group and so group 
(and group-time interaction) terms will not be included in these models. Analyses will 
follow a modified intention-to-treat principle with all participants analysed in the group to 
which they were randomised, regardless of actual sensor wear. All models will include 
variables used in minimization. Any missing values will be imputed using multiple 
imputation with chained equations with the imputation model including gender and HbA1c 
status as well as values of that variable from other time points. Statistical analyses will be 
performed using R or Stata software with two-sided p < 0.05 considered significant. To 
maintain the integrity of the study, statistical analyses will be performed by the 
biostatistician blinded to group allocation. 
 
Planning for future health economics analysis 
 
To enable a cost-benefit analysis of FreeStyle Libre vs blood glucose testing from data 
collected in future FSL intervention studies, it is necessary to determine the feasibility of 
collecting health economics data in this study and to determine if all the necessary 
measures are being collected.  
 
Upon consultation with Trudy Sullivan (DSM), it was suggested that this study collects 
data on days off from school directly related to diabetes and whether the parent/caregiver 
takes time off from work that is directly related to their child’s diabetes. It was also 
recommended that this study uses the EQ-5D-3L instead of the EQ-5D-Y because new 
weights for New Zealand will be available for the EQ-5D-3L in the future. 
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A health economic analysis is beyond the scope of the current study, but may be possible 
in the future. This study would compare: 
 
Blood glucose testing vs the FreeStyle Libre system 
 
- Difference in cost (eg, cost of blood glucose testing strips vs cost of 
FreeStyle Libre system) 
- Difference in benefit (eg, HbA1c, quality of life, savings, parent/caregiver 
taking time off from work due to their child’s diabetes) 
 




The objective of the qualitative study is to explore facilitators and barriers to glucose 
monitoring over time among adolescents with a history of sub-optimally controlled type 1 
diabetes using flash glucose monitoring technology. The main outcome measure will be 
the results from repeat in-depth interviews with participants over six months after starting 
FGM. Adolescents (ages 13-20 years, inclusive) with type 1 diabetes (for at least 12 
months) who were randomly allocated to FGM intervention in the RCT will be invited to 
participate in a longitudinal qualitative study. There are no exclusion criteria.  This study 
will commence at SDHB site, and only move to other sites if numbers are not reached 
locally. 
 
Participants will be interviewed twice over six months. The first interview will occur 1-
month from starting FGM and the second interview will occur 6-months from starting 
FGM. Written informed consent will be obtained before beginning the first interview. 
Semi-structured, one-to-one, in-depth interviews with a trained researcher or trained 
student using a topic guide (Appendix 5) will explore the lived experiences of FGM among 
adolescents with T1D. The line of questioning will be partially informed by an analysis of 
the responses to self-reported FGM acceptability related to sensor application, wear/use 
of the device and comparison to self-monitoring blood glucose levels. Interviews will take 
place in the participant’s home, in clinic, or via videoconference, will last approximately 60 
minutes, will be digitally recorded, and transcribed verbatim by an independent service. 
Participants will be given a $20 gift voucher as a token of appreciation after each 
interview. Age, sex, insulin regimen, and duration since diagnosis will be taken from 
clinical records in order to describe the sample. 
 
Nvivo software will be used to conduct a thematic analysis to identify key barriers and 
facilitators of FGM use. Furthermore, we will explore if barriers and facilitators change 
over time, and are dependent on patient characteristics (eg, age, sex, insulin regimen, 
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and duration since diagnosis). Themes will be compared between members of the 
analysis team until consensus is reached. It is anticipated that a minimum of 10 




Caregivers of adolescents in the FGM intervention group will be invited to participate in 
semi-structured interviews (45-60 minutes) approximately 6-months from the start of 
FGM. Interviews will take place in the caregiver’s home, in the clinic, or via 
videoconference with a trainer researcher or trained student. Semi-structured, one-to-one, 
in-depth interviews with a trained researcher or trained student using a topic guide 
(Appendix 5) will explore the lived experiences of caregivers with an adolescent using 
FGM. Interviews will be digitally recorded and transcribed verbatim by an independent 
service. Caregivers’ demographic information (age, sex, education, address [to determine 
NZDep2013 score]) reported at time of enrolment in the study will be used to describe the 
sample. Caregivers will be given a $20 gift voucher as a token of appreciation after the 
interview. We will use Nvivo software to conduct a thematic analysis to identify key 
themes of caregivers’ perceptions of their adolescents’ FGM use and the impact of FGM 
use on the family. It is anticipated that a minimum of 10 caregivers will provide enough 




Demographic characteristics (ie, age, sex, duration of diabetes, insulin regimen) of the 
sample will be reported. Interviews will be analysed using a content analysis approach, in 
which the entire transcript for each individual undergoes multiple readings, paragraphs 
are coded for content based on ‘meaning units’, and themes are identified from 
coding.(36, 37) Coding and content themes will be discussed amongst members of the 
research team to reach consensus on themes extracted from the data.  
 
 
4. Health and Safety 
 
Personal Safety Protocol 
 
Communicating with participants 
 
All communication with participants should be made on University landlines, the study 
email address and the phone purchased for the study. Research staff will not use their 
personal phone or email address to communicate with participants.   
 
Qualitative study – conducting home interviews 
 
Before the visit 
 
Study visits will be recorded in a study calendar. The calendar is shared within the 
research team and gives access to information about where research staff are going. 
Calendar events will include the following details: 
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• Research staff’s name, phone number 
• Participant ID and name 
• Participant’s address, phone number 
• The purpose of the visit (ie, 1- or 6-month interview with adolescent, 6-
month interview with parent/caregiver)  
 
Research staff will make sure that they have organised the visit and have reminded 
participants on the day or the day before to confirm the visit. Research staff will not arrive 
at a house unexpected. 
 
If the interview is during the workday, research staff will let a colleague know they are 
going to a home visit and what time they expect to return. Research staff will tell the 
colleague when they have returned. If it is in the evening, research staff will advise 
someone they live with or a colleague where they are going and when they will return. 
Research staff will notify someone when they have returned from the interview visit. 
 
Before research staff goes to the interview visit, they will check with the participant about 
access to the house and whether there is a dog. Research staff must take a charged 
phone to home visits. 
 
During the visit 
 
If research staff feel uncomfortable about going to into a home for any reason there are 
several options: 
• Organise for a colleague to also come to the visit 
• Meet the participant somewhere else outside the home (ie, a clinical room) 
 
If at any time research staff feel unsafe going into a home then they are requested not to 
continue. Visits can always be rescheduled and research staff can return with someone 
else.  
The University of Otago has detailed written guidelines for fieldwork in home and 
community based settings – research staff must read these prior to conducting the first 
home interview. They are available to download here: 
http://www.otago.ac.nz/humanresources/health-and-safety/hazards/otago067719.htm 
 
Sarah-Jane Robertson is the WCH Health and Safety Officer (University of Otago, 
Dunedin). She can provide a Health and Safety Introduction and advise of processes for 
reporting accidents and incidents. 
 
 
5.0 Dissemination and reporting 
 
Questions around equity and access to FGM when the study have been raised. This issue 








A summary of all key study results will be emailed to participants at the email address 
they provide. All study participants including whanau will be invited back to a group 




A locality report will be sent to the Māori Research Advisory Group in each region. The 
report will detail the numbers of Māori recruited and any specific issues or concerns 
recruiting or maintaining Māori in the study.  
 
Māori Research Advisory Groups 
 
Capital and Coast – ragm@ccdhb.org.nz 
Canterbury - catherine.grant@cdhb.health.nz  
South Canterbury - TBC 
University of Otago, Dunedin - mark.brunton@otago.ac.nz 
University of Otago, Christchurch - karen.keelan@otago.ac.nz  
 
Māori health organisations 
 
Christchurch 
Ms Debbie Rawiri, Maori Diabetes Clinical Nurse Specialist, Diabetes Service, CDHB – to 
identify other Maori forums or stakeholder groups who may have an interest in the 
findings from the study.  
 
Dunedin 
Arai Te Uru Whare Hauora 
25 College Street 
Caversham 
Dunedin 9012 
03 471 9960 
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6.1.4 Appendix 1d: Information sheet and assent form for participants 
aged 13-15  
Participant Information Sheet  
(Ages 13-15) 
 
Study title: Managing diabetes in a ‘flash’: A randomised controlled trial investigating flash glucose 
monitoring among adolescents with sub-optimally controlled type 1 diabetes  
Locality: Southern District Health Board Ethics committee ref.: 17/STH/240 
Lead investigator: Dr Ben Wheeler Contact phone number: 027 470 1980 
 
You are invited to take part in a study on a new device that constantly measures 
glucose levels in the tissue under your skin. It is called a ‘flash’ glucose monitoring 
system.    
 
This Information Sheet will help you decide if you’d like to take part. It sets out why 
we are doing the study, what it involves, what the benefits and risks are, and what 
happens when the study ends. We will also go through this information with you and 
answer any questions you may have. Before you decide you may want to talk about 
the study with other people, such as family, whānau, friends, or your diabetes team.  
Feel free to do this. 
 
If you don’t want to take part, you don’t have to give a reason, and it won’t affect the 
care you receive. If you do want to take part now, but change your mind later, you 
can pull out of the study at any time.   
 
If you agree to take part in this study, you will be asked to sign the Assent Form on 
the last page of this document. You will be given a copy of both this Information 
Sheet and the Assent Form to keep. 
 
WHAT IS THE PURPOSE OF THE STUDY? 
Checking glucose levels often is important for people with diabetes. The purpose of 
this study is to compare flash glucose monitoring with usual blood glucose testing 
among young people with type 1 diabetes. To do this, we need two groups of 
participants in the study. We will compare the two groups to see if the FreeStyle 
Libre provides any benefit over fingerstick glucose testing. This knowledge will help 
us understand if the FreeStyle Libre helps young people to manage their diabetes 
better. This study will also give the diabetes care team more experience working 
with this technology.  
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If you have any questions, you are welcome to contact Dr Ben Wheeler, principal 
investigator (ben.wheeler@otago.ac.nz or 027 4701980) or Sara Boucher, study 
coordinator (sara.boucher@otago.ac.nz or 03 470 9167). 
 
WHAT WILL MY PARTICIPATION IN THE STUDY INVOLVE? 
We are inviting you to join this study because you have been diagnosed with type 1 
diabetes, you are between 13 and 20 years of age, inclusive, your average HbA1c 
over the past 6 months is above your target HbA1c, and you take insulin every day.  
 
If you are interested in being part of the study, your lead paediatric endocrinologist 
will check your medical records to make sure you meet certain criteria. If you are 
female, you will need to do a pregnancy test before starting the study to ensure you 
are not pregnant. If you are eligible to participate in the study, you will be randomly 
assigned to a group. You will have a 50/50 chance of being assigned to either the 
intervention group or the comparison group.  
 
Both Groups, will attend seven visits at the diabetes clinic over 12 months. Before 
the first visit, the 6-month visit and the 12-month visit, you will be asked to wear an 
activity monitor (like a watch) for one week to collect information about your sleep 
and physical activity habits. The clinic visits will take approximately one hour. For 
the visits, you will be asked to: 
 
• complete questionnaires about yourself and your diabetes treatment. You 
do not have to answer any questions that make you feel uncomfortable. 
• have your HbA1c measured with a finger prick test 
• bring your glucose meter so that we can download your meter readings 
• bring the FreeStyle Libre reader so that we can download information from 
your sensor 
 
Your caregiver will be asked to complete questionnaires about your diabetes. We 
will also collect information about your diabetes history from your clinical records.  
 




If you are in the intervention group, you will receive FreeStyle Libre supplies for 12 
months to monitor your glucose levels. The FreeStyle Libre system uses a handheld 
reader to scan a tiny glucose sensor that is placed under the skin in the back of your 
arm. The reader will display the current glucose level in the tissue under your skin, 
which will be similar to your blood glucose level. You will not need to enter glucose 




The sensor will be applied during the first visit. You may feel slight discomfort when 
the sensor enters your skin, but the discomfort should not last long. Each sensor 
lasts for 14 days and then needs to be replaced. You will come back to the clinic 14 
days after the sensor is inserted so that research staff can check your skin for any 





If you are in the comparison group, you will continue monitoring your glucose levels 
with your glucose meter. After six months, you will be offered the FreeStyle Libre 
system for six months. 
 
WHAT ARE THE POSSIBLE BENEFITS AND RISKS OF THIS STUDY? 
You may benefit from using flash glucose monitoring technology to monitor your 
glucose levels, which will help you manage your diabetes.  
 
The sensor application may feel uncomfortable. You may experience a skin 
reaction to the sensor or the adhesive. You will be asked to report any reactions to 
the sensor or the adhesive so that we can monitor these events and provide 
medical advice, if necessary.  
 
Your general practitioner (GP) and diabetes care team will be informed of your 
participation in the study and will be responsible for your care during the study.  
 
WHAT ARE MY RIGHTS? 
You have a right to see information collected about you as part of the study and the 
information will only be shared with research staff. You will not be identified in any 
reports written about the study.  
 
WHAT HAPPENS AFTER THE STUDY OR IF I CHANGE MY MIND? 
We will destroy any information collected about you that may identify you as a 
person when we are finished with this project. The study information (questionnaire 
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responses, glucose monitor data) will be safely stored for 10 years after you turn 16 
years old (i.e. aged 26 years). Information collected about you may be used for other 
future research. 
 
Study findings are expected within one year of the end of the study. A summary of 
the study findings will be sent to you or your parent/caregiver at the email you or 
your parent/caregiver provide.  
 
WHO DO I CONTACT FOR MORE INFORMATION OR IF I HAVE CONCERNS? 
If you have any questions, concerns or complaints about the study at any stage, 
you can contact Dr Ben Wheeler (ben.wheeler@otago.ac.nz; phone: 027 
4701980).  
 
If you want to talk to someone who isn’t involved with the study, you can contact 
an independent health and disability advocate on: 
 
Phone:  0800 555 050 
Fax:   0800 2 SUPPORT (0800 2787 7678) 
Email:  advocacy@hdc.org.nz 
 
For Māori health support please contact : 
 
Arai Te Uru Whare Hauora 
25 College Street 
Caversham 
Dunedin 9012 
03 471 9960 
 
You can also contact the health and disability ethics committee (HDEC) that 
approved this study on: 
 
 Phone: 0800 4 ETHICS 
 Email:  hdecs@moh.govt.nz 
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Assent Form (ages 13-15) 
 
 
Declaration by participant: 
 







Declaration by member of research team: 
 
I have given a verbal explanation of the research project to the participant, and 
have answered the participant’s questions about it.   
 
I believe that the participant understands the study and has given informed 







6.1.5 Appendix 1e: Information sheet and consent form for parents of 
participants aged 13-15  
Participant Information Sheet  
(For parents of teens ages 13-15) 
 
Study title: Managing diabetes in a ‘flash’: A randomised controlled trial investigating flash glucose 
monitoring among adolescents with sub-optimally controlled type 1 diabetes  
Locality: Southern District Health Board Ethics committee ref.: 17/STH/240 
Lead investigator: Dr Ben Wheeler Contact phone number: 027 470 1980 
 
Your child is invited to take part in a study on a new device that constantly measures 
glucose levels in the tissue under their skin (also called a ‘flash’ glucose monitoring 
system).   
 
This Information Sheet will help you decide if you’d like your child to take part.  It 
sets out why we are doing the study, what your child’s participation would involve, 
what the benefits and risks to your child might be, and what would happen after the 
study ends. We will go through this information with you and answer any questions 
you may have.  Before you decide you may want to talk about the study with other 
people, such as family, whānau, friends, or your child’s diabetes team.  Feel free to 
do this. 
 
If you do not want your child to take part, you don’t have to give a reason, and it 
won’t affect the care your child will receive.  If your child does take part now, but 
you change your mind later, you can pull your child out of the study at any time.   
 
If you agree to your child taking part in this study, you will be asked to sign the 
Consent Form on the last page of this document.  You will be given a copy of both 
the Participant Information Sheet and the Consent Form to keep. 
 
This document is seven pages long, including the Consent Form.  Please make sure 
you have read and understood all the pages. 
 
There is a separate Participant Information Sheet to help you decide if you would 
like to take part in the study as well. 
 
WHAT IS THE PURPOSE OF THE STUDY? 
Monitoring glucose levels with daily finger prick blood tests is a major part of 
diabetes care. The purpose of the study is to compare using a flash glucose 
monitoring (FGM) system (FreeStyle Libre) with using a glucose meter for managing 
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diabetes among young people. To do this, we need two groups of participants in the 
study. We will compare the two groups to see if the FreeStyle Libre provides any 
benefit over finger prick glucose testing. This knowledge will help us understand if 
adding the FreeStyle Libre to diabetes management is useful for monitoring glucose 
levels and improves glucose control. If this technology is useful, our research 
findings will support publicly funded access to the FreeStyle Libre. This study will 
also give the diabetes care team more experience with this technology.  
This study is being funded by a Cure Kids grant with additional financial support 
from the Dunedin School of Medicine at the University of Otago. Neither the 
manufacturer nor the distributer of the FreeStyle Libre are funding this study in any 
way. This study has been approved by the Health and Disabilities Ethics Committee 
(ethics ref: 17/STH/240). 
 
If you have any questions, you are welcome to contact Dr Ben Wheeler, principal 
investigator (ben.wheeler@otago.ac.nz or 027 4701980) or Sara Boucher, study 
coordinator (sara.boucher@otago.ac.nz or 03 470 9167). 
 
WHAT WILL MY CHILD’S PARTICIPATION IN THE STUDY INVOLVE? 
Your child is invited to participate in the study because they have been diagnosed 
with type 1 diabetes, they are between 13 and 20 years of age, inclusive, your child’s 
average HbA1c over the past 6 months is above their target HbA1c, and your child 
takes insulin every day.  
 
If your child is interested in joining the study, their diabetes specialist will check your 
child’s medical records to make sure they meet certain criteria. If your child is 
female, she will need to do a pregnancy test before starting the study to ensure she 
is not pregnant.  
 
If your child is eligible to participate in the study, they will be randomly assigned to 
a group. Your child will have a 50/50 chance of being assigned to either the 
intervention group or the comparison group.  
 
Your child will be asked to attend seven visits at the diabetes clinic over 12 months. 
These visits will take approximately one hour. At the first visit, we will ask your child 
to sign the assent form and ask you to sign the consent form, and we will confirm 
that your child is eligible for the study. At the second visit (approximately 7 days 
later), your child will find out which group they are in.  
 
During the study visits, your child will be asked to: 
 
• complete questionnaires about their diabetes treatment and quality of life. 
Some questions may be sensitive (for example, questions asking if they feel 
scared when thinking about living with diabetes). Your child does not have to 
answer any questions that make them feel uncomfortable.  
• have their HbA1c measured with a finger prick test at each visit.  
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• bring their glucose meter and FreeStyle Libre reader so that we can 
download glucose monitoring information.  
•  
Your child will be asked to wear an activity monitor (like a watch) for one week prior 
to starting the study and 3- and 6-months after the study. The device will information 
about your child’s sleep and physical activity habits.  
Your child will be sent an electronic questionnaire to complete every 2 weeks during 
the 12-month study. This questionnaire will ask about any problems your child 
experienced related to their diabetes and glucose monitoring device(s).  
 
We will collect information about your child’s diabetes history from their clinical 
records. 
 
Your child will continue all of their usual diabetes care during the study period, the 
study is only providing the FreeStyle Libre system and technical support. The only 
difference between being in the study and not being in the study is the opportunity 




If your child is assigned to the intervention group, they will receive FreeStyle Libre 
supplies for 12 months (1 year) to monitor their glucose levels. The FreeStyle Libre 
continuous glucose monitoring system uses a handheld reader to scan a tiny 
glucose sensor that is placed under the skin in the back of their arm. The reader will 
display the current glucose level in the tissue under their skin, which will be similar 
to their blood glucose level. Your child will not need to enter glucose readings from 
finger prick blood tests to help the sensor read accurately. 
 
The sensor will be applied during the first visit. Your child may feel slight discomfort 
when the sensor enters their skin, but the discomfort should not last long. Each 
sensor lasts for 14 days and then needs to be replaced. Your child will come back 
to the clinic 14 days after the sensor is inserted so that research staff can check 
their skin for any reactions to the sensor or the adhesive. The research staff will also 
supervise your child inserting a new sensor by themselves. Your child may like your 





If your child is assigned to the comparison group, they will continue fingerstick blood 
testing with a glucose meter to monitor their glucose levels. The comparison group 
is very important for understanding whether or not the FreeStyle Libre system 
provides any benefits on top of standard blood glucose testing. After six months, 
your child will be offered the FreeStyle Libre system for six months. 
 
WHAT ARE THE POSSIBLE BENEFITS AND RISKS OF THIS STUDY? 
Your child may benefit from using flash glucose monitoring technology to monitor 
glucose levels, which will help them manage their diabetes. If you help your child 
with their diabetes management, this glucose information may help you manage 
their diabetes better. 
 
The sensor application may cause discomfort. Your child may experience a skin 
reaction to the sensor or the adhesive. Your child will be asked to report any 
reactions to the sensor or the adhesive so that we can monitor these events and 
provide medical advice, if necessary.  
 
Your child’s general practitioner (GP) and diabetes care team will be informed of 
your child’s participation in the study and will be responsible for your child’s care 
during the study.  
 
WHO PAYS FOR THE STUDY? 
You will not have to pay for your child to participate in the study. In addition to 
Freestlye Libre supplies, your child receives small tokens of appreciation helping 
with the study.  
 
WHAT IF SOMETHING GOES WRONG? 
If your child was injured in this study, which is unlikely, you would be eligible to apply 
for compensation from ACC just as you would be if they were injured in an accident 
at work or at home. You will have to lodge a claim with ACC, which may take some 
time to assess. If your claim is accepted, you will receive funding to assist in their 
recovery. If you have private health or life insurance, you may wish to check with 
your insurer that taking part in this study won’t affect your child’s cover. 
 
WHAT ARE MY RIGHTS? 
You have a right to see information collected about your child as part of the study 
and the information will only be shared with research staff for the purposes of the 
study. You will be told of any new information about harmful or helpful effects related 
to the FreeStyle Libre that become available during the study that may have an 
impact on your child’s health. All data obtained for the study will be securely stored 
in the Department of Women’s and Children’s Health, University of Otago, in such 
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a way that only the study investigators will be able to gain access to it. Your child 
will not be identified in any reports written about the study.  
 
WHAT HAPPENS AFTER THE STUDY OR IF I CHANGE MY MIND? 
No intervention will be available to participants after the study.  
 
Personal information about your child which can identify your child as an individual 
person will be destroyed when the researchers are finished with this project but the 
raw data (questionnaire responses, glucose monitor data) on which the results of 
the project depend will be safely stored for 10 years after your child turns 16 years 
old (i.e. aged 26 years). Information collected about your child may be used for other 
future research. 
 
Study findings are expected within one year of the end of the study. A summary of 
the study findings will be sent to you at the email you provide.  
 
WHO DO I CONTACT FOR MORE INFORMATION OR IF I HAVE CONCERNS? 
If you have any questions, concerns or complaints about the study at any stage, 
you can contact Dr Ben Wheeler (ben.wheeler@otago.ac.nz; phone: 027 
4701980). 
 
If you want to talk to someone who isn’t involved with the study, you can contact 
an independent health and disability advocate on: 
 
Phone:  0800 555 050 
Fax:   0800 2 SUPPORT (0800 2787 7678) 
Email:  advocacy@hdc.org.nz 
 
For Māori health support please contact : 
 
Arai Te Uru Whare Hauora 
25 College Street 
Caversham 
Dunedin 9012 
03 471 9960 
 
You can also contact the health and disability ethics committee (HDEC) that 
approved this study on: 
 
 Phone: 0800 4 ETHICS 
 Email:  hdecs@moh.govt.nz 
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Consent Form  






Please tick to indicate you consent to the following  
 
I have read, or have had read to me in my first language, and 
I understand the Participant Information Sheet.   
Yes  No  
I have been given sufficient time to consider whether or not 
my child will participate in this study. 
Yes  No  
I have had the opportunity to use a legal representative, 
whanau/ family support or a friend to help me ask questions 
and understand the study. 
Yes  No  
I am satisfied with the answers I have been given regarding 
the study and I have a copy of this consent form and 
information sheet. 
Yes  No  
I understand that my child taking part in this study is voluntary 
(my choice) and that I may withdraw my child from the study 
at any time without this affecting my child’s medical care. 
Yes  No  
I consent to the research staff collecting and processing my 
child’s information, including information about my child’s 
health. 
Yes  No  
If I decide to withdraw my child from the study, I agree that the 
information collected about my child up to the point when I 
withdraw my child may continue to be processed. 
Yes  No  
I consent to my child’s GP or current provider being informed 
about my child’s participation in the study and of any 
significant abnormal results obtained during the study. 
Yes  No  
I agree to an approved auditor appointed by the New Zealand 
Health and Disability Ethic Committees, or any relevant 
regulatory authority or their approved representative reviewing 
my child’s relevant medical records for the sole purpose of 
checking the accuracy of the information recorded for the 
study. 
Yes  No  
 
If you need an INTERPRETER, please tell us. 
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I understand that my child’s participation in this study is 
confidential and that no material, which could identify them 
personally, will be used in any reports on this study. 
Yes  No  
I understand the compensation provisions in case of injury 
during the study. 
Yes  No  
I know who to contact if I have any questions about the study 
in general. 
Yes  No  
I understand my child’s responsibilities as a study participant. Yes  No  
I wish to receive a summary of the results from the study. Yes  No  
I consent to being contacted for future research. Yes  No  
 
Declaration by participant: 
 
I hereby consent to my child taking part in this study. 
 
Child’s name: 





Declaration by member of research team: 
 
I have given a verbal explanation of the research project to the participant, and 
have answered the participant’s questions about it.   
 
I believe that the participant understands the study and has given informed 










6.1.6 Appendix 1f: Information sheet and consent form for participants 
aged 16+ 
Participant Information Sheet (ages 16+) 
 
Study title: Managing diabetes in a ‘flash’: A randomised controlled trial investigating flash glucose 
monitoring among adolescents with sub-optimally controlled type 1 diabetes  
Locality: Southern District Health Board Ethics committee ref.: 17/STH/240 
Lead investigator: Dr Ben Wheeler Contact phone number: 027 470 1980 
 
You are invited to take part in a study on a new ‘flash’ glucose monitoring system. 
This Information Sheet will help you decide if you’d like to take part.  It sets out why 
we are doing the study, what it involves, what the benefits and risks are, and what 
would happen after the study ends.  We will go through this information with you 
and answer any questions you may have. Before you decide you may want to talk 
about the study with other people, such as family, whānau, friends, or your diabetes 
team.  Feel free to do this. 
 
Whether or not you take part is your choice.  If you don’t want to take part, you don’t 
have to give a reason, and it won’t affect the care you receive.  If you do want to 
take part now, but change your mind later, you can pull out of the study at any time.   
 
If you agree to take part in this study, you will be asked to sign the Consent Form 
on the last page of this document. You will be given a copy of both this Information 
Sheet and the Consent Form to keep. 
 
WHAT IS THE PURPOSE OF THE STUDY? 
Monitoring glucose levels with daily finger prick blood tests is a major part of 
diabetes care. The purpose of this study is to compare using a flash glucose 
monitoring (FGM) system (FreeStyle Libre) with using a glucose meter for managing 
diabetes among young people. To do this, we need two groups of participants in the 
study. We will compare the two groups to see if the FreeStyle Libre provides any 
benefit over finger prick glucose testing. This knowledge will help us understand if 
adding the FreeStyle Libre to diabetes management is useful for monitoring glucose 
levels and improving glucose control. If this technology is useful, our research 
findings will support publicly funded access to the FreeStyle Libre. This study will 
also give the diabetes care team more experience working with this technology.  
 
This study is being funded by a Cure Kids grant with additional financial support 
from the Dunedin School of Medicine at the University of Otago. Neither the 
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manufacturer nor the distributer of the FreeStyle Libre are funding this study in any 
way. This study has been approved by the Health and Disabilities Ethics Committee 
(ethics ref: 17/STH/240). 
 
If you have any questions, you are welcome to contact Dr Ben Wheeler, principal 
investigator (ben.wheeler@otago.ac.nz or 027 4701980) or Sara Boucher, study 
coordinator (sara.boucher@otago.ac.nz or 03 470 9167). 
 
WHAT WILL MY PARTICIPATION IN THE STUDY INVOLVE? 
You have been invited to participate in the study because you have been diagnosed 
with type 1 diabetes, you are between 13 and 20 years of age, inclusive, your 
average HbA1c over the past 6 months is above your target HbA1c, and you take 
insulin every day.  
 
If you are interested in joining the study, your diabetes specialist will check your 
medical records to make sure you meet certain criteria. If you are female, you will 
need to do a pregnancy test before starting the study to ensure you are not 
pregnant.  
 
If you are eligible to participate in the study, you will be randomly assigned to one 
of the groups. You will have a 50/50 chance of being assigned to either the 
intervention group or the comparison group.  
 
You will attend seven visits at the diabetes clinic over 12 months. These visits will 
take approximately one hour. At the first visit, we will ask you to sign the consent 
form and we will confirm that you are eligible for the study. At the second visit 
(approximately 7 days later), you will find out which group you are in.  
 
During the visits, you will be asked to: 
 
• complete questionnaires about your diabetes treatment and your quality of 
life. Some questions may be sensitive (for example, questions asking if you 
feel scared when you think about living with diabetes). You do not have to 
answer any questions that make you feel uncomfortable. 
• have your HbA1c measured with a finger prick test  
• bring your glucose meter so we can download your meter readings 
 
You will be asked to wear an activity monitor (like a watch) for one week prior to 
starting the study and 3- and 6-months after starting the study. The device will 
collect information about your sleep and physical activity habits. 
 
You will be sent an electronic questionnaire to complete every 2 weeks during the 
12-month study. This questionnaire will ask about any problems you’ve experienced 
related to your diabetes and your glucose monitoring device(s). 
 
151 
You will continue all of your usual diabetes care during the study period, the study 
is only providing the FreeStyle Libre system and technical support. The only 
difference between being in the study and not being in the study is the opportunity 
to be provided with FreeStyle Libre supplies at no cost to you. 
 
If your caregiver/parent agrees to participate in the study, he or she will complete 
questionnaires about your diabetes (for example, answering questions about things 
you may do in order to avoid problems with your diabetes). We will also collect 




If you are assigned to the intervention group, you will receive FreeStyle Libre 
supplies for 12 months (1 year) to monitor your glucose levels. The FreeStyle Libre 
glucose monitoring system uses a handheld reader to scan a tiny glucose sensor 
that is placed under the skin in the back of your arm. The reader will display the 
current glucose level in the tissue under your skin, which will be similar to your blood 
glucose level. You will not need to enter glucose readings from fingerprick blood 
tests to help the sensor read accurately. 
 
 
The sensor will be applied during the first visit. You may feel slight discomfort when 
the sensor enters your skin, but the discomfort should not last long. Each sensor 
lasts for 14 days and then needs to be replaced. You will come back to the clinic 14 
days after the sensor is inserted so that research staff can check your skin for any 
reactions to the sensor or the adhesive. The research staff will also supervise you 
inserting a new sensor by yourself. You will need to bring the FreeStyle Libre reader 




If you are assigned to the comparison group, you will continue finger prick blood 
testing with your glucose meter to monitor your glucose levels. The comparison 
group is very important for understanding whether or not the FreeStyle Libre system 
provides any benefits on top of standard blood glucose testing. After six months, 
you will be offered the FreeStyle Libre system for six months. 
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WHAT ARE THE POSSIBLE BENEFITS AND RISKS OF THIS STUDY? 
You may benefit from using flash glucose monitoring technology to monitor your 
glucose levels, which will help you manage your diabetes.  
 
The sensor application may cause discomfort. You may experience a skin reaction 
to the sensor or the adhesive. You will be asked to report any reactions to the 
sensor or the adhesive so that we can monitor these events and provide medical 
advice, if necessary.  
 
Your general practitioner (GP) and diabetes care team will be informed of your 
participation in the study and will be responsible for your care during the study.  
 
WHO PAYS FOR THE STUDY? 
You will not have to pay for anything. In addition to freestyle Libre supplies, you will 
receive small tokens of appreciation for completing questionnaires at follow-up 
visits.  
 
WHAT IF SOMETHING GOES WRONG? 
If you were injured in this study, which is unlikely, you would be eligible to apply for 
compensation from ACC just as you would be if you were injured in an accident at 
work or at home. You will have to lodge a claim with ACC, which may take some 
time to assess. If your claim is accepted, you will receive funding to assist in your 
recovery.  If you have private health or life insurance, you may wish to check with 
your insurer that taking part in this study won’t affect your cover. 
 
WHAT ARE MY RIGHTS? 
You have a right to see information collected about you as part of the study and the 
information will only be shared with research staff for the purposes of the study.  You 
will be told of any new information about harmful or helpful effects related to the 
FreeStyle Libre that become available during the study that may have an impact on 
your health. Your study information will be safely stored in the Department of 
Women’s and Children’s Health, University of Otago, in such a way that only the 
study investigators will be able to gain access to it. You will not be identified in any 
reports written about the study.  
 
WHAT HAPPENS AFTER THE STUDY OR IF I CHANGE MY MIND? 
No intervention will be available to participants after the study.  
 
Personal information about you which can identify you as an individual person will 
be destroyed when the researchers are finished with this project but the raw data 
(questionnaire responses, glucose monitor data) on which the results of the project 
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depend will be safely stored for 10 years after you turn 16 years old (i.e. aged 26 
years). Information collected about you may be used for other future research. 
 
Study findings are expected within one year of the end of the study. A summary of 
the study findings will be sent to you at the email you provide.  
 
WHO DO I CONTACT FOR MORE INFORMATION OR IF I HAVE CONCERNS? 
If you have any questions, concerns or complaints about the study at any stage, 
you can contact Dr Ben Wheeler, Principal Investigator (ben.wheeler@otago.ac.nz
  or 027 470 1980). 
 
If you want to talk to someone who isn’t involved with the study, you can contact 
an independent health and disability advocate on: 
 
Phone:  0800 555 050 
Fax:   0800 2 SUPPORT (0800 2787 7678) 
Email:  advocacy@hdc.org.nz 
 
For Māori health support please contact : 
 
Arai Te Uru Whare Hauora 
25 College Street 
Caversham 
Dunedin 9012 
03 471 9960 
 
You can also contact the health and disability ethics committee (HDEC) that 
approved this study on: 
 
 Phone: 0800 4 ETHICS 









Please tick to indicate you consent to the following  
 
I have read, or have had read to me in my first language, and 
I understand the Participant Information Sheet.   
Yes  No  
I have been given sufficient time to consider whether or not to 
participate in this study. 
Yes  No  
I have had the opportunity to use a legal representative, 
whanau/ family support or a friend to help me ask questions 
and understand the study. 
Yes  No  
I am satisfied with the answers I have been given regarding 
the study and I have a copy of this consent form and 
information sheet. 
Yes  No  
I understand that taking part in this study is voluntary (my 
choice) and that I may withdraw from the study at any time 
without this affecting my medical care. 
Yes  No  
I consent to the research staff collecting and processing my 
information, including information about my health. 
Yes  No  
If I decide to withdraw from the study, I agree that the 
information collected about me up to the point when I 
withdraw may continue to be processed. 
Yes  No  
I consent to my GP or current provider being informed about 
my participation in the study and of any significant abnormal 
results obtained during the study. 
Yes  No  
I agree to an approved auditor appointed by the New Zealand 
Health and Disability Ethic Committees, or any relevant 
regulatory authority or their approved representative reviewing 
my relevant medical records for the sole purpose of checking 
the accuracy of the information recorded for the study. 
Yes  No  
 
If you need an INTERPRETER, please tell us. 
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I understand that my participation in this study is confidential 
and that no material, which could identify me personally, will 
be used in any reports on this study. 
Yes  No  
I understand the compensation provisions in case of injury 
during the study. 
Yes  No  
I know who to contact if I have any questions about the study 
in general. 
Yes  No  
I understand my responsibilities as a study participant. Yes  No  
I wish to receive a summary of the results from the study. Yes  No  
I consent to being contacted for future research. Yes  No  
 
 
Declaration by participant: 
 







Declaration by member of research team: 
 
I have given a verbal explanation of the research project to the participant, and 
have answered the participant’s questions about it.   
 
I believe that the participant understands the study and has given informed 











Managing Diabetes in a Flash - Study Enrolment - Adolescent 
Date: _______________    Study ID: _________________ 
 
PERSONAL INFORMATION: 
Name (first name and surname): ____________________________________ 
Home address (street, suburb, city and postcode):  
_______________________________________________________________________
__ 
Tel: _______________________________  Email: 
___________________________ 
Name of G.P. ________________________ Practice: 
_________________________ 
Name of lead diabetes clinician: _______________________ 
 
1.  Age: ________ Date of Birth: _________________ 
 
2.  How do you describe yourself? 
☐ Male  
 ☐ Female 
 ☐ Different identity (please state): ____________ 
 
3. What year are you in school? 
 ☐ Year 8 
 ☐ Year 9 
 ☐ Year 10 
 ☐ Year 11 
 ☐ Year 12 
 ☐ Year 13 




4.  Which ethnic group(s) do you belong to?  
Please tick the box or boxes that apply to you. 
 ☐ New Zealand European  
 ☐ Māori, iwi: _____________________________ 
 ☐ Samoan 
 ☐ Cook Island Māori  
 ☐ Tongan 
 ☐ Niuean 
 ☐ Chinese 
 ☐ Indian 
☐ Other such as Dutch, Japanese, Tokelauan (Please specify) 
________________________________________________________ 
 
5.  Do you have a paid occupation?  
☐ No 
☐ Yes, full-time (37.5 hours per week or more) 
☐ Yes, part-time (less than 37.5 hours per week)  
 ☐ Other, please describe: _____________________ 
 
6.  How many children aged 0 to 18 years, live in your household? ______ 
Include yourself if you are between 13 and 18 years old, inclusive. 
 
7.  On a typical day, how many times do you check your blood glucose level?  
☐ 0 
 ☐ 1  
 ☐ 2 
 ☐ 3 
 ☐ 4 
 ☐ 5 
☐ 6+ 
 
8.  What is your current diabetes therapy?  
☐ Insulin injections     ☐ Insulin pump ☐ Other: 
_______________________      
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9.  Do you have plans to change your therapy in the near future (for example, 
you have pump training booked)?  
☐ Yes     ☐ No 
 
10.  In the past 6 months, have you experienced any episodes of significant 
hypoglycaemia (e.g. resulting in seizure, loss of consciousness, ambulance, ED 
visit, hospitalisation)   
☐ No     ☐ Yes If yes, how many episodes? _____ 
 
11.  In the past 6 months, have you experienced any episodes of diabetic 
ketoacidosis (DKA; resulting in ambulance, ED visit, hospitalisation) 
  ☐ No      ☐ Yes If yes, how many episodes? _____ 
 
12.  In the past 6 months, have you experienced any episodes of skin conditions 
or allergies (e.g., eczema, irritant dermatitis, allergic contact dermatitis) 
  ☐ No      ☐ Yes    






























6.2 Appendix 2: ‘The ‘Flash’ adhesive study: A randomised 
crossover trial using an additional adhesive patch to prolong 
Freestyle Libre sensor life among youth with Type 1 Diabetes 
Mellitus’ study 
 
6.2.1 Appendix 2a: Research protocol 
 
‘Flash’ Adhesive Study: Randomized crossover trial investigating adhesive 
patches/supplemental tape to prolong the FreeStyle Libre sensor life among 
adolescents with type 1 diabetes 
Background 
Flash glucose monitoring (FGM) is a new technology which provides accurate and up-to-
date interstitial glucose information for people with diabetes, without requiring painful 
daily finger pricking to check blood glucose levels for making treatment decisions. In this 
way, FGM may offer particular advantages to an adolescent/young adult population 
where motivation is often lacking and disease burden is high.  
A key component of FGM is the sensor, which is held in place on the upper arm by an 
adhesive and can remain in situ for up to 14 days before being replaced. Little 
information is available on how well sensors are tolerated, or last, over this 14-day 
period. Activities such as farm work, contact sports, and even changing a shirt are 
opportunities for the sensor adhesive to be compromised. Reduced sensor life due to 
poor adhesion or a cutaneous adverse event (eg, pain, bleeding, swelling, itching) is a risk, 
and may considerably add to the burden and cost of using FGM. Sensors cost $95 NZD 
each and are currently not publically funded in NZ; therefore, prolonging sensor life 
would contribute not only to diabetes management benefits of FGM, but also to the cost 
effectiveness of the product. 
Specific aims: This project is a sub-study of a larger programme (HDEC reference number: 
17/STH/240) investigating the impact of ‘flash’ glucose monitoring on glycaemic control 
in youth with unhealthy glycaemic control. The main study is comprised of two phases 
that include a 6-month randomised controlled trial (RCT) followed by a 6-month 
continuation study where all participants will be given a 6-month FGM supply. We 
propose to add a sub-study to the 6-month continuation study investigate whether 
adding additional adhesive tape or dressings to FGM sensors: 1) prolongs FGM sensor life 
in youth and young adults with T1DM; and 2) does not contribute to additional cutaneous 
adverse events.  
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Research plan 
Participants will be recruited from the Managing diabetes in a “flash” RCT continuation 
phase. This study is a multisite study encompassing patients (n=64) from Southern, South 
Canterbury, Canterbury, and Capital and Coast DHBs.  
Main study inclusion criteria: 1) T1D diagnosis > 12 months; 2) aged 13 to 20 years 
(inclusive at study commencement); 4) >0.05 units of insulin/kg/day (with no restrictions 
based on insulin regimen), 5) mean HbA1c ≥75 mmol/mol over previous 6 months. 
Exclusion criteria: 1) Any severe diabetes related complications; 2) severe medical or 
psychiatric co-morbidity/severe mental illness; 3) participation in another device or drug 
study that could affect glucose measurements; 4) plans to leave study site regions prior 
to study completion. There are no additional inclusion/exclusion criteria for the proposed 
sub-study.  
The proposed sub-study spans 6 months and consists of all participants completing 2 x 3-
month intervention cycles, the order of which will be randomised. The two intervention 
options are: 1) standard FGM sensor with no additional adhesive or dressing; 2) standard 
FGM sensor with a circular ‘patch’ made from commercially available RockTape (a brand 
of kinesiology tape). Each 3-month intervention will consist of 6 sensor sessions, each 
lasting a maximum of 14 days. 
 
Randomisation  
The randomization sequence will be generated by one of the investigators (AG) using 
Stata software (version 11.2 for MAC; StataCorp, College Station, TX). and entered into a 
spreadsheet of group allocation (Rockadex patch or control) with sequence numbers and 
codes. The spreadsheet will be printed and cut so that individual slips of paper with the 
sequence number and group allocation will be put into an opaque envelope labelled with 
the sequence number. Once a participant’s 6-month visit is scheduled, the next envelope 
will be opened and the group assignment will be added to the 6-month study visit details 
in REDCap and the randomization process is completed.    
 
Procedures 
Before 6-month visit 
- Research staff to post ‘Flash’ Adhesive Study participant information sheet and 
consent/assent form with ActiGraph (activity monitor) approximately 2 weeks 
before 6-month visit is due. 
- Participants in the FGM group will have their visit scheduled for a day their sensor 
change is due. 
 
During 6-month visit 
- Research staff to obtain consent/assent as appropriate for ‘Flash’ Adhesive Study. 
168 
- At end of visit, research staff reveals sub-study group to participant. All 
participants to receive 3-month supply of patches and adhesive remover wipes. 
 
Intervention group 
Participants randomized to the intervention will be instructed to apply a pre-cut 
Rockadex ‘patch’ immediately after applying each new sensor for the next three months 
(13 sensors). Research staff will use the enclosed handout to educate the participant on 
preparing the skin for the patch and removing the patch to reduce risk of skin irritation. 
At the 9-month visit, intervention group participants will cross over to the control group.  
 
Control group 
Participants randomized to the control group will be instructed to use the Libre sensor as 
per manufacturer’s instructions.  At the 9-month visit, control group participants will 
cross over to the intervention group. 
 
Measures and data collection 
An event diary has been given to all participants to record day to day issues with FGM 
sensors. All participants will continue sending electronic photos of skin irritations via 
email or multimedia messaging service (MMS; ie, via their phone) and completing the 
usual electronic safety survey questionnaire, which collects information on skin-specific 
adverse events (i.e., redness, pain, itching, bruising, swelling) as well as sensor issues 
(e.g., sensor falling off before end of 14-day session), and more serious events such as 
FGM-associated diabetic ketoacidosis or severe hypoglycaemia. Clinical assessment will 
be conducted for cutaneous issues that arise.  
Overall acceptability data and patient satisfaction will be self-reported every 14 days via 
an electronic questionnaire.  
Duration of sensor wear will be extracted from Libre downloads at the 9-month and 12-
month visits. 
 
Statistical analysis and sample size 
As an illustration of the power in this study, given n=58 participants expected at the start 
of the six month period (90% of the n=64 starting the main trial), assuming each 
participant provides data from at least one 14 day period of the four cycles within each of 
the three treatments, and so a mean survival duration can be calculated for each 
treatment phase, and assuming that loss to follow-up is no more than 10% (so n=52 at six 
months), we would have 80% power to detect mean differences of 0.40 SDs (a small-
medium effect) in survival durations between any two treatments using.  
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MANAGING DIABETES IN A ‘FLASH’ 
SENSOR ADHESION GUIDE 
Skin preparation for sensor  
Adapted from FreeStyle LIbre System Sensor Adhesion Guide 
Select an area of skin on the back of your upper arm that generally stays flat during 
normal daily activities (no bending or folding). To prevent discomfort or skin irritation, 
you should select a different site other than the one most recently used.  
SITUATION SOLUTION 
Oily surface  
Soap, lotion, shampoo or conditioner 
might leave oily residue on the skin that 
may prevent the sensor from sticking 
properly. 
To improve adhesion, clean the skin with 
soap and water, dry the skin, clean the 
skin with an alcohol wipe and allow skin to 
air dry (do not blow on it) before 
proceeding.  
Wet surface  
Moisture gets in the way of adhesion. 
Keep the skin dry prior to application. 
To improve adhesion, dry the skin, clean 
the skin with an alcohol wipe and allow 
skin to air dry (do not blow on it) before 
proceeding. 
Hairy surface  
Hair gets in-between the skin & sensor 
adhesive. 
The site selected on the back of the upper 
arm should be clean-shaven. 
 
What are Rockadex patches? 
Rockadex patches are pieces of kinesiology tape pre-cut to the shape of the FreeStyle 
Libre sensor with a precut hole for ventilation. The patch is made from cotton, nylon, and 
acrylic (there is no latex or zinc oxide in the material), is water resistant, and can usually 
be worn for 3-5 days. If you have a history of skin irritation from RockTape then the study 
will provide you with Hypafix.  
Cleaning your skin before applying Rockadex patches 
Adapted from Messer et al, 2018 
Your skin needs to be free of oils, moisturisers and sweat to ensure the patch adheres 
effectively to your skin. Clean your skin around your sensor before applying the patch; 
however, do not apply the sensor and/or patch immediately after a shower/bath or in a 
steamy bathroom. It is very important that your skin is dry. You can minimize moisture 
with a hairdryer and humidity by applying in a dry environment.  
170 
Removing the patch – “low and slow” 
The patch comes off more easily when it is wet. We’ve provided you with adhesive 
remover wipes to help remove the patch. You are welcome to try baby oil, coconut oil, or 
olive oil instead. When using prepacked adhesive removal wipes, tear the outer package 
in half and discard the top half. Hold the bottom half to avoid touching the adhesive 
remover. Always wash the area thoroughly with soap, rinse, and dry after using a removal 
product to clean away residue. 
 
Peel the tape back on itself slowly, in the direction of hair growth, and support the skin 




Once the adhesive patch is removed, inspect the area for skin irritation.  
If skin is intact and not bothersome, you may choose to leave it alone or apply 
moisturizing lotion to sooth and protect skin.  
If skin is irritated or broken, but not obviously infected, contact the Flash Study (mobile: 
021 221 1182 or flashstudy@otago.ac.nz) and give a complete description of the skin 
problem (ie, where the skin is irritated or broken, what it looks like, how it feels, the 
degree of discomfort you feel).  
If skin is broken, and you experience worsening pain, itching, spreading redness, heat, 
pus, formation of pustules (looks like a pus-filled pimple/blister), or a burning sensation 
then infection is suspected. Contact the Flash Study (mobile: 021 221 1182 or 
flashstudy@otago.ac.nz)for assessment and prescription antibiotics if needed.  
ALWAYS TAKE A PHOTO OF IRRITATED SKIN AND SENT TO THE STUDY TEAM 







6.2.2 Appendix 2b: Information sheet and assent form for participants 
aged 13-15  
Participant Information Sheet (ages 13-15) 
 
Study title: ‘Flash’ adhesive study: A randomised trial comparing tape and dressings to prolong 
sensor life in youth using the FreeStyle Libre flash glucose monitoring system  
 
Localities: Canterbury District Health Board 
Capital and Coast DHB 
Southern DHB 




Regional lead  
co-investigators 
 
Dr Ben Wheeler 
 
Dr Martin de Bock (CDHB) 
Dr Esko Wiltshire (CCDHB) 
 
Contact phone number: 
 
021 221 1182 
 
You are invited to take part in a study to investigate whether applying a ‘patch’ on 
top of your FreeStyle Libre sensors protects the sensors from falling off before the 
end of their 14-day session. This Information Sheet will help you decide if you’d like 
to take part.  It sets out why we are doing the study, what it involves, what the 
benefits and risks are, and what would happen after the study ends. We will go 
through this information with you and answer any questions you may have. Before 
you decide you may want to talk about the study with other people, such as family, 
whānau, friends, or your diabetes team.  Feel free to do this. 
 
Whether or not you take part is your choice. If you don’t want to take part, you don’t 
have to give a reason, and it won’t affect the care you receive, or your ongoing 
participation in the “Flash” study. If you do want to take part now, but change your 
mind later, you can pull out of the study at any time.   
 
If you agree to take part in this study, you will be asked to sign the Consent Form 
on the last page of this document. You will be given a copy of both this Information 
Sheet and the Consent Form to keep. 
 
WHAT IS THE PURPOSE OF THE STUDY? 
This is a new add-on study to the Managing Diabetes in a ‘Flash’ study, which is 
investigating the impact of flash glucose monitoring among adolescents with type 1 
diabetes. A key component of flash glucose monitoring is the sensor, which is held 
in place on the upper arm by an adhesive. Ideally, the sensor stays in place for the 
full 14-day period. Sometimes, however, the sensor falls off, which is disruptive to 
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checking and monitoring glucose levels. For patients outside of this study who buy 
their own sensors, this sensor failure can become costly.  
 
The ‘Flash’ Adhesive Study will investigate if an inexpensive ‘patch’ made from 
RockTape (a brand of hypoallergenic tape made from cotton, nylon, and acrylic) 
placed over the sensor at the start of the session prolongs the life of the sensor. 
The patches have already been supplied to participants in this study with minimal 
skin problems occurring with use. For participants with a known sensitivity to 
RockTape, the study will provide an alternative tape such as Hypafix. We will also 
investigate skin problems related to wearing the sensor patch.  
 
If wearing tape over the sensor is shown to prolong the sensor life, then patients 
and diabetes care teams can easily incorporate adding tape as part of the flash 
glucose monitoring routine, potentially saving money for self-funders and possibly 
be considered for government funding in the future.  
 
This sub-study is being funded by an APEG Sanofi grant. Neither the manufacturer 
nor the distributer of the FreeStyle Libre or RockTape are funding this study in any 
way. This study has been approved by the Health and Disabilities Ethics Committee 
(ethics ref: 17/STH/240). 
 
If you have any questions, you are welcome to contact Dr Ben Wheeler, principal 
investigator (ben.wheeler@otago.ac.nz or 027 4701980) or Sara Boucher, study 
coordinator (sara.boucher@otago.ac.nz or 03 470 9167). 
 
WHAT WILL MY PARTICIPATION IN THE STUDY INVOLVE? 
You have been invited to participate in the ‘Flash’ Adhesive Study because you are 
already enrolled in Managing Diabetes in a ‘Flash’ and have been, or will begin, 
using the FreeStyle Libre flash glucose monitoring system.  
 
If you decide to participate in this add-on study, you will be randomly assigned to 
one of two groups. You will have a 50/50 chance of being assigned to either the 
intervention group for 3 months or the comparison group for 3 months. After 3 
months, you will cross over to the other group.  
 
You will continue completing electronic safety survey questionnaires every 2 weeks 
and continue all of your usual diabetes care during the study period, the ‘Flash’ 
Adhesive Study is only providing sensor patches and adhesive remover wipes. The 
only difference between being in the study and not being in the study is being 
randomised to either using a patch at the start of your sensor sensors for 3 months 
or to not using a patch (or other protective material) for 3 months if the sensor 
adhesive is loose. If you choose not to be randomised to a group, you will still 






If you are assigned to begin the intervention group first, you will be asked to apply 
the protective patch at the start of each sensor session for 3 months. Patches 
typically last for 3-5 days. When the patch is no longer providing a protective benefit, 
you will use adhesive remover wipes provided by the study to remove the old patch 
and apply a new one. At the end of 3 months, you will cross over to the comparison 




If you are assigned to begin in the comparison group, you will receive a supply of 
patches to protect your FreeStyle Libre sensor. For 3 months, you will be asked to 
apply the patch only if you notice the adhesive coming loose. After 3 months, you 
will cross over to the intervention group for 3 months. 
 
WHAT ARE THE POSSIBLE BENEFITS AND RISKS OF THIS STUDY? 
You may benefit from using protective sensor patches by possibly experiencing 
fewer disruptions to monitoring your glucose levels due to sensor loss associated 
with adhesive failure.  
You may experience a skin reaction to the protective sensor patch. You will be 
asked to report any reactions to the sensor or the adhesive so that we can monitor 
these events and provide medical advice, if necessary.  
WHO PAYS FOR THE STUDY? 
You will not have to pay for anything. The patches are being paid for by a Sanofi 
grant. 
 
WHAT IF SOMETHING GOES WRONG? 
If you were injured in this study, which is unlikely, you would be eligible to apply for 
compensation from ACC just as you would be if you were injured in an accident at 
work or at home. You will have to lodge a claim with ACC, which may take some 
time to assess. If your claim is accepted, you will receive funding to assist in your 
recovery.  If you have private health or life insurance, you may wish to check with 
your insurer that taking part in this study won’t affect your cover. 
 
WHAT ARE MY RIGHTS? 
You have a right to see information collected about you as part of the study and the 
information will only be shared with research staff for the purposes of the study.  You 
will be told of any new information about harmful or helpful effects related to the 
FreeStyle Libre and protective sensor patches that become available during the 
study that may have an impact on your health. Your study information will be safely 
stored in the Department of Women’s and Children’s Health, University of Otago, in 
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such a way that only the study investigators will be able to gain access to it. You will 
not be identified in any reports written about the study.  
 
WHAT HAPPENS AFTER THE STUDY OR IF I CHANGE MY MIND? 
Personal information about you which can identify you as an individual person will 
be destroyed when the researchers are finished with this project but the raw data 
(questionnaire responses, glucose monitor data) on which the results of the project 
depend will be safely stored for 10 years after you turn 16 years old (i.e. aged 26 
years). Information collected about you may be used for other future research. 
 
Study findings are expected within one year of the end of the study. A summary of 
the study findings will be sent to you at the email you provide. The ‘Flash’ Adhesive 
Study results will be presented at an Australasian Paediatric Endocrine Group 
annual scientific meeting and the findings will be submitted to a scientific journal. 
 
WHO DO I CONTACT FOR MORE INFORMATION OR IF I HAVE CONCERNS? 
If you have any questions, concerns or complaints about the study at any stage, 
you can contact Dr Ben Wheeler, Principal Investigator (ben.wheeler@otago.ac.nz
  or 027 470 1980), Sara Boucher, Study Coordinator 
(sara.boucher@otago.ac.nz), or the lead regional co-investigator (Christchurch: Dr 
Martin de Bock, martin.debock@otago.ac.nz; Wellington: Dr Esko Wiltshire, 
esko.wiltshire@otago.ac.nz). 
 
If you want to talk to someone who isn’t involved with the study, you can contact 
an independent health and disability advocate on: 
 
Phone:  0800 555 050 
Fax:   0800 2 SUPPORT (0800 2787 7678) 
Email:  advocacy@hdc.org.nz 
 
For Māori health support please contact : 
 
Arai Te Uru Whare Hauora 
25 College Street 
Caversham 
Dunedin 9012 
03 471 9960 
 
Debbie Rawiri 
Diabetes Centre (Canterbury DHB) 
Phone: 03 364 0860 
Email: Debbie.rawiri@cdhb.health.nz 
 









You can also contact the health and disability ethics committee (HDEC) that 
approved this study on: 
 
 Phone: 0800 4 ETHICS 
 Email:  hdecs@moh.govt.nz 
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Assent Form (ages 13-15) 
 
Declaration by participant: 







Declaration by member of research team: 
I have given a verbal explanation of the research project to the participant, and 
have answered the participant’s questions about it.   
 
I believe that the participant understands the study and has given informed 






6.2.3 Appendix 2c: Information sheet and consent form for parents of 
participants aged 13-15  
Participant Information Sheet (for parents of 
participants aged 13-15) 
 
Study title: ‘Flash’ adhesive study: A randomised trial comparing tape and dressings to prolong 
sensor life in youth using the FreeStyle Libre flash glucose monitoring system  
 
Localities: Canterbury District Health Board 
Capital and Coast DHB 
Southern DHB 







Dr Ben Wheeler 
 
Dr Martin de Bock (CDHB) 
Dr Esko Wiltshire (CCDHB) 
 
Contact phone number: 
 
021 221 1182 
 
Your child is invited to take part in a study to investigate whether applying a ‘patch’ 
on top of their FreeStyle Libre sensors protects the sensors from falling off before 
the end of the 14-day session. This Information Sheet will help you decide if you’d 
like your child to take part.  It sets out why we are doing the study, what it involves, 
what the benefits and risks are, and what would happen after the study ends. We 
will go through this information with you and answer any questions you may have. 
Before you decide you may want to talk about the study with other people, such as 
family, whānau, friends, or your diabetes team.  Feel free to do this. 
 
Whether or not your child takes part is your choice. If you don’t want your child to 
take part, you don’t have to give a reason, and it won’t affect the care your child 
receives, or your child’s ongoing participation in the “Flash” study. If you do want 
your child to take part now, but change your mind later, your child can pull out of the 
study at any time.   
 
If you agree for your child to take part in this study, you will be asked to sign the 
Consent Form on the last page of this document. You will be given a copy of both 
this Information Sheet and the Consent Form to keep. 
 
WHAT IS THE PURPOSE OF THE STUDY? 
This is a new add-on study to the Managing Diabetes in a ‘Flash’ study, which is 
investigating the impact of flash glucose monitoring among adolescents with type 1 
diabetes. A key component of flash glucose monitoring is the sensor, which is held 
in place on the upper arm by an adhesive. Ideally, the sensor stays in place for the 
full 14-day period. Sometimes, however, the sensor falls off, which is disruptive to 
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checking and monitoring glucose levels. For patients outside of this study who buy 
their own sensors, this sensor failure can become costly.  
The ‘Flash’ Adhesive Study will investigate if an inexpensive ‘patch’ made from 
RockTape (a brand of hypoallergenic tape made from cotton, nylon, and acrylic) 
placed over the sensor at the start of the session prolongs the life of the sensor. 
The patches have already been supplied to participants in this study with minimal 
skin problems occurring with use. For participants with a known sensitivity to 
RockTape, the study will provide an alternative tape such as Hypafix. We will also 
investigate skin problems related to wearing the sensor patch.  
 
If wearing tape over the sensor is shown to prolong the sensor life, then patients 
and diabetes care teams can easily incorporate adding tape as part of the flash 
glucose monitoring routine, potentially saving money for self-funders and possibly 
be considered for government funding in the future.  
 
This sub-study is being funded by an APEG Sanofi grant. Neither the manufacturer 
nor the distributer of the FreeStyle Libre or RockTape are funding this study in any 
way. This study has been approved by the Health and Disabilities Ethics Committee 
(ethics ref: 17/STH/240). 
 
If you have any questions, you are welcome to contact Dr Ben Wheeler, principal 
investigator (ben.wheeler@otago.ac.nz or 027 4701980) or Sara Boucher, study 
coordinator (sara.boucher@otago.ac.nz or 03 470 9167). 
 
WHAT WILL MY PARTICIPATION IN THE STUDY INVOLVE? 
Your child has been invited to participate in the ‘Flash’ Adhesive Study because 
they are already enrolled in Managing Diabetes in a ‘Flash’ and have been, or will 
begin, using the FreeStyle Libre flash glucose monitoring system.  
 
If your child decides to participate in this add-on study, your child will be randomly 
assigned to one of two groups. Your child will have a 50/50 chance of being 
assigned to either the intervention group for 3 months or the comparison group for 
3 months. After 3 months, your child will cross over to the other group for 3 months.  
 
Your child will continue completing electronic safety survey questionnaires every 2 
weeks and continue all of their usual diabetes care during the study period, the 
‘Flash’ Adhesive Study is only providing sensor patches and adhesive remover 
wipes (to clean off adhesive residue). The only difference between being in the 
study and not being in the study is being randomised to either using a patch at the 
start of the sensor session for 3 months or not using a patch at all for 3 months, 
then each group will cross over to the other group for 3 months. If you choose not 
to be randomised to a group, you will still receive protective sensor patches to use 





If your child is randomised to begin in the intervention group first, your child will be 
asked to apply the protective patch at the start of each sensor session for 3 months. 
Patches typically last for 3-5 days. When the patch is no longer providing a 
protective benefit, your child will use adhesive remover wipes provided by the study 
to remove the old patch and apply a new one. At the end of 3 months, your child will 
cross over to the comparison group for 3 months. 
 
Comparison Group 
If your child is randomised to begin in the comparison group, your child will be asked 
to not put anything on top of their sensor if it becomes loose. After 3 months, your 
child will cross over to the intervention group for 3 months. 
 
WHAT ARE THE POSSIBLE BENEFITS AND RISKS OF THIS STUDY? 
Your child may benefit from using protective sensor patches by possibly 
experiencing fewer disruptions to monitoring their glucose levels due to sensor 
loss associated with adhesive failure.  
 
Your child may experience a skin reaction to the protective sensor patch. Your 
child will be asked to report any reactions to the sensor or the adhesive so that we 
can monitor these events and provide medical advice, if necessary.  
 
WHO PAYS FOR THE STUDY? 
You will not have to pay for anything. The patches are being paid for by a Sanofi 
grant. 
 
WHAT IF SOMETHING GOES WRONG? 
If your child was injured in this study, which is unlikely, you would be eligible to apply 
for compensation from ACC just as you would be if you were injured in an accident 
at work or at home. You will have to lodge a claim with ACC, which may take some 
time to assess. If your claim is accepted, you will receive funding to assist in your 
recovery.  If you have private health or life insurance, you may wish to check with 
your insurer that taking part in this study won’t affect your cover. 
 
WHAT ARE MY RIGHTS? 
You have a right to see information collected about your child as part of the study 
and the information will only be shared with research staff for the purposes of the 
study.  You will be told of any new information about harmful or helpful effects 
related to the FreeStyle Libre and protective sensor patches that become available 
during the study that may have an impact on your health. Your child’s study 
information will be safely stored in the Department of Women’s and Children’s 
Health, University of Otago, in such a way that only the study investigators will be 
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able to gain access to it. You will not be identified in any reports written about the 
study.  
 
WHAT HAPPENS AFTER THE STUDY OR IF I CHANGE MY MIND? 
Personal information about your child which can identify your child as an individual 
person will be destroyed when the researchers are finished with this project but the 
raw data (questionnaire responses, glucose monitor data) on which the results of 
the project depend will be safely stored for 10 years after you turn 16 years old (i.e. 
aged 26 years). Information collected about your child may be used for other future 
research. 
 
Study findings are expected within one year of the end of the study. A summary of 
the study findings will be sent to you at the email you provide. The ‘Flash’ Adhesive 
Study results will be presented at an Australasian Paediatric Endocrine Group 
annual scientific meeting and the findings will be submitted to a scientific journal. 
 
WHO DO I CONTACT FOR MORE INFORMATION OR IF I HAVE CONCERNS? 
If you have any questions, concerns or complaints about the study at any stage, 
you can contact Dr Ben Wheeler, Principal Investigator (ben.wheeler@otago.ac.nz
  or 027 470 1980), Sara Boucher, Study Coordinator 
(sara.boucher@otago.ac.nz), or the lead regional co-investigator (Christchurch: Dr 
Martin de Bock, martin.debock@otago.ac.nz; Wellington: Dr Esko Wiltshire, 
esko.wiltshire@otago.ac.nz). 
 
If you want to talk to someone who isn’t involved with the study, you can contact 
an independent health and disability advocate on: 
 
Phone:  0800 555 050 
Fax:   0800 2 SUPPORT (0800 2787 7678) 
Email:  advocacy@hdc.org.nz 
 
For Māori health support please contact : 
 
Arai Te Uru Whare Hauora 
25 College Street 
Caversham 
Dunedin 9012 
03 471 9960 
 
Debbie Rawiri 
Diabetes Centre (Canterbury DHB) 












You can also contact the health and disability ethics committee (HDEC) that 
approved this study on: 
 
 Phone: 0800 4 ETHICS 









Please tick to indicate you consent to the following  
 
I have read, or have had read to me in my first language, and 
I understand the Participant Information Sheet.   
Yes  No  
I have been given sufficient time to consider whether or not 
allow my child to participate in this study. 
Yes  No  
I have had the opportunity to use a legal representative, 
whanau/ family support or a friend to help me ask questions 
and understand the study. 
Yes  No  
I am satisfied with the answers I have been given regarding 
the study and I have a copy of this consent form and 
information sheet. 
Yes  No  
I understand that my child taking part in this study is voluntary 
(my choice) and that I may withdraw my child from the study 
at any time without this affecting my child’s medical care. 
Yes  No  
I consent to the research staff collecting and processing my 
child’s information, including information about my child’s 
health. 
Yes  No  
If I decide to withdraw my child from the study, I agree that the 
information collected about my child up to the point when I 
withdraw my child may continue to be processed. 
Yes  No  
I consent to my child’s GP or current provider being informed 
about my child’s participation in the study and of any 
significant abnormal results obtained during the study. 
Yes  No  
I agree to an approved auditor appointed by the New Zealand 
Health and Disability Ethic Committees, or any relevant 
regulatory authority or their approved representative reviewing 
my child’s relevant medical records for the sole purpose of 
checking the accuracy of the information recorded for the 
study. 
Yes  No  
 
If you need an INTERPRETER, please tell us. 
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I understand that my child’s participation in this study is 
confidential and that no material, which could identify my child 
personally, will be used in any reports on this study. 
Yes  No  
I understand the compensation provisions in case of injury 
during the study. 
Yes  No  
I know who to contact if I have any questions about the study 
in general. 
Yes  No  
I understand my child’s responsibilities as a study participant. Yes  No  
I wish to receive a summary of the results from the study. Yes  No  
I consent to being contacted for future research. Yes  No  
 
 
Declaration by participant: 
I hereby consent to my child taking part in this study. 
 
Child’s name: 





Declaration by member of research team: 
I have given a verbal explanation of the research project to the participant, and 
have answered the participant’s questions about it.   
 
I believe that the participant understands the study and has given informed 






6.2.4 Appendix 2d: Information sheet and consent form for participants 
aged 16+ 
Participant Information Sheet (ages 16+) 
 
Study title: ‘Flash’ adhesive study: A randomised trial comparing tape and dressings to prolong 
sensor life in youth using the FreeStyle Libre flash glucose monitoring system  
 
Localities: Canterbury District Health Board 
Capital and Coast DHB 
Southern DHB 







Dr Ben Wheeler 
 
Dr Martin de Bock (CDHB) 
Dr Esko Wiltshire (CCDHB) 
 
Contact phone number: 
 
021 221 1182 
 
You are invited to take part in a study to investigate whether applying a ‘patch’ on 
top of your FreeStyle Libre sensors protects the sensors from falling off before the 
end of their 14-day session. This Information Sheet will help you decide if you’d like 
to take part.  It sets out why we are doing the study, what it involves, what the 
benefits and risks are, and what would happen after the study ends. We will go 
through this information with you and answer any questions you may have. Before 
you decide you may want to talk about the study with other people, such as family, 
whānau, friends, or your diabetes team.  Feel free to do this. 
 
Whether or not you take part is your choice. If you don’t want to take part, you don’t 
have to give a reason, and it won’t affect the care you receive or your ongoing 
participation in the “Flash” study. If you do want to take part now, but change your 
mind later, you can pull out of the study at any time.   
 
If you agree to take part in this study, you will be asked to sign the Consent Form 
on the last page of this document. You will be given a copy of both this Information 
Sheet and the Consent Form to keep. 
 
WHAT IS THE PURPOSE OF THE STUDY? 
This is a new add-on study to the Managing Diabetes in a ‘Flash’ study, which is 
investigating the impact of flash glucose monitoring among adolescents with type 1 
diabetes. A key component of flash glucose monitoring is the sensor, which is held 
in place on the upper arm by an adhesive. Ideally, the sensor stays in place for the 
full 14-day period. Sometimes, however, the sensor falls off, which is disruptive to 
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checking and monitoring glucose levels. For patients outside of this study who buy 
their own sensors, this sensor failure can become costly.  
 
The ‘Flash’ Adhesive Study will investigate if an inexpensive ‘patch’ made from 
RockTape (a brand of hypoallergenic tape made from cotton, nylon, and acrylic) 
placed over the sensor at the start of the session prolongs the life of the sensor. 
The patches have already been supplied to participants in this study with minimal 
skin problems occurring with use. For participants with a known sensitivity to 
RockTape, the study will provide an alternative tape such as Hypafix. We will also 
investigate skin problems related to wearing the sensor patch.  
 
If wearing tape over the sensor is shown to prolong the sensor life, then patients 
and diabetes care teams can easily incorporate adding tape as part of the flash 
glucose monitoring routine, potentially saving money for self-funders and possibly 
be considered for government funding in the future.  
 
This sub-study is being funded by an APEG Sanofi grant. Neither the manufacturer 
nor the distributer of the FreeStyle Libre or RockTape are funding this study in any 
way. This study has been approved by the Health and Disabilities Ethics Committee 
(ethics ref: 17/STH/240). 
 
If you have any questions, you are welcome to contact Dr Ben Wheeler, principal 
investigator (ben.wheeler@otago.ac.nz or 027 4701980) or Sara Boucher, study 
coordinator (sara.boucher@otago.ac.nz or 03 470 9167). 
 
WHAT WILL MY PARTICIPATION IN THE STUDY INVOLVE? 
You have been invited to participate in the ‘Flash’ Adhesive Study because you are 
already enrolled in Managing Diabetes in a ‘Flash’ and have been, or will begin, 
using the FreeStyle Libre flash glucose monitoring system.  
 
If you decide to participate in this add-on study, you will be randomly assigned to 
one of two groups. You will have a 50/50 chance of being assigned to either the 
intervention group for 3 months or the comparison group for 3 months. After 3 
months, you will cross over to the other group.  
 
You will continue completing electronic safety survey questionnaires every 2 weeks 
and continue all of your usual diabetes care during the study period, the ‘Flash’ 
Adhesive Study is only providing sensor patches and adhesive remover wipes. The 
only difference between being in the study and not being in the study is being 
randomised to either using a patch at the start of your sensor sensors for 3 months 
or to not using a patch (or anything else) for 3 months. If you choose not to be 






If you are assigned to begin the intervention group first, you will be asked to apply 
the protective patch at the start of each sensor session for 3 months. Patches 
typically last for 3-5 days. When the patch is no longer providing a protective benefit, 
you will use adhesive remover wipes provided by the study to remove the old patch 
and apply a new one. At the end of 3 months, you will cross over to the comparison 
group for 3 months. 
 
Comparison Group 
If you are assigned to begin in the comparison group, you will be asked not to protect 
your FreeStyle Libre sensors with any tape or patch for 3 months. After 3 months, 
you will cross over to the intervention group for 3 months. 
 
WHAT ARE THE POSSIBLE BENEFITS AND RISKS OF THIS STUDY? 
You may benefit from using protective sensor patches by possibly experiencing 
fewer disruptions to monitoring your glucose levels due to sensor loss associated 
with adhesive failure.  
 
You may experience a skin reaction to the protective sensor patch. You will be 
asked to report any reactionns to the sensor or the adhesive so that we can 
monitor these events and provide medical advice, if necessary.  
 
WHO PAYS FOR THE STUDY? 
You will not have to pay for anything. The patches are being paid for by a Sanofi 
grant. 
 
WHAT IF SOMETHING GOES WRONG? 
If you were injured in this study, which is unlikely, you would be eligible to apply for 
compensation from ACC just as you would be if you were injured in an accident at 
work or at home. You will have to lodge a claim with ACC, which may take some 
time to assess. If your claim is accepted, you will receive funding to assist in your 
recovery.  If you have private health or life insurance, you may wish to check with 
your insurer that taking part in this study won’t affect your cover. 
 
WHAT ARE MY RIGHTS? 
You have a right to see information collected about you as part of the study and the 
information will only be shared with research staff for the purposes of the study.  You 
will be told of any new information about harmful or helpful effects related to the 
FreeStyle Libre and protective sensor patches that become available during the 
study that may have an impact on your health. Your study information will be safely 
stored in the Department of Women’s and Children’s Health, University of Otago, in 
such a way that only the study investigators will be able to gain access to it. You will 
not be identified in any reports written about the study.  
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WHAT HAPPENS AFTER THE STUDY OR IF I CHANGE MY MIND? 
Personal information about you which can identify you as an individual person will 
be destroyed when the researchers are finished with this project but the raw data 
(questionnaire responses, glucose monitor data) on which the results of the project 
depend will be safely stored for 10 years after you turn 16 years old (i.e. aged 26 
years). Information collected about you may be used for other future research. 
 
Study findings are expected within one year of the end of the study. A summary of 
the study findings will be sent to you at the email you provide. The ‘Flash’ Adhesive 
Study results will be presented at an Australasian Paediatric Endocrine Group 
annual scientific meeting and the findings will be submitted to a scientific journal. 
 
WHO DO I CONTACT FOR MORE INFORMATION OR IF I HAVE CONCERNS? 
If you have any questions, concerns or complaints about the study at any stage, 
you can contact Dr Ben Wheeler, Principal Investigator (ben.wheeler@otago.ac.nz
  or 027 470 1980), Sara Boucher, Study Coordinator 
(sara.boucher@otago.ac.nz), or the lead regional co-investigator (Christchurch: Dr 
Martin de Bock, martin.debock@otago.ac.nz; Wellington: Dr Esko Wiltshire, 
esko.wiltshire@otago.ac.nz). 
 
If you want to talk to someone who isn’t involved with the study, you can contact 
an independent health and disability advocate on: 
 
Phone:  0800 555 050 
Fax:   0800 2 SUPPORT (0800 2787 7678) 
Email:   advocacy@hdc.org.nz 
 
For Māori health support please contact : 
 
Arai Te Uru Whare Hauora 
25 College Street 
Caversham 
Dunedin 9012 
03 471 9960 
 
Debbie Rawiri 
Diabetes Centre (Canterbury DHB) 
Phone: 03 364 0860 
Email: Debbie.rawiri@cdhb.health.nz 
 









You can also contact the health and disability ethics committee (HDEC) that 
approved this study on: 
 
 Phone: 0800 4 ETHICS 









Please tick to indicate you consent to the following  
 
I have read, or have had read to me in my first language, and 
I understand the Participant Information Sheet.   
Yes  No  
I have been given sufficient time to consider whether or not to 
participate in this study. 
Yes  No  
I have had the opportunity to use a legal representative, 
whanau/ family support or a friend to help me ask questions 
and understand the study. 
Yes  No  
I am satisfied with the answers I have been given regarding 
the study and I have a copy of this consent form and 
information sheet. 
Yes  No  
I understand that taking part in this study is voluntary (my 
choice) and that I may withdraw from the study at any time 
without this affecting my medical care. 
Yes  No  
I consent to the research staff collecting and processing my 
information, including information about my health. 
Yes  No  
If I decide to withdraw from the study, I agree that the 
information collected about me up to the point when I 
withdraw may continue to be processed. 
Yes  No  
I consent to my GP or current provider being informed about 
my participation in the study and of any significant abnormal 
results obtained during the study. 
Yes  No  
I agree to an approved auditor appointed by the New Zealand 
Health and Disability Ethic Committees, or any relevant 
regulatory authority or their approved representative reviewing 
my relevant medical records for the sole purpose of checking 
the accuracy of the information recorded for the study. 
Yes  No  
 
If you need an INTERPRETER, please tell us. 
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I understand that my participation in this study is confidential 
and that no material, which could identify me personally, will 
be used in any reports on this study. 
Yes  No  
I understand the compensation provisions in case of injury 
during the study. 
Yes  No  
I know who to contact if I have any questions about the study 
in general. 
Yes  No  
I understand my responsibilities as a study participant. Yes  No  
I wish to receive a summary of the results from the study. Yes  No  
I consent to being contacted for future research. Yes  No  
 
 
Declaration by participant: 







Declaration by member of research team: 
I have given a verbal explanation of the research project to the participant, and 
have answered the participant’s questions about it.   
 
I believe that the participant understands the study and has given informed 
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